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Increased platelet activation and inflammation play a key role in atherothrombosis. Patients with 
peripheral arterial disease are at increased risk of adverse cardiovascular events, particularly at the time 
of surgery. We postulated that the increase in peri-operative cardiovascular events is mediated by 
increased platelet activation and inflammation.  We hypothesized that peri-operative dual anti-platelet 
therapy would improve biomarkers of atherothrombosis without causing unacceptable bleeding in 
patients undergoing surgery for critical limb ischaemia (CLI). 
 
Prior to interventional study, I validated a sensitive flow cytometric technique for the reproducible 
assessment of in vivo platelet activation in patients with peripheral arterial disease. Thirty patients with 
stable claudication, attended on two occasions to permit within-day and between-day comparisons. A 
variety of platelet activation markers were compared to the gold standard of platelet–monocyte 
aggregation. Platelet-monocyte aggregation demonstrated comparable within-day (mean difference ± 
co-efficient of reproducibility; 0.9±15.4%) and between-day reproducibility (2.0±12.4%). Platelet-
monocyte aggregates correlated well with other platelet activation markers (P selectin r=0.30; Platelet 
CD40L r=0.41; Platelet microparticles r=0.27; P≤0.026) and monocyte activation markers (monocyte 
CD40 r=0.27;monocyte CD11b r=0.47; P≤0.026). 
 
In a cross sectional study, I demonstrated that resting in vivo platelet activation and inflammation was 
increased in patients with CLI in comparison to healthy controls, patients with stable claudication and 
those undergoing treatment for acute coronary syndromes.  In addition, platelet activation and 
inflammation throughout the peri-operative period was markedly increased in CLI patients compared 
with non-vascular patients undergoing arthroplasty, and exceeded the rise attributable to the stress of 
surgery itself. 
 
In a prospective double-blind randomised controlled trial, 108 patients undergoing infra-inguinal 
revascularisation or amputation for CLI were maintained on aspirin (75 mg daily) and randomised to 
clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n=50) or matched placebo (n=58). 
Peri-operative in vivo platelet activation and inflammation, cardiac-Troponin I (c-TnI) release and 
bleeding outcomes were recorded. Clopidogrel reduced markers of platelet activation and inflammation 
before surgery and throughout the post-operative period. Overall, there were 18 troponin-positive 
events (16.7%), with half of the troponin rises (9) occurring prior to surgery. Patients with post-
operative elevations in c-Tn I had significantly greater levels of pre-operative platelet-monocyte 
aggregation, monocyte CD40, IL-6 and hsCRP. However, despite reducing platelet and inflammatory 
markers, clopidogrel did not have a direct effect on peri-operative c-Tn I. There was no increase in 
major life-threatening or minor bleeding, although blood transfusions and wound haematomas were 
significantly increased.  
 
Using sensitive and validated methodologies, I have provided a detailed examination of in vivo platelet 
activation and inflammation in high-risk vascular surgical patients. This approach has provided the first 
objective assessment of the risks and benefits of intensive peri-operative anti-platelet therapy in this 
patient group. Dual anti-platelet therapy reduced biomarkers of atherothrombosis without causing 
unacceptable bleeding. However, large-scale clinical trials would be required to confirm whether these 
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Patients with critical limb ischaemia are at particularly high risk of serious cardiovascular 
events, especially when undergoing surgery. Despite this risk, there has been little study of 
platelet activation and inflammation during this high-risk period. Increased platelet activation 
and systemic inflammation are central to the propagation of intravascular thrombus and 
subsequent clinical sequelae. We propose to investigate whether, in patients undergoing 
surgery for critical limb ischaemia, increased markers of systemic inflammation and platelet 
activation are associated with cardiac troponin-I (cTnI) and highly sensitive C-reactive protein 
(hsCRP) release. Although effective in the treatment of acute coronary syndromes, combined 
anti-platelet therapy with clopidogrel and aspirin is not routinely used in the peri-operative 
period because of the potential for bleeding complications. However, there is currently no 
level-one evidence in this population to compare the relative risks of adverse bleeding with 
improvements in cardiovascular outcome. We therefore propose to establish whether combined 
aspirin and clopidogrel therapy will reduce peri-operative cardiac troponin in addition to 
markers of systemic inflammation and platelet activation. This may provide the rationale for a 





1.2  PERIPHERAL ARTERIAL DISEASE AND CARDIOVASCULAR 
             RISK  
 
Peripheral arterial disease affects nearly 30 million people in Western Europe and North 
America. It encompasses a spectrum of atherosclerotic disease, ranging from asymptomatic 
disease and stable intermittent claudication to critical limb ischaemia.  Progression of the 
disease requiring surgical intervention (reconstruction, angioplasty or amputation) occurs in 5-
10% [Khan S et al, 2007]. However, this is relatively benign in comparison to overall 
cardiovascular mortality. Cardiovascular risk increases with the severity of disease, with 
progressive reductions in ankle brachial pressure index being an independent predictor of 
cardiovascular outcome [Lee AJ et al, 2004; O’Hare AM et al, 2004]. In up to three-quarters of 
cases, patients have co-existent coronary artery disease and a 3-fold increased risk of 
cardiovascular events and death compared to the general population [Criqui MH et al, 1992]. 
Approximately one third will die within 2 years of presentation and two-thirds within 5 years 
as a result of myocardial infarction or stroke [Dormandy J et al, 1999; Leng GC et al, 1996].  
 
These patients are particularly at risk during the peri-operative period. Myocardial infarction is 
the commonest life-threatening complication of major vascular surgery with a reported peri-
operative incidence ranging from 8 to 40% depending on the diagnostic criteria
 
[Hobbs SD et 
al 2005; Kim LJ et al 2002; Landesburg G et al 2003]. This is comparable to the 
cardiovascular risk seen in patients with acute coronary syndromes (ACS): 30-day death and 
re-infarction rate of 8-20% [Bertrand ME et al 2002]. The “Guidelines for Peri-operative 
Cardiovascular Evaluation for Noncardiac Surgery” from the American College of Cardiology 
and American Heart Association categorise peripheral vascular operations as high risk 
procedures with a >5% risk of non-fatal myocardial infarction or cardiac death. In a recent 
large observational study (n=5,460), patients with peripheral arterial disease scheduled for 
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open vascular surgery had a worse prognosis (2.4-fold increase in cardiovascular morbidity) 
than matched patients with severe myocardial ischaemia referred for percutaneous coronary 
intervention [Welten GM et al, 2008]. Interestingly the occurrence of peri-operative cardiac 
complications following vascular surgery was associated with long-term cardiac death. There is 
therefore a clear unmet need to reduce cardiovascular events in patients with peripheral arterial 
disease, especially in the peri-operative period.  
 
Despite increased cardiovascular risk, this patient population has attracted relatively little 
attention as a study group for the investigation of atherothrombosis. In addition, in spite of 
attempts to raise awareness of peripheral arterial disease as an important marker of 
cardiovascular risk, patients are often poorly provided with evidence-based therapies such as 
anti-platelet and lipid lowering therapies [Cassar K et al, 2003; Burns P et al 2003; Hirsch AT 
et al, 2001; Khan S et al, 2007]. The reasons for this are unclear, but appear to be related to a 
lack of awareness amongst health professionals of the severity of the disease. Patients with 
peripheral arterial disease may potentially benefit from risk-stratification and appropriately 







Emerging evidence has demonstrated atherosclerosis as a dynamic inflammatory process of 
which endothelial dysfunction is one of the earliest features [Ross, 1999]. Endothelial 
activation results in the up-regulation of leukocyte adhesion proteins and initiates local 
vascular inflammation. The release of growth factors and pro-inflammatory cytokines results in 
leukocyte and monocyte recruitment, induction of atheroma formation and further arterial 
damage. Indeed, interventions to reduce mononuclear cell recruitment to vessels have been 
demonstrated to protect animals from atherosclerosis [Johnson RC et al, 1997; Gu L et al, 
1998; Boring L et al, 1998; Cybulsky et al, 2001].  
 
Plaque expansion and disruption can lead to atherothrombosis and subsequent acute coronary 
syndromes, including myocardial infarction [Blum and Miller, 1996; Ross, 1999]. Areas of 
endothelial denudation and thrombus deposition are a common finding on the surface of 
atheromatous plaques and are usually sub-clinical [Davies M, 2000]. It is the dynamic 
regulation of intravascular thrombus formation that is crucial in determining the resolution and 
clinical outcome from a complex atherosclerotic plaque. Indeed, over 80% of coronary 
atherosclerotic lesions causing >50% luminal stenosis have evidence of previous healed plaque 
disruption with incorporation of old thrombus within the atherosclerotic lesion [Mann J et al, 
1999].  
 
1.3.1What converts a stable plaque into an unstable lesion prone to rupture? 
The structural morphology, cellular composition, and biological activity of coronary plaques 
appear to be closely linked. Indeed, it is has been demonstrated that plaque instability 
correlates more with biological activity and cellular composition than with angiographical 
findings of stenosis. Exogenous factors (e.g. mechanical stress, vasomotor tone, infection, 
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blood viscosity, coagulability) further modify such interaction, making the final outcome even 
less predictable. 
In the presence of platelet activation or marked vascular inflammation, microthrombi on the 
surface of atherosclerotic plaques may propagate, ultimately leading to arterial occlusion and 
myocardial infarction [Rosenburg RD et al, 1999]. Thus increases in platelet activation or 
inflammatory mediators may reflect plaque instability and provide information on the 
intracoronary dynamics of thrombosis and inflammation. Given this pathophysiological basis 
for atherothrombosis, markers of platelet activation and vascular inflammation have been 
extensively studied. There is emerging evidence to suggest that some markers may provide a 
more sensitive reflection of in vivo platelet activation and vascular inflammation than others. In 
addition, these markers have been shown to correlate with clinical risk and therefore, 















1.4   ASSESSMENT OF ATHEROTHROMBOTIC RISK  
 
1.4.1 Cardiac Troponin I (cTnI) 
Cardiac troponin I (cTnI) is a contractile protein that is released into the circulation after 
myocardial cell injury. Unlike creatine kinase and its MB isoenzyme (CK-MB), cTnI is not 
found in skeletal muscle and is therefore highly sensitive and specific for myocardial necrosis. 
Levels of cTnI have been demonstrated to predict increased risk of mortality and reinfarction in 
patients presenting with an acute coronary syndrome, and as such have been used to stratify 
clinical treatment [Galvani M et al, 1997; Antman EM et al, 1996; Luscher MS et al, 1997, 
Hamm CW et al, 1997]. Indeed, even small increases in cardiac troponins are associated with 
worse outcomes [Morrow DA et al, 2001; Reed MJ et al, 2012].  Studies have demonstrated 
correlation of levels of platelet activation markers with troponin release in patients with acute 
coronary syndromes [Zhang SZ et al, 2007], with markers such as platelet-monocyte 
aggregates predicting troponin rise after percutaneous coronary intervention [Ray MJ et al, 
2005].  
 
Although myocardial ischaemia commonly complicates vascular surgery, early detection of 
clinically meaningful ischaemia remains a challenge in the peri-operative setting [Raby KE et 
al, 1992]. During surgery, cTnI is reported to be more specific for myocardial necrosis than 
CK-MB. Several studies have now demonstrated that even at low cut-off levels, post-operative 
cTnI is an independent predictor of both short and long term mortality after major vascular 
surgery [Andrews A et al, 2001; Kim LJ et al, 2002; Landesberg G et al, 2003]. However, it 
has yet to be shown whether intervention aimed at reducing platelet activation and peri-




1.4.2 in vivo Platelet Activation 
Although markers of myocyte necrosis are invaluable diagnostic tools for patients with acute 
coronary syndromes, and are routinely used for risk stratification, only 22% to 50% of patients 
with unstable angina have positive troponin (I or T) tests [Hamm CW et al, 1997; Heeschen C 
et al, 1999; Morrow DA et al, 2000]. Many patients with troponin-negative acute coronary 
syndromes who have vulnerable coronary plaques remain at high risk for future ischemic 
events. Serum cardiac markers reflect evidence of myocardial necrosis, but they provide no 
information about the patho-physiological state within the coronary artery. In contrast, levels of 
in vivo circulating activated platelets may reflect plaque disruption and thrombosis.  
 
A variety of techniques have been proposed for the assessment of platelet activation including 
platelet aggregometry, point of care devices, flow cytometric assessment of platelet surface 
antigens, and soluble plasma markers of platelet activation: all have advantages and 
disadvantages [Michelson AD, 2009]. Historically considered the gold standard, platelet 
aggregometry requires the preparation of platelet-rich plasma and a high sample volume. 
Centrifugation and washing procedures may produce cell loss and artefactually activate 
platelets. Many of the point-of-care systems assess ex vivo platelet aggregation to various 
exogenous agonists. Although more labour intensive, flow cytometry is emerging as the new 
sensitive gold standard with measurement of surface expression of platelet antigens providing 
an assessment of in vivo platelet activation.  It requires only a small sample volume, is 
performed on whole blood, and allows analysis of platelets in their physiological milieu. 
 
One of the most commonly studied markers of platelet activation is the α-granule membrane 
protein, P-selectin, that is present only on the surface of activated degranulated platelets. 
However, in vivo degranulated platelets rapidly lose their surface P-selectin, but continue to 
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circulate and function [Michelson AD et al, 1996]. In contrast, P-selectin-positive platelets 
very rapidly bind to leucocytes (mainly monocytes) via their constitutively expressed counter 
receptor, P-selectin glycoprotein ligand-1 (PSGL-1) to form platelet-monocyte aggregates 
(PMAs) [Michelsen AD et al, 2001]. 
 
Adherence of platelets to monocytes has been shown to regulate various monocyte actions. The 
binding of thrombin-stimulated platelets induces monocyte cytokine expression [Neumann F-J 
et al, 1997]. Platelets supply cholesterol to monocytes that may then mature into lipid-laden 
macrophages characteristic of atherosclerosis. In addition, platelet surface P-selectin induces 
the expression of tissue factor on monocytes [Celi A et al, 1994] and promotes fibrin 
deposition [McEver RP et al, 2002] within a growing thrombus at sites of vascular injury. 
Furthermore, platelet-monocyte aggregation promotes monocyte adhesion to activated 
endothelium and the growth of atherosclerotic lesions in ApoE
-/-
 mice [Huo Y et al, 2003].  
 
Increased levels of PMAs have been detected in smokers, patients with diabetes and coronary 
artery disease [Harding SA et al, 2004; Sarma J et al, 2002]. Indeed, increased levels have been 
shown to correlate with severity of acute coronary syndrome and be predictive of re-current 
thrombosis following percutaneous coronary intervention [Gurbel PA et al, 2005]. Thus, 
PMAs may not only contribute to the initiation and progression of atherosclerosis, but act as 
surrogate markers of clinical risk.  Therefore, detection of circulating PMAs may be a more 




1.4.3 Inflammatory markers 
It is increasing recognised that inflammatory mechanisms play a central role in the 
pathogenesis of atherosclerosis and its complications [Ross R. 1999].  Many inflammatory 
mediators have been investigated but two of the most extensively studied include the 
CD40/CD40L complex and C-Reactive Protein (CRP). 
 
CD40/CD40L 
The interaction between transmembrane glycoprotein receptor CD40 and its counterpart CD40 
ligand (CD40L) has been shown to play an integral part in the inflammatory pathways of the 
vascular system. The CD40/CD40L system is expressed in human atheroma and on a range of 
atheroma-associated cells including endothelial cells, smooth muscle cells, monocytes and 
platelets [Mach F et al, 1997; Schonbeck U et al, 2001]. Binding of the CD40 receptor 
mediates an array of pro-inflammatory effects including the expression of cytokines, 
chemokines, adhesion molecules, matrix metalloproteinases, and growth factors [Schonbeck U 
et al, 2001]. These activities are crucial to the process of atherogenesis and promote plaque 
instability. Indeed, disruption of CD40/CD40L interactions in hypercholesterolemic mice 
retards the initiation and progression of atherosclerotic lesions [Mach F et al, 1998]. 
CD40L induces tissue factor expression on endothelial cells and monocytes [Lindmark E et al, 
2000], and contains a RGD integrin recognition sequence allowing it to bind to glycoprotein 
IIb/IIIa, activate platelets, and stabilize arterial thrombi [Andre P et al, 2002]. Thus CD40L has 
the potential to mediate both pro-inflammatory and pro-thrombotic activities within the 
vasculature.  
 
Consistent with these activities, elevation of sCD40L is increased in patients with diabetes 
mellitus [Harding SA et al, 2004] and cigarette smokers [Harding SA et al, 2004], and is 
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associated with an increased risk of subsequent cardiovascular events in both healthy women 
[Schonbeck U et al, 2001] and patients presenting with acute coronary syndromes [Heeschen C 
et al, 2003]. CD40L has also been shown to correlate with PMAs and often parallels elevations 
in C-reactive protein [Niccoli G et al, 2008], which is, in turn, associated with acute coronary 
syndromes. 
 
Highly sensitive C-reactive Protein (hs-CRP) 
It has been widely demonstrated that plasma markers of inflammation are predictive of 
cardiovascular risk [Blake GJ et al, 2001]. Of these potential markers, C-reactive protein 
(CRP) has been the most extensively studied. Produced in the liver in response to interleukin 
(IL)-6, CRP is an acute phase reactant.  
 
Numerous large-scale epidemiological studies among apparently healthy men and women have 
found that CRP is a strong independent predictor of future cardiovascular risk [Kuller LH et al, 
1996; Ridker PM et al, 1997; Tracy RP et al, 1997; Ridker PM et al, 1998; Koenig W et al, 
1999; Ridker PM et al, 2000; Ridker PM et al, 2001]. CAPTURE trial investigators found that, 
although only troponin T was predictive in the initial 72-h period, both CRP and troponin T 
were independent predictors of risk at six months [Heeschen C et al, 2000], while the FRISC II 
investigators reported that the risk associated with elevated CRP levels at the time of index 
event continues to increase for several years [Lindahl B et al, 2000]. In each of these studies, 
the predictive value of CRP was independent of, and additive to, troponin.  
Recent publications suggest that an elevated CRP may also be an independent predictor of 
adverse cardiac events following vascular surgery [Rossi E et al, 2002; Owens CD et al, 2007]. 
A recent meta-analysis of prospective studies, demonstrated that patients undergoing vascular 
surgery with a pre-operative CRP > 3 mg/L were at significantly increased risk of long term 
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mortality and cardiac morbidity. There was no association with early or immediate-term 
adverse events [Padayachee L et al, 2009]. 
 
Initially thought of as a downstream bystander marker of vascular inflammation, recent data 
suggest that CRP may also play an active role in atherogenesis. C-reactive protein opsonization 
of low-density lipoprotein (LDL) mediates LDL uptake by macrophages [Zwaka TP et al, 
2001], and CRP also stimulates monocyte release of pro-inflammatory cytokines such as IL-
1b, IL-6, and tumour necrosis factor-alpha [Ballou SP et al, 1992]. Furthermore, CRP mediates 
monocyte chemotactic protein-1 induction in endothelial cells [Pasceri V et al, 2001] and 
causes expression of intercellular adhesion molecule-1 and vascular cellular adhesion 
molecule-1 by endothelial cells [Pasceri V et al, 2000].  
 
Statin therapy may have powerful anti-inflammatory effects, and in recent clinical studies, 
statin therapy has been shown to lower CRP levels, an effect that is independent of lipid 
lowering [Ridker PM et al, 2001; Albert M et al, 2001; Jialal I et al, 2001]. In CARE trial 
population, patients with persistent low-grade vascular inflammation, as evidenced by high 
CRP and serum amyloid A levels, were at increased risk of recurrent events. Randomization to 
pravastatin therapy prevented 54% of recurrent events among those with persistent 
inflammation, compared with 25% among those without [Ridker PM et al, 1998]. The effect of 
aspirin on CRP levels is controversial [Ikonomidis I et al, 1999; Feldman M et al, 2001], but 
the benefit of aspirin therapy in preventing future MI appears to be greatest among those with 
elevated CRP levels [Ridker PM et al, 1997]. In addition, data from the FRISC-II study 
suggest that the benefits of an early invasive approach may be greatest among those with 
evidence of a heightened inflammatory response [Lindmark E et al, 2001]. Prospective 
randomized studies are required to test these hypotheses directly, but individuals with evidence 
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of heightened inflammation may benefit most from an aggressive modification of lifestyle and 
an intensification of proven preventive therapies such as antiplatelet and lipid-lowering agents. 
 
1.5 PERIPHERAL ARTERIAL DISEASE, PLATELET ACTIVATION AND 
            INFLAMMATION 
 
Despite suffering significant cardiovascular risk, there has been relatively little investigation of 
platelet activation and inflammation in high-risk vascular surgical patients in comparison to 
patients with coronary atherosclerosis.  
 
Several studies have assessed baseline platelet activation in patients with peripheral 
atherosclerosis. Although smaller studies have reported some conflicting results [Galt SW et 
al, 1991], larger series have demonstrated that activation is greater than in healthy controls, 
with a progressive increase in activation with increasing severity of disease [Cassar K et al, 
2003, Robless PA et al 2003, Rajagopalan S et al, 2007].   
 
Other than a few early, small size studies, utilising a variety of platelet and coagulation factors 
as outcome measures [McDaniel MD et al, 1984; Reininger CB et al, 1994], most data 
regarding peri-operative platelet activation in the vascular patient come from 2 UK centres. 
Studies from Aberdeen have investigated platelet activation in patients with lifestyle-limiting 
claudication undergoing aorto-iliac or fem-pop angioplasty [Cassar K et al, 2005]; patients 
undergoing major vascular surgery (arterial re-vascularisation for sub-clinical ischaemia and 
infra-renal aortic aneurysm repair) [Rajagopalan S et al, 2007], and a small group (n=22) of 
patients undergoing surgery for critical limb ischaemia [Collins P et al, 2006]. These studies all 
showed an increase in post-procedural markers of platelet activation, with the greatest change 
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occurring in samples stimulated with agonists ex vivo as opposed to resting levels. However, 
the patient populations were heterogeneous in terms of underlying disease and severity. Platelet 
activation was assessed by flow cytometric and aggregometry measurements of both resting 
and ex vivo agonist stimulated samples. As discussed earlier, the process of aggregometry and 
agonist stimulation can cause artificial changes to platelet marker levels, and may not provide 
the most sensitive reflection of circulating activated platelets in vivo. In addition, assessment of 
resting platelet P- selectin may be inaccurate due to shedding of the molecule from the platelet 
surface. 
Rajagopalan S et al demonstrated that post-operative platelet aggregation to arachodonic acid 
was significantly increased in those patients who developed a post-operative elevation in 
cardiac Troponin I. There was no other relationship between other markers of platelet 
activation and post-operative cardiac Troponin I. 
 
Researchers in Leicester have studied platelet activation in patients undergoing carotid 
endarterectomy. They have demonstrated that elevated pre-operative levels of platelet 
activation are related to increases in post-operative transcranial emboli [Hayes PD et al, 1999 
and 2003 and Payne DA et al, 2004]. They also measured platelet activation at 8 points 
throughout the pre-, intra- and post-operative period and demonstrated a significant rise in 
activation with the infusion of heparin [Webster SE et al, 2004]. Following heparin infusion, 
platelet activation levels fell but remained above baseline for 24 hours post surgery. Platelet 
activation was assessed using aggregometry or flow cytometric measurements of resting and 
agonist stimulated samples.  
 
These studies support the concept that platelet activation is increased in the peri-operative 
period and may account for the high incidence of peri-operative cardiovascular events in 
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vascular patients. However the heterogeneity of patients studied and variety of ex vivo platelet 
markers utilisied make it difficult to specifically examine what occurs in vivo in patients with 
the highest risk of atherothrombosis. Patients undergoing peripheral angioplasty for 
claudication or carotid endarterectomy for carotid atherosclerosis could be expected to have a 
different profile of platelet activation and clinical risk compared to those with the greater 
disease burden and symptoms of critical limb ischaemia undergoing open surgery.  
 
Coronary atherosclerosis has a spectrum of clinical presentations which have been shown to 
carry different degrees of cardiovascular risk. Risk-stratified treatment algorithms have 
subsequently been devised. Patients with peripheral arterial disease could benefit from similar 
targeted medical therapies, appropriately tailored to clinical risk. Although different anti-
platelet regimes have been studied in peripheral angioplasty and carotid endarterectomy 
[Cassar K et al, 2005; Payne DA et al 2004] it would be logical to identify those with the 





1.6 PHYSIOLOGICAL RESPONSE TO SURGERY AND PERI-OPERATIVE 
     MYOCARDIAL INJURY 
 
The physiological response to injury encompasses a wide range of endocrinological, metabolic, 
immunological and haematological effects, all of which have an impact on the vasculature.  
The initial phase includes a pro-inflammatory immune response. This is characterized by pro-
inflammatory cytokine release, microcirculatory disturbance, and injury-induced activation of 
the coagulation cascade. 
 
1.6.1 Acute-phase response  
Pro inflammatory cytokine production in the intraoperative and early postoperative period is 
initiated by macrophages and monocytes at the initial site of injury as part of the acute-phase 
response [Baumann H et al, 1994]. These cytokines include tumor necrosis factor α (TNF-α) 
and interleukin 1β (IL-1β), which are primarily responsible for the non-hepatic manifestations 
of the acute-phase response, including fever and tachycardia. In turn, TNF-α and IL-1β 
stimulate the production and release of other cytokines, including IL-6 [Baigrie RJ et al, 1992; 
Desborough JP, 2000]. 
 
Interleukin 6 primarily regulates the hepatic component of the acute-phase response resulting 
in the generation of acute-phase proteins, including C-reactive protein [Baumann H et al, 
1994]. Acute phase proteins act as inflammatory mediators, anti-proteinases and scavengers in 
tissue repair.  
 
Concentrations of circulatory cytokines are normally low and often undetectable. Within 30–60 
minutes after the start of surgery, Interleukin‐ 6 concentration increases after 2–4 hours. 
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Studies demonstrate that levels of IL-6 are proportional to degree of tissue trauma or duration 
of surgery, with lower levels of IL-6 being observed after laparoscopic surgery in comparison 
to open [Kloosterman T et al, 1994; Mokart D et al, 2002; Shenkin A et al, 1989; Ueo H et al, 
1994]. A study by Cruickshank AM et al, 1990, demonstrated higher levels of IL-6 in patients 
undergoing abdominal aortic and colorectal surgery than in those undergoing hip replacement 
despite similar operating times. Additionally, both elevated peri-operative CRP and IL-6 levels 
correlate with subsequent development of postoperative complications [Choileain NN et al, 
2006]  
 
1.6.2 Vascular Dysfunction 
The local microcirculatory inflammatory response to surgery is characterized by a pronounced 
leukocyte accumulation and adherence to the endothelial lining of blood vessels. [Yamauchi J 
et al, 1999]. In animal studies, mobilisation of bowel mesentery during laparotomy results in a 
marked increase of venular leukocyte accumulation secondary to enhanced rolling and 
adhesion interactions [Fiebig E et al, 1991]. 
Several studies have indicated that adhesion molecules also appear to be involved in the 
inflammatory response to trauma. Major surgery elevates serum levels of P-selectin, E- 
selectin, and vascular cell adhesion molecules as well as increasing expression of leukocytic 
CD11a and CD11b, and endothelial intercellular adhesion molecule 1 [Shijo H et al, 1998; 
Klava  A et al, 1997; Sendt  W et al, 1999]. During the initial phase of adherence, selectins on 
leukocytes (L-selectin), endothelial cells (E-selectin), and platelets (P-selectin) interact to 
produce leukocyte “rolling”. Subsequently, up- regulation of leukocyte integrins can be 
observed after surgical injury [Seekamp A et al, 1998] Combined with the capillary leakage 
caused by proinflammatory cytokine release and increased nitric oxide production, the 
interaction of these adhesion molecules leads to a stable cell to cell contact with 
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polymorphonuclear cell attachment, resulting in microcirculatory obstruction and failure of 
transcapillary exchange. 
 
The physiological response to vascular injury also induces a hypercoaguble state in order to 
achieve haemostasis. Sympathetic vessel constriction occurs and circulating platelets adhere to 
the vessel wall. Activated platelets aggregate and activation of the coagulation proteins 
produce fibrin to form a stable plug. 
 
1.6.3 Peri-operative cardiac complications following surgery  
Peri-operative myocardial infarction (PMI) is the most common cardiovascular complication 
following non-cardiac surgery and is one of the most important predictors of short- and long-
term morbidity and mortality [Priebe HJ et al, 2005].  
The pathophysiology of peri-operative MI is highly debated. As discussed above, the 
physiological response to surgery induces large changes in sympathetic tone, cardiovascular 
performance, coagulation and inflammatory response. Although supply demand mismatch (e.g 
due to hypotension or tachycardia) has long been thought to explain many peri-operative MIs, 
there is pathological and angiographic evidence to suggest that acute plaque disruption and 
haemorrhage is often the underlying culprit (as occurs in acute coronary syndromes out-with 
the peri-operative period) [Cohen MC et al, 1999; Dawood MA et al, 1996].  
There are several features of the stress response to trauma that will increase plaque instability 
and chance of rupture. Most ischaemic episodes tend to start at the end of surgery and during 
emergence from anaesthesia. [Landesberg G et al, 2001]. This period is characterized by 
increases in heart rate, arterial pressure, sympathetic tone, and pro-coagulant activity. Increased 
sympathetic tone can result in increases in arterial pressure, heart rate, contractility, coronary 
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vasomotor tone, and coronary vascular shear stress. This, in turn, may trigger coronary 
vasospasm, plaque disruption, and coronary thrombosis. Surgery-induced pro-coagulant and 
anti- fibrinolytic activity combined with enhanced inflammatory cell may trigger coronary 
artery thrombosis during low-flow conditions in the presence of underlying stable coronary 
atherosclerosis even in the absence of acute plaque disruption. 
 
 
1.6.4 Surgical stress in patients with underlying vascular disease  
If the physiological response to surgical trauma increases a patient’s risk of vascular 
thrombosis, what happens when there is also underlying vascular dysfunction, as in patients 
with peripheral arterial disease? A large proportion of these patients have pre-existing coronary 
disease, so the increase in vasomotor tone, shear stress and pro-thrombotic state induced by 
surgery could pre-dispose to coronary plaque rupture.  In addition, patients with peripheral 
arterial disease also have a baseline elevation in platelet activation and inflammation.  It could 
be hypothesized that this baseline pro-thrombotic state combined with the stress response to 
surgery accounts for the particularly high incidence of peri-operative cardiovascular events 
















1.7 ANTI-PLATELET THERAPY 
 
 
Despite advances in the understanding of atherosclerotic disease, anti-platelet therapies remain 
integral in both the prevention and treatment of atherothrombosis.  
 
Paradoxically, despite the epidemiological and prognostic importance of peripheral arterial 
disease, relatively few clinical trials with cardiovascular protective agents have been carried 
out specifically in these patients. In particular, anti-platelet therapy is used in peripheral arterial 
disease based essentially on meta-analyses,
 
extrapolation of results from trials in other 
conditions,
 
or subgroup analyses of large clinical trials enrolling patients with various clinical 
manifestations of atherothrombosis,
 
and not on results of clinical trials specifically designed in 
this clinical condition. The role of aspirin in the secondary prevention of cardiovascular events 
in patients with peripheral arterial disease has been established by the Antithrombotic Trialists’ 
Collaboration with a reduction of 23% in the rate of death, myocardial infarction and stroke 
[Antithrombotic Trialists’ Collaboration, 2002]. Prophylactic use of the thienopyridine 
clopidogrel has modest additional secondary preventative benefits in comparison to [CAPRIE 
investigators, 1996], or in combination with aspirin [CHARISMA Investigators, 2006]. Sub-
group analysis of patients in the CAPRIE trial demonstrated that patients with peripheral 
arterial disease derived the greatest benefit from clopidogrel therapy in comparison to other 
patients at risk of ischaemic events (24% relative risk reduction in composite end point 
compared to an 8.7% reduction across all study groups). However the limitations of post-hoc 
sub-group analysis must be taken into consideration. 
 
Although vascular patients are at high risk of cardiovascular events, bleeding concerns are a 
major disincentive for the investigation of peri-operative intensive anti-platelet regimes, and 
perhaps underlie the paucity of such data. Currently, vascular surgeons continue aspirin 
 30 
throughout the surgical period, but other anti-platelet agents are discontinued. Most published 
reports of anti-platelet use in peripheral vascular surgery are observational [Smout J et al, 
2003; Assadian A et al, 2005] although randomised-controlled trials of dual anti-platelet 
therapy have been performed in patients undergoing carotid endarterectomy [Payne PD et al, 
2004] and peripheral angioplasty [Cassar K et al, 2005]. These studies reported reductions in 
surrogate markers of risk with no increases in major bleeding complications, although bleeding 
time was increased. However, there have been no randomised-controlled trials of dual anti-
platelet therapy in open surgery for critical limb ischaemia, where the potential for both peri-
operative bleeding and cardiac complications is greater. 
 
Most surgical data on the peri-operative bleeding risks associated with anti-platelet agents, 
comes from patients undergoing coronary artery bypass grafting. Several small scale trials and 
observational studies of combination therapy have produced conflicting evidence, with either 
no difference [Cannon CP et al, 2005; Karabulut H et al, 2004; Carpino PA et al, 2001] or an 
increased risk of bleeding and bleeding related complications [Chu MWA et al, 2004; Hongo 
RH et al, 2002; Kapetanakis EI et al, 2005] being reported. These studies have been 
confounded by lack of randomization, small sample size and variation in defined end points. In 
addition, often no distinction is made between patients undergoing CABG in the setting of an 
ACS (where pre-surgical anti-platelet therapy is an essential part of medical therapy) and those 
undergoing CABG for stable coronary vascular disease, when intensive anti-platelet regimes 
are discontinued prior to surgery. In addition to discrepancies in cardiovascular risk, given the 
differences in the extent of platelet inhibition, the bleeding risk could be expected to differ 
greatly between these two patient populations.  
 
 31 
Currently, patients presenting with acute coronary syndromes (ACS) frequently undergo early 
invasive investigation with a view to urgent coronary revascularisation (FRISC, RITA, 
TACTICS, CRUSADE, GRACE). Up to 14% of these patients currently undergo CABG 
during the index hospitalisation, leading to a significant increase overall, in the number of 
patients undergoing CABG in the urgent setting [Largerqvist B et al, 2006; Fox KA et al, 
2005, Cannon CP et al, 1998]. Current guidelines on the management of patients with non-ST 
elevation ACS recommend that both aspirin and clopidogrel be administered on hospital 
admission and continued for 9 to 12 months (Braunwald E et al, 2002; Bassand JP et al, 2007]. 
To date, although the surgical patients were not prospectively randomised, the CURE trial 
(Clopidogrel in Unstable angina to prevent Recurrent ischaemic Events) provides the most 
robust data for anti-platelet therapy in patients with ACS in whom CABG is performed [Fox 
KA et al, 2004]. Subgroup analysis of the 2072 patients undergoing CABG, revealed an overall 
relative reduction in adverse events similar to the entire study population (16.2% Placebo, 
14.5% Clopidogrel, RR 0.89 for all CABG subjects, compared to 11.4% Placebo, 9.3% 
Clopidogrel, RR 0.80 for all CURE patients). The CURE trial reported an overall 1% absolute 
excess of major bleeding complications with the additional use of clopidogrel when compared 
to placebo in patients with ACS. There was no significant increase in life-threatening bleeding. 
In the subgroup undergoing CABG, there was no excess of major (RR 1.27, P=0.095 ns) or 
life-threatening bleeding (RR=1.24, P=0.2 ns). However, only a small number of patients 
continued dual anti-platelet therapy within 5 days of surgery. Despite these limitations, the trial 
proposed that the potential cardiovascular benefits of dual anti-platelet therapy may outweigh 
the risks of bleeding in the high-risk surgical patient. 
 
Whether these outcomes can be applied to patients undergoing surgery for peripheral vascular 





Despite suffering significant cardiovascular morbidity, patients with peripheral arterial disease 
are poorly provided with cardio-protective therapies. There is clearly an unmet need to 
establish improved treatment for these patients, but the potential for both benefit and hazard 
associated with anti-platelet therapies during surgery requires careful consideration. There has 
been little investigation of the role of in vivo platelet activation and inflammation in 
contributing to the high incidence of peri-operative adverse cardiovascular events. An 
appreciation of the pathophysiology of atherothrombosis has guided the diagnosis, 
classification and management of coronary atherosclerotic disease. However, it is still unclear 
how inhibition of platelet function could be utilised appropriately to prevent peri-operative 




1.9 AIMS AND HYPOTHESES 
 
The principle aim of this thesis is to explore in vivo platelet activation and inflammation during 
the period of greatest risk for those patients with severe peripheral vascular disease – the peri-
operative period. Specifically, we propose to investigate the effects of additional clopidogrel 
therapy in patients undergoing infra-inguinal revascularisation or amputation for critical limb 
ischaemia. We aim to demonstrate reproducible methodology for the assessment of in vivo 
platelet activation, and demonstrate that these markers are significantly elevated in our study 
population in comparison to other high-risk groups. We will determine whether additional 
clopidogrel has beneficial effects on surrogate markers of cardiovascular risk during the peri-
operative period. In addition, this study will provide the first objective evidence of bleeding 
risk associated with peri-operative dual anti-platelet therapy in this population. 
 
This proof of concept study could inform the design of larger scale clinical trials, which could 




We hypothesise that in patients undergoing surgical intervention for criticial limb ischaemia: 
 
 
1. Flow cytomteric assessment of platelet-monocyte aggregation in whole blood, provides 
a reproducible assessment of in vivo platelet activation, which correlates well with other 
markers of platelet activation and inflammation, [Chapter 3]. 
 
2. Markers of inflammation and platelet activation will be increased in comparison to 
healthy controls, patients with stable claudication, patients with acute coronary 
syndromes and those undergoing non-vascular surgery, [Chapter 4]. 
 
3. Markers of inflammation and platelet activation will be increased in patients who 
subsequently develop a post-operative rise in cardiac Troponin, [Chapters 5 and 6]. 
 
4. Additional thienopyridine (clopidogrel) therapy will reduce markers of inflammation 









METHODOLOGY – ASSESSMENT OF IN VIVO PLATELET ACTIVATION AND 
INFLAMMMATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 
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2.1 INTRODUCTION   
 
This thesis comprises a series of studies examining markers of platelet activation and 
inflammation in patients with peripheral arterial disease. The rationale behind these 
investigations was the concept that platelet hyperactivity and elevated inflammation is 
associated with an increased risk of atherothrombosis and could therefore account for the high 
incidence of peri-operative cardiovascular events in this patient group. However, despite 
increasing knowledge regarding the role of platelets in a number of medical disorders, there is 
no consensus on the ideal measure of platelet activation. In the introduction we discussed why 
some platelet markers provide a more sensitive reflection of in vivo platelet activation. What 
follows includes an overview of the methodology of platelet activation assessment, with an in-
depth discussion of flow cytometric analysis and the protocols utilised in our studies. Detailed 
descriptions of the assays used in the assessment of inflammatory proteins (hsCRP), cardiac 
Troponin I, and serum platelet activation markers (soluble P-selectin and CD40L) are also 
provided. Clinical details of the individual study designs and patient selection criteria can be 




2.2 TECHNIQUES FOR THE ASSESSMENT OF PLATELET ACTIVATION 
 
Platelet activation comprises a change in platelet shape, platelet aggregation and release of 
platelet constituents. Platelet activation may therefore be quantified by factors such as change 
in shape, tendency to aggregate, and also by measuring blood or urine levels of relevant 
platelet metabolic products. However, in contrast to coagulation assessment, where screening 
tests (e.g APTT and PT) are cheap, quick and widely standardised, platelet function testing 
varies widely. Tests examine different aspects of platelet function and are poorly standardised. 
Different laboratories often use different protocols for sample preparation, different panels of 
agonists, often at different concentration ranges, and different types of assay utilising different 
control ranges. In addition, each technique has associated methodological issues that can affect 
the accuracy of the end measurement. There is a wide variation in the methodology utilised to 
assess platelet function within the literature, which makes it extremely difficult to compare and 
interpret results across studies. This is critical in quantifying the effect of intervention. A full 













Historically considered the gold standard, platelet aggregometry uses turbidometric or 
impedance methods to assess platelet function. Spontaneous platelet aggregation or 
aggregation in response to agonists such as ADP or thrombin in platelet rich plasma (PRP) or 
whole blood can be assessed. 
 
The turbidometric procedure is based on the detection of light transmission through a 
suspension of PRP before or after addition of agonists, while platelets are kept in motion by a 
stirring system (Light Transmission Aggregometry, LTA). The increase in light transmission is 
related to the extent of aggregation. The advantage of this method is that it is widely used and 
relatively simple to perform and interpret. However, these are in vitro studies, which may not 
reflect platelet activation in vivo. In addition, the preparation of platelet rich plasma and a high 
sample volume is required. Centrifugation and washing procedures may produce cell loss and 
artefactually activate platelets.  
Whole blood aggregometry by the impedance method can also be performed. Whole blood is 
anticoagulated with citrate and constantly stirred. After the insertion of an electrode, 
impedance changes are recorded before and after addition of agonist. The detection of platelet 
aggregation is obtained in a millieu closer to that of platelets in vivo, however the process is 
slower and has been demonstrated to have poorer reproducibility. 
 
Serum platelet activation markers 
Substances stored in platelet granules and only released upon activation (such as P-selectin) 
can be detected in the serum by enzyme-linked immunosorbent assay (ELISA) or 
radioimmunoassay methods.   
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In brief, the fundamental principle of the ELISA is that the target analyte (the antigen) is 
recognised with high specificity by antibodies. ELISAs are plate-based assays designed for 
detecting and quantifying substances such as peptides, proteins, antibodies and hormones. In an 
ELISA, an antigen must be immobilized to a solid surface and then complexed with an 
antibody that is linked to an enzyme. Detection is accomplished by assessing the conjugated 
enzyme activity via incubation with a substrate to produce a measureable product. The most 
crucial element of the detection strategy is a highly specific antibody-antigen interaction. 
The use of such techniques allows serum samples to be stored for bulk and convenient 
processing. In addition, ELISA’s have a level of sensitivity and robustness and allow easy 
visualization of results.  
Although, stages in the assay such as anticoagulation of serum with heparin or citrate can 
artefactually affect results, the main limitations depend on the choice of marker. For example, 
Beta-thromboglobulin, β-TG, is artefactually elevated in renal insufficiency, whilst soluble P-
selectin and CD40L demonstrate poor correlation with cell-bound measurements of the 
proteins [Gurbel PA et al, 2000; Ahn ER et al, 2004]. 
 
Point of care devices 
Several bedside monitors have been developed for the rapid assessment of platelet function in 
whole blood (e.g platelet function analyser, PFA-100; rapid platelet function assay-RPFA; 
plateletworks, VerifyNow (Accumetrics) P2Y12, Table. 2.1). In general, they assess ex vivo 
platelet aggregation in response to agonists. Although relatively quick and easy to use, there is 
a lack of standardisation and validation with other more established methods. They do not 
provide a representation of in vivo platelet activation, are mostly utilised to assess efficacy of 
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anti-platelet therapy, and as such only represent a single aspect of platelet activation and 
function.   
However, the European Society of Cardiology (ESC) has incorporated a recommendation 
under class IIb (B) to consider platelet function testing. The guidelines also include a second 
recommendation under class IIb (B) that addresses modifying treatment strategies based on 
platelet reactivity measurements in selected cases [Patti G et al, 2008]. 
However, the accuracy of point-of-care assays is still unclear. The VerifyNow-P2Y12 test was 
designed to overcome the limitations of conventional optical platelet aggregation assays. It is a 
rapid test that uses ADP to stimulate platelets in the presence of prostaglandin (PG) E1, which 
inhibits activation downstream of a second ADP receptor P2Y1, thus making the assay more 
sensitive to the activity of P2Y12. The test can be performed directly in the catheterization 
laboratory prior to percutaneous coronary intervention (PCI). 
Early prospective, observational studies suggested that the VerifyNow P2Y12 assay could 
provide prognostic information in clopidogrel-treated patients undergoing PCI [Patti G et al, 
2008; Price MJ et al, 2008; Marcucci R et al, 2009]. 
Some authors reported good correlation between the VerifyNow P2Y12 assay and ADP-
induced platelet aggregation by LTA [Paniccia R et al, 2007; Malinin A et al, 2006]. However, 
more recent studies report poorer concordance. The dynamic range appears narrower than that 
of LTA; therefore, the assay may not be able to discriminate between very strong or between 
very weak levels of P2Y12 receptor inhibition [Jakubowski JA et al, 2008]. In addition, the 
percent inhibition reported by the device as a surrogate for the degree of P2Y12-mediated 
inhibition without a baseline pre-clopidogrel sample maybe inaccurate compared with the 
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Flow Cytomtery 
Although more labour intensive, flow cytometry is emerging as the new sensitive gold 
standard.  It requires only a small sample volume (around 2μL), is performed on the more 
physiological milieu of whole blood, and the minimal manipulation of samples prevents 
artifactual in vitro platelet activation and loss of sub-populations. Flow cytomtery can be used 
to assess a variety of platelet abnormalities and functions. With the use of fluorescent labelled 
anti-bodies platelet activation can be measured by detection of activation dependent molecules 
on the platelet surface (e.g P-selectin, GP IIb-IIIa), platelet surface bound proteins (such as 
fibrinogen), platelet-monocyte aggregates and pro-coagulant platelet-derived microparticles. In 
addition, with the exogenous addition of agonists, the reactivity of circulating platelets can also 
be determined.  
Disadvantages include the expensive equipment required and the complicated sample 
preparation. Ex vivo platelet activation can still occur, especially if there is a delay between 
blood draw and processing. Flow cytometry also only assesses circulating platelets. If activated 
platelets are rapidly cleared from the circulation or are adherent to blood vessel walls or 
extracorporeal circuits, artefactually low measurements are reported. However, it remains a 






2.3 FLOW CYTOMETRIC ASSESSMENT OF PLATELET ACTIVATION 
  
2.3.1 General principles of flow cytometry 
Flow cytometry utilises the principles of light scattering and light emission from fluorochrome 
molecules to provide rapid analysis of multiple characteristics of single cells (in the size range 
0.5μm to 40 μm). 
 
Physical properties, such as size (represented by forward angle light scatter) and internal 
complexity (represented by right-angle scatter) can resolve different cell populations. 
Additionally, antibodies conjugated to fluorescent dyes can bind specific proteins on cell 
membranes or inside cells. When labelled cells are passed by a light source, the fluorescent 
molecules are excited to a higher energy state. Upon returning to there resting states, the 
fluorochromes emit light energy at higher wavelengths. The use of multiple fluorochromes, 
each with similar excitation wavelengths but different emission wavelengths, allows several 
cell properties to be measured simultaneously. 
 
In the flow cytometer, cells in suspension are drawn into a stream created by a surrounding 
sheath of isotonic fluid that creates laminar flow, forcing the cells to pass individually through 
an interrogation point. At this point, a beam of monochromic light, usually from a laser, 
intersects the cells. Emitted light is given off in all directions and is collected via optics that 
direct the light to a series of filters and dichroic mirrors that isolate particular wavelength 
bands. The light signals are detected by photomultiplier tubes and are digitized for computer 




Hydrodynamic focusing in flow cytometry 
 
The different light signals are converted into electrical pulses, which are processed by a series 
of linear and log amplifiers. Logarithmic amplification is often used to measure fluorescence in 
cells. After the different pulses are amplified they are then processed by an analog to digital 
converter, which allows for events to be plotted on a graphical scale (one-parameter or two-
parameter histograms).  
 
A one-parameter histogram, is a graph of cell count on the y-axis and the measurement 
parameter (voltage generated at a certain wavelength) on the x-axis, Figure 2.2. A two-
parameter histogram is a graph representing two measurement parameters (e.g voltages 
generated at 2 wavelengths by 2 fluorochromes) on the x and y axes and cell count height on a 
density gradient. This is like a topographical map, Figure 2.3 [Givan AL et al, 1992; Brown M 












2.3.2 Sample preparation for flow cytometry  
Clinical studies that utilise washed platelets or platelet-rich plasma for flow cytometry, are, like 
other assays of platelet function, potentially susceptible to artifactual in vitro platelet activation 
as a result of the obligatory separation procedures. However, flow cytometry can be performed 
on whole blood and therefore improve the sensitivity of the technique [Shattil SJ et al, 1987]. 
The general stages of sample preparation for whole blood flow cytometry are depicted in 
Figure 2.4.  
 
Blood sampling 
The technique of blood drawing is important as it can result in artefactual in vitro activation of 
platelets. For this reason, in our studies, blood was drawn by venepuncture of a large 
anticubital vein using a 19-gauge needle. Care was taken to ensure a smooth blood draw 
without venous stasis, and avoid artefactual activation by turbulent flow through a cannula. 
Our centre has previously reported that our technique of sampling results in reproducible 
measurements in healthy volunteers [Harding S.A et al, 2007]. 
 
Anticoagulation 
If platelets are aggregated, the amount of antigen per platelet cannot be determined. Various 
measures to reduce platelet aggregation include smooth sample technique, reduced agitation of 
sample, prompt processing and anti-coagulation, dilution and fixation. The anticoagulant is 
often buffered sodium citrate, however, our centre has previously shown platelet-monocyte 
aggregation to be increased by heparin and reduced by sodium citrate and EDTA [Harding S.A, 
et al, 2007]. In our studies, samples for the assessment of in vivo platelet activation were 
collected into tubes containing the direct thrombin inhibitor, D-phenylalanyl-L-propyl-L-
arginine chloromethyl ketone (PPACK, Cambridge Biosciences). 
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Dilution 
The purpose of the dilution stage is to minimise the formation of platelet aggregates. This is 
important as flow cytometry measures the amount of fluorescence per individual particle, 
irrespective of whether the particle is a single platelet or an aggregate of an unknown number 
of platelets.  Further aggregation can be minimized by a smooth blood draw through a large 
gauge needle, avoidance of washing steps and avoidance of delays in procedure.  
 
Fixation 
Fixation is typically with 1% paraformaldehyde. The purpose of fixation is to prevent 
artifactual in vitro platelet activation. Once blood is drawn, in vitro platelet activation is time-
dependent, so a greater length of time until sample analysis can lead to an increase in measures 
of platelet activation [Michelson AD et al, 1996]. Fixation is therefore advantageous if there is 
no immediate access to a flow cytometer. Antibody labelling can be performed before or after 
fixation, however the binding of activation dependent antibodies to fixed platelets is often 
decreased in comparison to unfixed platelets [Michelson AD et al, 1996]. In our studies, all 
samples were processed immediately, with immunolabelling of whole blood within 5 min of 
collection and prior to fixation. 
 
Antibody labelling 
Different epitopes reflect different aspects of platelet activation. Therefore use of different 
labelled antibodies may distinguish specific activation profiles. Monoclonal antibodies are 
preferable to polyclonal antibodies in whole blood flow cytometry as they are more reliable at 
saturating all specific epitopes and result in less non-specific binding. Platelet-specific 
antibodies are available from several commercial sources already conjugated to fluorochromes 
such as fluorescein isothiocyanate (FITC) or phycoerythrin (PE). This eliminates the need for 
 48 
an additional conjugation step in sample preparation requiring additional antibodies, that may 
result in increased background fluorescence and decreased sensitivity.  
 
Platelets can be detected in whole blood by light scatter only (i.e identified by size and shape). 
However, sometimes, some particles falling within the light scatter gate for platelets may not 
bind any platelet-specific monoclonal antibody. Therefore a 2 colour/ 2 antibody technique can 
be used – one antibody to identify the platelet as a platelet and another to quantify the 
glycoprotein of interest. 
 
The saturating concentration of each antibody for platelet binding must also be determined. 
This is usually between 1 and 20 μg/mL. Increasing concentrations of antibody should be titred 
to establish the minimal concentration of antibody required to produce saturation of cell 
binding sites. This is done to optimize the separation of positive and negative cell populations. 
For many surface and intracellular markers, the positive peak will not be clearly distinct from 
the negative peak, so titrating antibodies can significantly improve this. If the antibody 
concentration is below saturation, this will appear as very dim staining at low antibody 
concentrations. 
 
In addition, control antibodies to examine non-specific binding can also be used. During 
staining, conjugated antibodies can bind to cells that would not specifically bind the antibody – 
i.e do not actually express the antigen of interest. In order to assess this level of background 
binding, isotype control antibodies of the same species class as the primary antibody and 
conjugated to the same fluorochrome, should be used. Ideally their specific saturation 
concentration should also be determined. The use of isotype controls can be used to set gates 
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2.4 FLOW CYTOMETRIC PROTOCOL  
 
We utilised the following stages in our flow cytometric assessment of platelet and monocyte 
activation markers 
 
Blood collection and anticoagulation 
Blood was drawn by venepuncture of a large anticubital vein using a 19-gauge needle. Care 
was taken to ensure a smooth blood draw without venous stasis, and avoid artefactual 
activation by turbulent flow through a cannula. Samples were all processed immediately.  
Blood samples for assessment of platelet-monocyte aggregates, platelet expression of P-
selectin and monocyte CD40 and 11b expression, were collected into tubes containing the 
direct thrombin inhibitor, D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone (PPACK, 
Cambridge Biosciences). Our centre has previously shown platelet-monocyte aggregation to be 
increased by heparin and reduced by sodium citrate and EDTA [Harding S.A et al, 2007]. Flow 
cytometric measurement of platelet microparticles was performed on platelet poor plasma 
(PPP). Blood was collected into 10 mL sodium citrate tubes and PPP prepared by 
centrifugation at 2000 g at 4
 0
C for 10 min and confirmed by a platelet count of <10
9
/L / 
(dilution with autologous plasma as required). Blood for the assay assessment of platelet 
microparticles and soluble P-selectin and CD40L was collected into tubes containing sodium 
citrate. 
 
Immunolabelling, fixation and flow cytometry 
Flow cytometric measurements of platelet-monocyte aggregation, platelet surface expression of 
P-selectin, and monocyte CD40 and 11b expression were performed as described previously 
[Sarma J et al, 2002; Harding SA et al, 2004].  
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Immunolabelling was performed in whole blood within 5 min of collection. Directly 
conjugated monoclonal antibodies were obtained from DakoCytomation (Cambridge, UK) and 
Serotec (Oxford, UK).  
 
In order to assess platelet-monocyte aggregates, 60 µL of blood were incubated for 15 min 
with a FITC-conjugated anti-CD42a monoclonal antibody (GRP-P, platelet marker) and a PE-
conjugated anti-CD14 monoclonal antibody (Tuk-4, monocyte marker) before fixation and 
erythrocyte lysis with 500 µL of FACSLyse solution. Samples were processed using a 
BeckmanCoulter flow cytometer and at least 2,500 cell events were analysed by EXPO32 
software. Platelet-monocyte aggregates were detected by gating for cells that were positive for 
both CD14 PE and CD42a FITC (Figure 2.5).  
 
Platelet surface expression of P-selectin was assessed by gating for cells that were positive for 
both FITC-conjugated anti-CD42a monoclonal antibody, (platelet marker), and PE conjugated 
anti-CD62P monoclonal antibody (TRAP 1, IgG1). Isotype controls were used to reduce error 




CD40 and CD11b on monocytes, blood was diluted 1:2 with PBS
 
and incubated 
with the following monoclonal antibodies: anti-CD14:FITC
 
(Serotec), anti-CD40:PE (Serotec), 
anti-CD11b:PE (Serotec) and
 










In this flow cytometric profile, whole peripheral blood has been analysed by light scatter 
properties, indicating cellular size and morphology, and showing a mixed leukocyte population 
(2.5a). By specifically staining for CD14, a surface marker of human monocytes, this distinct 
sub-population of leukocytes may be highlighted (2.5b). Further counter-staining using CD42a, 
a surface platelet marker (GP IX), allows us to distinguish those monocytes that have bound 
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2.5   ASSAYS OF INFLAMMATORY PROTEINS, TROPONIN AND 
        PLASMA PLATELET ACTIVATION MARKERS 
 
 
Highly Sensitive C-reactive Protein (hsCRP) 
Serum hsCRP concentrations were determined with a validated highly sensitive assay 
(Department of Clinical Biochemistry; Fife NHS Trust, UK) using the method of particle-
enhanced immunonephelometry (Behring BN II nephelometer, Dade Behring Inc). 
Nephelometry is based on the principle that a dilute suspension of small particles will scatter 
light (usually a laser) passed through it rather than simply absorbing it. The amount of scatter is 
determined by collecting the light at an angle (usually at 30 and 90 degrees). In dilute 
solutions, where absorption and reflection are minimal, the intensity of the scattered light is a 
function of the concentration of scattering particles, Figure 2.6. 
Antibody and the antigen are mixed in concentrations such that only small aggregates are 
formed that do not quickly settle to the bottom. The amount of light scatter is measured and 
compared to the amount of scatter from known mixtures. The amount of the unknown is then 
determined from a standard curve. 
In our assay (Dade Behring Inc), particles consisting of a polystyrene core and a hydrophilic 
shell were used in order to link anti-CRP antibodies covalently. A dilute solution of the test 
sample was mixed with latex particles coated with mouse monoclonal anti-CRP antibodies. 
CRP present in the test sample formed an antigen-antibody complex with the latex particles. 
Light scattering was measured by a nephelometer after 6 min, and was proportional to the 











The Dade Behring method is one of the most commonly used in the field of acute cardiac care, 
enabling detection of CRP concentrations at the micro-inflammatory range. This assay has a 
detection limit of 0.18mg/L. Intra-assay and inter-assay coefficients of variability for hsCRP 
were 3.7% and 4.2% respectively. All assays were performed in duplicate and the mean value 
taken. Whole blood samples for the measurement of hsCRP were collected into citrated tubes, 
centrifuged and plasma collected at each time point. The serum was frozen and stored until the 








Cardiac Troponin-I (cTnI) is a regulatory subunit of the troponin complex associated with the 
actin thin filament within muscle cells.1 cTnI, in conjunction with troponin-C and troponin-T, 
plays an integral role in the regulation of muscle contraction. These three distinct tissue 
specific isoforms of Troponin have been identified from skeletal and cardiac muscles. 
However, the cardiac isoform (cTnI) exhibits only 60% similarity with the skeletal muscle 
isoform. Clinical studies have demonstrated the release of cTnI into the blood stream within 
hours following myocardial infarction (MI) or ischemic damage. Elevated levels of cTnI 
(above the values established for non-MI specimens) are detectable in serum within 4 to 6 
hours after the onset of chest pain, reach peak concentrations in approximately 8 to 28 hours, 
and remain elevated for 3 to 10 days following MI. Cardiac troponin I is the preferred 
biomarker for the detection of myocardial injury based on improved sensitivity and superior 
tissue-specificity compared to other available biomarkers of necrosis, including CK-MB, 
myoglobin, lactate dehydrogenase, and others. 
 
The World Health Organization (WHO) criteria for defining myocardial infarction are the 
presence of two of the following three elements: ECG changes, serum cardiac enzyme changes, 
and prolonged chest pain. More recently, a Global Task Force with joint leadership among the 
European Society of Cardiology (ESC), the American College of Cardiology Foundation 
(ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF) 
refined past criteria with a universal definition of myocardial infarction that also supports use 
of cardiac Troponin I as a preferred biomarker for myocardial injury. This has nearly absolute 
myocardial tissue specificity as well as high clinical sensitivity, thereby reflecting even 
microscopic zones of myocardial necrosis. Their universal definition of myocardial infarction 
is a typical rise and gradual fall of cardiac biomarkers (preferably troponin) with at least one 
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value above the 99th percentile of the upper reference limit (URL) together with evidence of 
myocardial ischemia with at least one of the following: ischemic symptoms, pathological Q 
waves on electrocardiogram (ECG), ischemic ECG changes, or imaging evidence of new loss 
of viable myocardium or new regional wall motion abnormality.  
 
In our studies a blinded independent cardiologist reviewed all clinical data and applied the 
universal definition of myocardial infarction [ESC/ACC/WHF, 2007]. An increased value for 
cardiac troponin I is defined as a measurement exceeding the 99th percentile of a normal 
reference population (URL = upper reference limit). The above-mentioned discriminatory 
percentile is designated as the decision level for the diagnosis of myocardial infarction, and 
must be determined for each specific assay with appropriate quality control. Optimal precision 
[coefficient of variation (CV)] at the 99th percentile URL for each assay should be defined as 
<10%. To establish the diagnosis of myocardial infarction, one elevated value above the 
decision level is required.  
 
In our studies, the reference clinical biochemistry laboratory measured absolute plasma cardiac 
troponin I (cTnI) concentrations using the ARCHITECT Troponin I STAT assay (Abbott 
Diagnostics, Maidenhead, UK) using an autoanalyser. This is a sensitive cTnI assay, which has 
been shown to have a high diagnostic accuracy. 
 
This assay is a two-step immunoassay to determine the presence of cTnI in human serum and 
plasma. In the first step, sample, assay diluent and anti-troponin-I antibody-coated 
paramagnetic microparticles are combined. Cardiac Troponin-I present in the sample binds to 
the anti-troponin-I coated microparticles. After incubation and wash, anti-troponin-I 
acridinium-labeled conjugate is added in the second step. Following another incubation and 
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wash, pre-trigger and trigger solutions are then added to the reaction mixture. The resulting 
chemi-luminescent reaction is measured as relative light units (RLUs). A direct relationship 
exists between the amount of cTnI in the sample and the RLUs detected by the ARCHITECT 
i* System optics. The concentration of cTnI is read relative to a standard curve established with 
calibrators of known cTnI concentrations. Heterophilic antibodies in human serum can react 
with reagent immunoglobulins, causing anomalous values to be observed.  
 
This assay has an analytical sensitivity of 0.009 ng/mL and a functional sensitivity of 0.032 
ng/mL with a co-efficient of variation of <10%. This was the manufacturers guide, and was 
achieved by our host laboratory. The latter threshold was employed for the clinical case 
definition of myocardial infarction.  
Analytical sensitivity is defined as the concentration at two standard deviations above the 
ARCHITECT STAT Troponin-I Calibrator A (0.00 ng/mL, 0.00 μg/L) grand mean and 
represents the lowest concentration of troponin that can be distinguished from zero (i.e the 
limit of detection). The ARCHITECT STAT Cardiac Troponin-I assay analytical sensitivity is ≤ 
0.01 ng/mL (≤ 0.01 μg/L) at the 95% level of confidence. 
 
Whole blood samples for the measurement of cardiac Troponin I were collected into citrated 
tubes, centrifuged and plasma collected at each time point. The plasma was frozen and stored 
until the end of the trial when samples were processed en masse using the same assay. 






Soluble P-selectin and CD40L 
P-selectin is found in both platelets α-granules and on endothelial cells. P-selectin is not 
expressed on normal resting platelets. Platelet activation leads to a rapid release and surface 
expression of P-selectin. It then either remains attached to the platelet surface membrane or is 
released into the plasma. The majority of soluble P-selectin is thought to originate from platelet 
granules. Therefore increased plasma soluble P-selectin has been proposed as a marker of in 
vivo platelet activation. Elevated soluble P-selectin levels have been demonstrated in patients 
with stable, coronary disease [Atalar E et al, 2000] and in women who have subsequently 
developed cardiovascular events [Ridker PM et al, 2001]. However, although soluble P-
selectin determination in plasma can be performed easily by a standard ELISA method, 
variations in anti-coagulants (heparin, EDTA, sodium citrate in different concentrations) and 
pipetting and washing techniques can influence the outcome level. In addition, groups have 
reported a lack of agreement between soluble levels of P-selectin and platelet bound P-selectin 
[Gurbel PA et al, 2000]. 
In our studies we used a solid phase sandwich ELISA from R and D systems to detect human 
soluble P-selectin (CD62P) in plasma. This had a lower detection limit of 0.5ng/mL, an assay 
range of 0.82-45.94ng/mL and a mean intra-assay co-efficient of variation of 5% and a mean 
inter-assay co-efficient of variation of 10%. 
 
The soluble form of CD40 ligand (sCD40L) has emerged as a diagnostic and prognostic 
marker for cardiovascular events. Platelets are the main source of sCD40L, being responsible 
for >95% of circulating sCD40L levels [Heeschen C et al, 2003]. However, as platelets can 
shed CD40L upon activation, accurate measurement has proved challenging. Methodological 
issues regarding the measurement of circulating sCD40L levels in humans are thought to 
explain the variation in results in results between clinical studies. sCD40L concentrations are 
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much higher in serum than in plasma, because platelet CD40L is released during clotting [Ahn 
ER et al, 2004; Weber M et al. 2006]. Moreover, sCD40L increases during pre-analytical 
sample processing, suggesting that in vitro platelet activation may account for the release of 
sCD40L [Halldorsdottir AM et al, 2005]. 
We used a solid phase sandwich ELISA from BenderMed Systems, which detects human 
soluble CD40L in plasma. This has a lower detection limit of 10.1pg/mL; an assay range of 
62.5-4000pg/mL and a mean intra-assay co-efficient of variation of <8% and a mean inter-
assay co-efficient of variation of <10%. 
 
Whole blood samples for the measurement of soluble P-selectin and CD40L were collected 
into EDTA tubes, centrifuged and plasma collected at each time point. The plasma was frozen 





Quantification of PMPs is usually performed with flow cytometry. Flow cytometry requires 
fresh or fixed blood, and is unable to detect PMPs with a diameter less than 0.1 μm. Through 
collaboration with Michelsen AE et al at the Research Institute for Internal Medicine, Oslo, 
Norway we also sent frozen plasma samples to be assessed for platelet-microparticles utilizing 
their new time-resolved immunofluorometric assay. This quantifies the amount of PMP-located 
GPIIb antigen in detergent-treated platelet-free plasma (PPP) and has been shown to correlate 





2.5 ETHICAL CONSIDERATIONS 
 
 
Patients and subjects were recruited between June 2005 and February 2008, and gave written 
informed consent prior to study participation. All studies were undertaken in accordance with 
the regulations of the Lothian Research Ethics Committee (Eudract Number: 2005-000960-25, 
REC reference number: 05/S0501/41; Granted 29/04/05) and with the Declaration of Helsinki 
of the World Medical Association.  The prospective double-blind randomised controlled trial 
was given Clinical Trial Authorisation by the Medicines and Healthcare products Regulatory 
Agency (UK), CTA number: 11449/0002/001-0001 (Granted 05/04/05). The study was 
registered on the International Standard Randomised Controlled Trial Number Register. 




2.6 SAMPLE SIZE CALCULATION 
 
The primary end-point of our intervention study was platelet-monocyte aggregation. The 
sample size (n=50 per group) was based on our previous studies [Sarma J et al, 2002; Harding 
SA et al, 2004] and gave an 80% power of detecting an absolute difference of 4.8% in platelet-
monocyte aggregates at a significance level of 5%. Mechanistic studies of dual anti-platelet 
therapy in patients with acute coronary syndromes have shown relative reductions in platelet 
markers of around 30% with additional clopidogrel therapy [Xiao Z et al, 2004]. Clinically, in 
patients with non–ST elevation MI, additional clopidogrel therapy leads to a risk reduction of 
20% less adverse cardiovascular events [Fox KA et al, 2004]. Hence, there is evidence to 
suggest that even moderate reductions in platelet activation have clinical benefits.   
This sample size also gave an 80% power of detecting a 3.6% difference in CD40 expression 
on monocytes, 3.7% in CD40L expression on platelets, and 0.11 ng/mL in plasma sCD40L 
concentrations, at a significance level of 5%. Secondary outcomes included plasma troponin 
concentration, and bleeding complications. This study was not powered to examine clinical 




2.7 DATA AND STATISTICAL ANALYSIS 
 
The Bland Altman method was used to analyse the differences between paired measurements 
and to test the reproducibility of each measurement [Bland JM et al, 1986]. The co-efficient of 
reproducibility was calculated as 1.96 x the standard deviation of the differences between pairs 
of measurements in the same subjects. Correlation between variables was analysed using 
Pearson and Spearman’s correlation coefficients as appropriate. Continuous variables were 
reported as mean ± SD. Analysis of variance with repeated measures, two-tailed Student’s t-
test and Chi-squared analysis were performed as appropriate using GraphPad Prism Version 4 
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Many markers of platelet activation have been described but their reproducibility and 
comparability in patient populations are poorly defined. We sought to compare markers of 
platelet and monocyte activation with platelet-monocyte aggregates, a proposed gold standard 
of in vivo platelet activation, and assess their reproducibility in patients with peripheral arterial 
disease: a population with substantial platelet activation, inflammation and risk of thrombotic 
events.  
 
Thirty patients with peripheral vascular disease attended on two occasions to permit within-day 
and between-day comparisons. In vivo platelet and monocyte activation were determined by 
flow-cytometric quantification of platelet-monocyte aggregation, platelet surface expression of 
P-selectin and CD40L, platelet-derived microparticles, and monocyte surface expression of 
CD40 and CD11b. Plasma concentrations of platelet-derived microparticles, soluble P-selectin 
and CD40L were measured by enzyme-linked immunosorbant assays. 
 
Platelet-monocyte aggregation (36.7±7.86%), and platelet surface expression of P-selectin 
(5.8±1.65%) and CD40L (3.3±1.45%) demonstrated comparable within-day (mean 
difference±co-efficient of reproducibility; 0.9±15.4%, 0.21±1.65% and 0.2±2.8% respectively) 
and between-day reproducibility (2.0±12.4%, 0.10±2.25% and 0.9±6.4% respectively). 
Platelet-monocyte aggregates correlated well with other platelet (r=0.30-0.50, P<0.02) and 
monocyte (r=0.27-0.47, P<0.03) activation markers. Flow cytometric and assay quantified 
platelet-derived microparticles showed poorer reproducibility (co-efficient of reproducibility 
>40%).  
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In conclusion, in patients with peripheral arterial disease, measurements of platelet-monocyte 
aggregates have good reproducibility and consistently reflect other markers of platelet and 










3.2   Introduction 
 
Atherothrombosis is the leading cause of mortality in the western world. Platelets play a major 
role in the inflammatory and thrombotic progression of atherosclerosis [Freedman JE et al, 
2002, McGregor L et al, 2006]. Indeed, increased platelet activity is present in patients at 
increased risk of atherothrombotic events and predicts adverse cardiovascular events [Harding 
SA et al,  2004; Cassar K et al, 2003; Sarma J et al, 2002; Lee YJ et al, 1993; Bernal-Mizrachi 
L et al, 2003]. The measurement of platelet activity is therefore crucial to our understanding of 
the pathophysiology of atherothrombosis, the prediction of adverse cardiovascular events, and 
the development of novel therapeutic interventions.  
 
Despite the development of several techniques, there is still no generally accepted ideal 
measure of platelet activation. A variety of methods exist, including platelet aggregometry, 
point of care devices, flow cytometric assessment of platelet surface antigens, and plasma 
markers of platelet activation: all have advantages and disadvantages [Michelson AD, 2009]. 
Historically considered the gold standard, platelet aggregometry requires the preparation of 
platelet rich plasma and a high sample volume. Centrifugation and washing procedures may 
produce cell loss and artefactually activate platelets. Many of the point-of-care systems assess 
ex vivo platelet aggregation to various exogenous agonists. Although more labour intensive, 
flow cytometry is emerging as the new sensitive gold standard with measurement of surface 
expression of platelet antigens providing an assessment of in vivo platelet activation.  It 
requires only a small sample volume, is performed on whole blood, and allows analysis of 
platelets in their physiological milieu. One of the most commonly studied markers of platelet 
activation is the α-granule membrane protein, P-selectin, that is present only on the surface of 
activated degranulated platelets. However, in vivo degranulated platelets rapidly lose their 
surface P-selectin, but continue to circulate and function [Michelson AD, et al, 1996]. In 
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contrast, P-selectin-positive platelets very rapidly bind to leucocytes (mainly monocytes) via 
their constitutively expressed counter receptor, P-selectin glycoprotein ligand-1 (PSGL-1) 
[Sarma J et al, 2002]. Hence circulating platelet-monocyte aggregates provide a more sensitive 
measure of in vivo platelet activation [Michelson AD et al, 2001]. In addition platelet-
monocyte aggregation may alter leucocyte function, causing monocyte arrest on the 
endothelium and potentially enhance the growth of atherosclerotic plaques [Huo Y et al, 2003]. 
 
Many methods and protocols for the measurement of platelet activation have been described 
[Tocchetti EV et al, 2001; Perez-Pujol S, 2007; Li N et al, 1997; Hagberg IA et al, 2000; 
Barnard MR et al, 2003]. Importantly, aspects of the techniques themselves can lead to 
artefactual platelet activation, thus altering the end result. However, there are few reports of 
test reproducibility. Even when studying the same platelet marker, the methodology and end 
unit of measurement may differ, making it extremely difficult to interpret and compare results. 
An appreciation of these issues is crucial for the meaningful interpretation of interventional 
studies, and the development of anti-platelet therapies. 
 
In the present study we sought to assess the reproducibility of an established protocol [Harding 
SA et al, 2004; Sarma J et al, 2002] in measuring platelet-monocyte aggregation in a patient 
population expected to have elevated resting platelet activation. In addition, we wished to 
compare the reproducibility and correlation of other markers of platelet activation to a 







The study was performed with the approval of the local ethics committee, in accordance with 
the Declaration of Helsinki and the written informed consent of all participants. 
 
Subjects 
Peripheral venous blood was obtained from 30 patients with peripheral arterial disease. 
Inclusion criteria were (i) symptoms of claudication, without rest pain or ulceration, (ii) 




In order to assess reproducibility, four samples were taken from each subject – two were taken 
on the same day one hour apart (within-day reproducibility), and two were taken the following 
day at the same time points (between-day reproducibility).  
 
Platelet activation was assessed by measuring percent platelet-monocyte aggregation, platelet 
expression of P-selectin and platelet-derived microparticles using flow cytometry. Platelet-
derived microparticles, and plasma soluble P-selectin and CD40L concentrations were 
measured by enzyme-linked immunosorbant assays (ELISAs). Monocyte activation was 
measured via flow cytometric measurement of percent monocyte CD40 expression and mean 
fluorescent intensity of monocyte CD11b expression. 
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Blood Collection  
Blood was drawn by venepuncture of a large anticubital vein using a 19-gauge needle. Care 
was taken to ensure a smooth blood draw without venous stasis. Samples were processed 
immediately. Blood samples for assessment of platelet-monocyte aggregates, platelet 
expression of P-selectin and monocyte CD40 and 11b expression, were collected into tubes 
containing the direct thrombin inhibitor, D-phenylalanyl-L-propyl-L-arginine chloromethyl 
ketone (PPACK, Cambridge Biosciences). Flow cytometric measurement of platelet 
microparticles was performed on platelet poor plasma (PPP). Blood was collected into 10 mL 
sodium citrate tubes and PPP prepared by centrifugation at 2000 g at 4
 0
C for 10 min and 
confirmed by a platelet count of <10
9
/L / (dilution with autologous plasma as required). Blood 
for the assay assessment of platelet microparticles and soluble P-selectin and CD40L was 
collected into tubes containing sodium citrate. 
 
Immunolabelling and flow cytometry 
Flow cytometric measurements of platelet-monocyte aggregation, platelet surface expression of 
P-selectin, and monocyte CD40 and 11b expression were performed as described previously 
[Harding SA et al, 2004; Sarma J et al, 2002]. Immunolabelling was performed in whole blood 
within 5 min of collection. Directly conjugated monoclonal antibodies were obtained from 
DakoCytomation (Cambridge, UK) and Serotec (Oxford, UK). In order to assess platelet-
monocyte aggregates, 60 µL of blood were incubated for 15 min with a FITC-conjugated anti-
CD42a monoclonal antibody (GRP-P, platelet marker) and a PE-conjugated anti-CD14 
monoclonal antibody (Tuk-4, monocyte marker) before fixation and erythrocyte lysis with 500 
µL of FACSLyse solution (Sarma J et al, 2002). Samples were processed using a 
BeckmanCoulter flow cytometer and at least 2,500 cell events were analysed by EXPO32 
software. Platelet-monocyte aggregates were detected by gating for cells that were positive for 
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both CD14 PE and CD42a FITC. Platelet surface expression of P-selectin was assessed by 
gating for cells that were positive for both FITC-conjugated anti-CD42a monoclonal antibody 
(platelet marker) and PE conjugated anti-CD62P monoclonal antibody (TRAP 1, IgG1). 
Isotype controls were used to reduce error from non-specific binding. To evaluate
 
CD40 and 
CD11b on monocytes, blood was diluted 1:2 with PBS
 
and incubated with the following 
monoclonal antibodies: anti-CD14:FITC
 
(Serotec), anti-CD40:PE (Serotec), anti-CD11b:PE 
(Serotec) and
 
appropriate isotype-matched controls for 20 min. 
 
Platelet microparticles were identified by both size and expression of platelet markers CD41 
(GPIIb) and CD31 (GPIIa; PECAM). Aliquots (25 µL) of PPP were incubated for 30 min with 
a PE-conjugated anti-CD31 monoclonal antibody and a FITC-conjugated anti-CD41 
monoclonal antibody (Serotec, Oxford, UK), before dilution with phosphate buffered saline to 
form a volume of 1 mL. Platelet microparticles were gated according to their size (events < 1.0 
µm) by assessment of their forward light scatter. TruCOUNT beads of 1.0 µm (Becton 
Dickenson) of a known concentration were used to calculate the volume of sample analysed 
over 120 s at medium flow rate. This allowed the absolute number of platelet microparticles to 
be measured. Isotype controls were used to reduce error from non-specific binding. Platelet 
microparticles were detected by gating for events that were <1 μm in size (based on forward 




Platelet-derived microparticles  
Platelet-derived microparticles were assessed using a time-resolved immunofluorometric assay 
previously reported by Michelsen et al (Michelson AE et al, 2006). This method quantifies the 
amount of platelet-microparticle-located CD41 (GPIIb) antigen in detergent-treated platelet-
free plasma (μg/L). In brief, PPP is filtered to remove any platelet micro-particle larger than 
0.1 μm (Ultra-free-MC Filter Units, Millipore, Billerica, MA, USA). The GPIIb/GPIIIa 
complex (CD41/CD61) is then released from the microparticle membrane and solubilized by 
mixing 1 volume PPP and 1 volume Delfia Assay buffer containing 1% of the non-ionic 
detergent Igepal CA-630. Two different monoclonal antibodies to GPIIb (CD41) are used, one 
labelled with Europium (Diatec, Oslo, Norway), and the other conjugated with biotin (clone 
DD4.1, Southern Biotechnology, Birmingham, AL, USA). Samples (50 μL) of the solubilized 
GPIIb/IIIa were then added to a Delfia streptavidin-coated plate (Perkin-Elmer Life Sciences, 
Boston, MA, USA) and 150 μL of antibody mixture added. Following incubation for 2 hours at 
room temperature, the wells are washed and Delfia Enhancement solution (200 μL/well) added 
prior to measurement of time-resolved fluorescence in a Victor
2
1420 (Perkin-Elmer Life 
Sciences, Boston, MA,USA).  
 
Soluble plasma markers 
Soluble human P-selectin and CD40L were assessed using ELISAs from RnD systems and 




The Bland Altman method was used to analyse the differences between paired measurements 
and to test the reproducibility of each measurement (Bland JM et al, 1986). The co-efficient of 
reproducibility was calculated as 1.96 x the standard deviation of the differences between pairs 
of measurements in the same subjects. Statistical significance was assessed using a paired 
student’s t-test. Correlation between variables was analysed using Pearson and Spearman’s 
correlation coefficients as appropriate. The statistical package employed was GraphPad Prism, 





All 30 patients were male, aged 58±4 years and had a mean ankle-brachial pressure index of 
0.38±0.18. All patients were receiving maintenance aspirin (75-300 mg daily) and statin 




Repeated measurements were similar for all markers used (Table 3.1) P>0.05. Flow cytometric 
measurements of per cent platelet-monocyte aggregation, and platelet surface expression of P-
selectin and CD40L, showed good reproducibility (Table 3.1), with monocyte markers 
demonstrating a wider standard deviation (although statistically not significant). There was 
minimal difference when comparing within-day and between-day reproducibility although 
monocyte activation markers appeared to show better within-day reproducibility. Flow 
cytometric-derived measures of platelet-derived microparticles appeared to demonstrate better 
within-day and between-day reproducibility than immunoassay-derived measures, although 
both measurement techniques demonstrated poor co-efficients of reproducibility in comparison 
to the other markers. 
 
Correlation Between Platelet Markers 
Platelet-monocyte aggregates correlated with all activation markers suggesting that it 
represented a reliable measure of global activation (Table 3.2, Figure 3.1). Platelet surface 
expression of P-selectin showed the best correlation with platelet-monocyte aggregation (r = 
0.50) although platelet CD40L and platelet-derived microparticles also showed statistically 
significant correlations. Monocyte activation markers also correlated with platelet-monocyte 
aggregation (monocyte CD11b P=0.0002; monocyte CD40; P=0.0026) but not with other 
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markers of platelet activation (P>0.05), suggesting that monocyte activation may also 
determine platelet-monocyte aggregate formation. 
 
Immunoassay-derived measures of platelet activation, including plasma concentrations of 
soluble P-selectin and soluble CD40L, demonstrated poor or no correlations with flow 
cytometric-derived measures of platelet activation, except platelet-monocyte aggregates (Table 
3.3). Indeed, when assessing the same variable, platelet-derived microparticles or P-selectin, 










Within-day and between-day reproducibility of platelet activation markers. 
 
A. Within Day Reproducibility 
 






PMA (%) 36.7 0.9 7.86 15.4 0.53 
Platelet P-selectin (%) 5.8 0.21 1.65 3.2 0.56 
Platelet CD40L (%) 3.3 0.2 1.45 2.8 0.55 
PMP: Flow (no./μL) 157.2 8.1 42.4 83.1 0.81 
PMP: Assay (GPIIb/μg/L) 25.9 5.7 24.2 47.4 0.28 
Monocyte CD40 (%) 69.5 0.2 7.2 14.1 0.88 
Monocyte 11b (MFI) 47.4 3.7 11.9 11.4 0.16 
Soluble P-selectin (ng/mL) 42.3 1.2 16.8 32.9 0.74 
Soluble CD40L (ng/mL) 0.6 0.1 0.35 0.6 0.46 
 
B. Between Day Reproducibility 
Variable Mean Mean Difference SD of 
difference 




PMA (%) 37.3 2.0 6.35 12.4 0.08 
Platelet P-selectin (%) 5.9 0.1 1.15 2.25 0.81 
Platelet CD40L (%) 4.2 0.9 3.25 6.37 0.28 
PMP: Flow (no./μL) 161.9 7.2 39.9 78.2 0.43 
PMP: Assay (GPIIb/μg/L) 58.4 0.9 27.65 54.2 0.84 
Monocyte CD40 (%) 69.6 2.5 24.1 47.2 0.39 
Monocyte 11b (MFI) 49.9 0.8 11.45 22.4 0.68 
Soluble P-selectin (ng/mL) 41.7 5.0 19.3 37.8 0.08 
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Table 3.2  
 



















































Monocyte CD40 (%) 
 















Comparison of percent platelet-monocyte aggregation versus (A) per cent platelet P-selectin 
expression (r=0.50 , P<0.0001), (B) plasma soluble P-selectin concentrations (ng/mL; r=0.37, 
P=0.002) (C) immunoassay-derived measures of platelet microparticles (μg/L; r =0.44, 
P=0.0002), and (D) flow cytometric-derived measures of platelet microparticles (number/µL; 
r=0.27, P=0.028).  
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Table 3.3  
 






























































We have assessed the reproducibility and consistency of platelet activation markers in a patient 
population with high baseline levels of platelet activation. We have shown that most measures 
of platelet activation in patients with peripheral arterial disease have good reproducibility both 
within and between days. Platelet-monocyte aggregates appear to consistently reflect other 
markers of platelet and monocyte activation. We suggest that platelet-monocyte aggregates are 
reproducible and provide the best measure of in vivo platelet activation for clinical study.  
 
Several reports have demonstrated an association between increased platelet activation and 
adverse cardiovascular events [Harding SA et al, 2004; Cassar K et al, 2003; Sarma J et al, 
2002; Lee YJ et al, 1993; Bernal-Mizrachi L et al, 2003]. Proof-of-concept studies hypothesise 
that reductions in platelet activation by anti-platelet regimes should correlate with improved 
clinical outcomes. It is therefore useful to quantify the degree by which antiplatelet 
medications reduce platelet activation markers. However, clinically meaningful interpretation 
of these studies must account for the normal variation in marker levels that occur within patient 
populations and that associated with measurement techniques. A variety of methods are 
currently employed for the assessment of platelet activation and the reproducibility of 
techniques is poorly reported. Certain processing stages in the assessment of platelet activation 
markers can contribute to artefactual activation. Differences in technique make it difficult to 
compare results across studies, even when examining the same subject population. In addition, 
units of measurement often vary (e.g % platelet expression, versus mean fluorescent intensity). 
Therefore, for a given patient population, the range of platelet activation levels often varies 
widely between studies. If platelet activation markers are to be utilised in guiding 
 80 
interventional studies, readers must have a clear appreciation of the limits of the methological 
techniques, and how they compare against an accepted ‘gold standard’.  
 
In the present study, we utilised a two-colour whole blood technique incorporating erythrocyte 
lysis and fixation to quantify platelet-monocyte aggregates [Harding SA et al, 2004; Sarma J et 
al, 2002]. We have previously reported a number of methodological considerations in the 
preparation and processing of samples for flow-cytometric quantification of platelet-monocyte 
aggregates, and this technique has shown good reproducibility in healthy volunteers (co-
efficient of variation, 7.8%) [Blann AD et al, 2005]. We collected whole blood through direct 
venepuncture as opposed to via a cannula to avoid turbulent flow and increased activation. We 
chose to anticoagulate blood with a direct thrombin inhibitor as opposed to heparin or citrate as 
these compounds have been shown to increase and decrease aggregates respectively. We also 
chose not to stimulate samples with agonists ex vivo as we wanted to assess resting circulating 
in vivo levels.  
 
We appreciate that our procedures differed when it came to the detection of platelet 
microparticles (when platelet poor plasma had to be prepared from whole blood) and when 
assays were used instead of flow cytometry. It is inevitable that processing may differ with the 
detection of different markers, however, as long as the methodology is fully reported (with 
clarity over the stages known to affect outcomes e.g anti-coagulant agent) then the relationship 
between measurements can still be examined.  
Recently there has been increasing evidence to suggest that the role of platelets in 
atherosclerosis may be mediated by the production of microparticles [Lee WJ et al, 2006]. 
Platelet-derived microparticles (diameter <1 µm and bearing platelet-derived surface antigens) 
are involved in several stages of atherosclerosis from coagulation (tissue factor release; 
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inhibition of fibrinolysis) [Harding SA et al, 2007; Tan KT et al, 2005] to direct effects on the 
blood vessel wall (platelet adhesion) and angiogenesis [Leroyer AS et al, 2007; Muller I et al, 
2003]. In addition, increased platelet-derived microparticles have been demonstrated in 
individuals with a smoking habit, diabetes mellitus, cerebrovascular disease and acute coronary 
syndromesis [Lee YJ et al, 1993; Bernal-Mizrachi L et al, 2003]. A variety of methods have 
been proposed for the assessment of platelet-derived microparticles.  However, platelet 
microparticles are heterogeneous with respect to both size and composition, and can carry a 
range of antigenic markers from their parent platelet. We decided to compare flow cytometric 
and immunoassay based methods of quantification: both techniques identifying the same 
platelet antigen (CD41, GPIIb). The preparation of platelet poor plasma and use of counting 
beads is well validated and the assay has been reported as demonstrating good sensitivity for in 
vitro generated platelet microparticles [Michelson AE et al, 2006]. Although reproducibility 
was good for other markers, our measures of platelet microparticles were less consistent. This 
is likely to reflect several factors.  First, significant additional processing was required by these 
assays and this will inevitably increase variability. Second, the accuracy of flow cytometry is 
reduced when assessing particles <1 μm in size. Finally, our flow protocol identified 
microparticles that were positive for two platelet markers, CD41 (GPIIb) and CD31 (GPIIa, 
PECAM) whereas the immunoassay only identified microparticles positive for CD41 (GPIIb).  
 
Although platelet P-selectin and CD40L demonstrated good reproducibility (co-efficients<7), 
platelet monocyte aggregates showed the best global correlation with other markers. Platelet-
monocyte aggregates primarily form through the binding of P-selectin on the platelet surface to 
the leucocyte counter-receptor, P-selectin glycoprotein ligand-1 (PSGL-1), on monocytes. It is 
therefore not surprising that platelet expression of P-selectin shows good correlation with 
levels of platelet-monocyte aggregates. Platelet microparticles modulate monocyte interactions 
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with other cell types by increasing expression of adhesion molecules [Podor TJ et al, 2002; 
Salonen et al, 1989]. The correlatation between microparticles and platelet-monocyte 
aggregates could reflect this, although the relationship is less strong. It is interesting to note the 
lack of correlation between soluble P-selectin and platelet expression of the molecule ((r=0.05; 
P=0.69). This has been previously reported [Nomura S et al, 2001]. Dissociation between 
platelet expressed and soluble P-selectin suggests that the soluble form cannot serve as a 
surrogate marker of platelet activation. 
 
Inflammation plays a central role in the pathogenesis of atherosclerosis. Platelet-monocyte 
aggregation is not only a sensitive measure of platelet activation but also has important pro-
inflammatory consequences. Platelet-monocyte adhesion activates (NF)-κB; a transcriptional 
activator thought to be important in the regulation of CD40 gene expression (Kim HK et al, 
2004). The correlation between platelet-monocyte aggregates and CD40 expression on 
monocytes may reflect this process. Induction of nuclear factor (NF)-κB also stimulates 
expression of Mac-1 or CD11b/CD18 [Barry OP et al, 1998].  This could be reflected in the 
excellent correlation between monocyte CD11b expression and platelet-monocyte aggregation 
(Table 3). Subsequent activation of CD11b is associated with neutrophil recruitment to sites of 
inflammation. 
 
In conclusion, we have demonstrated that, in patients with peripheral arterial disease, our 
measurement of platelet and monocyte activation markers demonstrated good reproducibility. 
Platelet-monocyte aggregates consistently reflected other markers of platelet and monocyte 
activation and we propose them as a sensitive ‘gold standard’ of in vivo platelet activation. In 
contrast, measures of platelet-derived microparticles appeared less reproducible. We plan to 
employ these techniques in a study of different anti-platelet regimes in this patient population. 
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The co-efficients of reproducibility will allow us to interpret the true contribution of such drugs 
to reductions in platelet activation. With increasing interest in the manipulation of platelet and 
inflammatory mediators for therapeutic gain, an understanding of the reproducibility and 
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    4.1 Summary 
  
Patients with critical limb ischaemia (CLI) have a high rate of adverse cardiovascular 
events, particularly when undergoing surgery. We sought to determine the effect of surgery 
and vascular disease on platelet and monocyte activation in vivo in man. 
 
An observational, cross sectional study was performed at a tertiary referral hospital in the 
South East of Scotland. Platelet and monocyte activation were measured in whole blood, in 
patients with CLI scheduled for infra-inguinal bypass/amputation and compared with 
matched healthy controls, patients with chronic intermittent claudication, patients with acute 
myocardial infarction and those undergoing arthroplasty (n=30 per group). Platelet and 
monocyte activation were quantified using flow cytometric assessment of platelet-monocyte 
aggregation, platelet P-selectin expression, platelet-derived microparticles, and monocyte 
CD40 and CD11b expression respectively. 
 
In comparison to those with intermittent claudication, patients with CLI had increased 
platelet-monocyte aggregates (41.7±12.2% versus 32.6±8.5% respectively), platelet 
microparticles (178.7±106.9 versus 116.9±53.4) and monocyte CD40 expression 
(70.0±12.2% versus 52.4±15.2%) (P<0.001 for all). Indeed, these levels were equivalent (P-
selectin, 4.4±2.0 versus 4.9±2.2%; P>.05) or higher (platelet-monocyte aggregation, 
41.7±12.2 versus 33.6±7.0%; P<0.05: platelet microparticles, 178.7±106.9 versus 
114.4±55.0 /µL; P<.05) than patients with acute myocardial infarction. All platelet and 
monocyte activation markers remained elevated throughout the peri-operative period in 
patients with CLI (P<.01) but not those undergoing arthroplasty. 
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Patients undergoing surgery for CLI have the highest level of in vivo platelet and monocyte 
activation and these persist throughout the peri-operative period.  Additional anti-platelet 
therapy may be of benefit in protecting vascular patients with more severe disease during this 








Patients with peripheral arterial disease (PAD) are at increased risk of adverse cardiovascular 
events
 
[Criqui MH et al, 1992]. This risk increases with the severity of disease, with 
progressive reductions in ankle brachial pressure index being an independent predictor of 
cardiovascular outcome
 
[Lee AJ et al, 2004; O’Hare AM et al, 2004]. Cardiovascular risk 
factor management is therefore the first line treatment of patients with PAD. These patients are 
particularly at risk during the peri-operative period. Myocardial infarction is the commonest 
life-threatening complication of major vascular surgery with a reported peri-operative 
incidence ranging from 8 to 40% depending on the diagnostic criteria
 
[Hobbs SD et al, 2005; 
Kim LJ et al, 2002; Landesburg G et al, 2003]. This is comparable to the cardiovascular risk 
seen in patients with acute coronary syndromes (ACS): 30-day death and re-infarction rate of 
8-20% [Bertrand ME et al, 2002]. Despite this, patients with PAD often fail to receive 
evidence-based medical therapies. There is clearly an unmet need for improved risk-
stratification of these patients with appropriately tailored intensive medical regimes. 
 
Atherogenesis and its complications are complex processes involving both inflammatory and 
thrombotic mechanisms [Freedman JE et al, 2002; Urbich et al, 2004; Rizvi et al, 2008]. 
Monocyte adhesion to a damaged endothelium is a central step in the initiation and progression 
of atherosclerosis and appears to play a key role in plaque destabilisation. In contrast, platelets 
can adhere to atherosclerotic lesions in the presence or absence of an overlying endothelium 
[Freedman JE et al, 2002] and contribute to thrombus formation that is responsible for acute 
cardiovascular events. Hence, both platelet and monocyte activation, pre-dispose to plaque 
growth, instability, and rupture. Platelets and monocytes also directly interact to form platelet-
monocyte aggregates that promote expression of vascular cell adhesion molecules, and increase 
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leucocyte adhesion to the inflamed endothelium [Neuman F et al, 1997]. In addition, the CD40 
/CD40 ligand dyad (expressed on the surface of activated monocytes and platelets) is a major 
inflammatory trigger, promoting release of inflammatory cytokines, adhesion molecules and 
procoagulant activity [Schonbeck U et al, 2001]. Disruption of either CD40/CD40L or platelet-
monocyte aggregation, leads to the retardation of atherosclerotic lesions in animal studies 
[Mach F et al, 1998;  Huo Y et al, 2003]. 
 
Raised levels of platelet-monocyte aggregates and monocyte CD40 have been detected in 
smokers, patients with diabetes mellitus, acute coronary syndromes, and those at risk of re-
thrombosis following PCI [Harding SA et al, 2004; Sarma J et al, 2002; Gurbel PA et al, 
2005]. They are surrogate markers of clinical risk and are predictive of adverse cardiac events. 
Several studies have assessed platelet activation in peripheral atherosclersosis and 
demonstrated a progressive increase in activation with increasing severity of disease [Cassar K 
et al, 2003; Robless PA et al, 2003; Rajagopalan S et al, 2007]. However, there have been 
relatively few reports of platelet activation and cellular inflammation at the time of operation
 
 
[Payne AD et al, 2004; Cassar K et al, 2005; Rajagopalan S et al, 2007], and none comparing 
PAD patients with other high risk populations.  
 
We wished to investigate platelet and monocyte activation in patients with PAD specifically at 
the time of surgery and compare this to levels of activation in other high-risk populations. The 
high incidence of peri-operative adverse cardiovascular events in patients with severe PAD 
could be mediated by increased systemic inflammation and platelet activation. These patients 
may potentially benefit from risk-stratification and appropriately tailored medical regimes, as 
occurs in patients with coronary atherosclerotic disease. This exploratory study may support 
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the conduct of interventional projects aimed at reducing surrogate markers of clinical risk, prior 
to clinical trials of intensive anti-platelet and anti-inflammatory strategies.  
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4.3 Methods 
This observational, cross-sectional study was performed with the approval of the local ethics 




Subjects were recruited from 5 different groups (n=30 per group): (i) patients with non-
thromboembolic critical limb ischaemia, (ii) patients with chronic intermittent claudication, 
(iii) patients with a non-ST segment elevation myocardial infarction, (iv) otherwise healthy 
patients undergoing hip or knee arthroplasty, and (v) healthy volunteers. (Table 4.1 Inclusion 
and exclusion criteria). 
 
Patients with critical limb ischaemia (CLI), defined by the presence of rest pain and/or skin 
ulceration and a reduced ankle brachial pressure index (ABPI), who were scheduled to undergo 
infra-inguinal bypass or amputation were recruited from the surgical vascular unit. Patients 
who had symptoms of intermittent claudication with a reduced ABPI, were recruited from the 
out-patient claudication clinic. All 60 patients with peripheral arterial disease were receiving 
maintenance aspirin (75 mg daily) and statin therapy for at least 6 weeks prior to inclusion. We 
wished to examine platelet activation under the standard medical regime, therefore patients 
receiving clopidogrel or warfarin were excluded. (At present, the only evidence-based 
indication for dual anti-platelet therapy in PAD is co-existing history of recent (< 6months) 
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Patients presenting to the coronary care unit and diagnosed with a non-ST elevation myocardial 
infarction (chest pain with electrocardiographic (ECG) changes and elevated plasma troponin I 
concentration (>0.2 μg/L)) were recruited.  
We wished to examine the contribution of surgical stress (without underlying PAD) to in vivo 
platelet activation. Following discussion with a panel of consultant vascular surgeons and 
anaesthetists it was felt knee or hip arthroplasty represented surgery of a similar magnitude to 
peripheral bypass or amputation, and was likely to be performed in patients of a comparable 
age. Patients undergoing elective arthroplasty over the age of 50 were approached. In order to 
limit the effect of atherosclerosis on platelet activation, patients with a history of diabetes, 
hypertension, ischaemic heart disease or stroke, smoking or anti-platelet, anti-hypertensive or 
statin use, were excluded. Patients undergoing arthroplasty did not receive peri-operative 
heparin according to the unit policy.  
Sequential healthy subjects over the age of 50 were recruited.  
 
Blood Sampling 
Single baseline samples were taken from all 150 subjects. In patients with non-ST segment 
elevation myocardial infarction, samples were taken within 24 hours of hospitalisation and 
after the initiation of dual anti-platelet medication with aspirin and clopidogrel. In order to 
compare peri-operative platelet and monocyte activation, three blood samples were taken from 
subjects undergoing vascular or orthopaedic surgery: pre-operatively, immediately post-
operatively and on the day after the operation. 
 
Blood was drawn by venepuncture of a large anticubital vein using a 19-gauge needle. Care 
was taken to ensure a smooth blood draw without venous stasis. Samples were processed 
immediately. Blood for assessment of platelet-monocyte aggregates, platelet expression of P-
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selectin, and monocyte CD40 and CD11b, was collected into tubes containing the direct 
thrombin inhibitor, D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone (PPACK, 
Cambridge Biosciences). Blood for the assessment of platelet microparticles was collected into 
sodium citrate. Platelet poor plasma (PPP) was then prepared by centrifugation at 2000 g at 4
 
0





Assessment of in vivo platelet activation  
Flow cytometric measurements of platelet-monocyte aggregates and platelet surface expression 
of P-selectin were performed as described previously [Harding SA et al, 2004] 
Immunolabelling was performed in whole blood within 5 min of collection. Directly 
conjugated monoclonal antibodies, were obtained from DakoCytomation (Cambridge, UK) and 
Serotec (Oxford, UK). In order to assess platelet-monocyte aggregates, 60 µL of blood were 
incubated for 15 min with a FITC-conjugated anti-CD42a monoclonal antibody (GRP-P, 
platelet marker) and a PE-conjugated anti-CD14 monoclonal antibody (Tuk-4, monocyte 
marker) before fixation and erythrocyte lysis with 500 µL of FACSLyse solution (Sarma J et 
al,2002). Samples were processed using a BeckmanCoulter flow cytometer and at least 2,500 
cell events were analysed by EXPO32 software. Platelet-monocyte aggregates were detected 
by gating for cells that were positive for both CD14 PE and CD42a FITC. Platelet surface 
expression of P-selectin was assessed by gating for cells that were positive for both FITC-
conjugated anti-CD42a monoclonal antibody, (platelet marker) and PE conjugated anti-CD62P 
monoclonal antibody (TRAP 1, IgG1). Isotype controls were used to reduce error from non-
specific binding. 
 
Platelet microparticles were identified by both size and expression of platelet markers CD41 
(GPIIb) and CD31 (GPIIIa; PECAM). Aliquots (25 µL) of PPP were incubated for 30 min with 
a PE-conjugated anti-CD31 monoclonal antibody and a FITC-conjugated anti-CD41 
monoclonal antibody (Serotec, Oxford, UK), before dilution with phosphate buffered saline to 
form a volume of 1 mL. Platelet microparticles were gated according to their size (events <1.0 
µm) by assessment of their forward light scatter. TruCOUNT beads of 1.0 µm (Becton 
Dickenson) of a known concentration were used to calculate the volume of sample analysed 
over 120 s at medium flow rate. This allowed the absolute number of platelet microparticles to 
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be measured. Isotype controls were used to reduce error from non-specific binding. Platelet 
microparticles were detected by gating for events that were <1 µm in size (based on forward 
scatter) and positive for both CD31 and CD41.  
 
Assessment of in vivo monocyte activation  
Monocyte activation was assessed via flow cytometric measurement of per cent monocyte 
CD40 expression and mean fluorescent intensity (MFI) of monocyte CD11b expression, as 
described previously (Harding SA et al, 2004). Immunolabelling was performed in whole 
blood within 5 min of collection. To evaluate
 
CD40 and CD11b on monocytes, blood was 
diluted 1:2 with PBS
 
and incubated with the following monoclonal antibodies: anti-CD14: 
FITC
 
(Serotec), anti-CD40:PE (Serotec), anti-CD11b:PE (Serotec) and
 
appropriate isotype-
matched controls for 20 min, before fixation and erythrocyte lysis with 500 µL of FACSLyse 
solution. Monocytes were identified by gating for CD14-positive cells. 
 
Statistical analysis 
Data are shown as scatter plots or mean±SD. Data were analysed by analysis of variance, chi-
squared and Bonferroni post-hoc tests where appropriate using GraphPad Prism Version 4 (La 
Jolla, USA). Statistical significance was taken as a two-sided P value <0.05.  
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4.4 Results 
Subjects were predominantly middle-aged men, with groups having similar distribution of ages 
and no significant difference in mean age (Table 4.2). In keeping with their clinical 
presentation, patients with peripheral arterial and coronary heart disease had a range of 
cardiovascular risk factors and medications that were not present in the healthy volunteers or 
patients undergoing orthopaedic surgery (Table 4.2). Of the 30 patients with CLI, 18 
underwent femoral-popliteal bypass and 12 underwent below knee amputations. We 
deliberately chose not to recruit patients with CLI undergoing angioplasty. We specifically 
wanted to assess platelet activation peri-operatively where the changes in such variables could 
be assumed to be greater than when undergoing a less invasive endovascular procedure. 
























Mean age  59+3 60+4 68±2 58+2 57+4 
Male Sex  16 (53%) 22 (73%) 23 (77%) 20 (67%) 17 (57%) 
CV RISK FACTORS 
n (%) 
         
Hypertension 0 18 (60%) 24 (80%) 20 (67%) 0 
Diabetes 0 7 (23%) 10 (33%) 8 (27%) 0 
CAD 0 10 (33%) 16 (53%) 13 (43%) 0 
Current smoker 0 17 (57%) 16 (53%) 16 (53%) 0 
MEDICATIONS 
n (%) 
          
Aspirin 0 30 (100%) 30 (100%) 30 (100%) 0 
Clopidogrel 0 0 0 30 (100%) 0 
Statin therapy 0 30 (100%) 30 (100%) 24 (80%) 0 
ACE inhibitor 0 3 (10%) 12 (40%) 21 (70%) 0 
B-blocker 0 2 (6.7%) 6 (20%) 16 (53%) 0 
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Baseline Platelet Activation 
Platelet activation markers were lowest in healthy volunteers and patients scheduled for 
arthroplasty (Figure 4.1). Baseline platelet-monocyte aggregation (41.7±12.2%) and platelet 
microparticles (178.7±106.9) were highest in patients with CLI compared to all other groups 
(Figure 4.1). Although patients with CLI had higher values of platelet P-selectin than healthy 
volunteers or those undergoing arthoplasty (P<0.001), there was no demonstrable difference 
between these patients and those with claudication or non-ST elevation myocardial infarction 
(4.4+2.0% versus 4.2+2.0% and 4.9+2.2% respectively; P>0.05; Figure 4.1). 
 
Baseline Monocyte Activation  
Monocyte activation markers were lowest in healthy volunteers and patients scheduled for 
arthroplasty (Figure 4.2). Baseline monocyte expression of CD40 (70±12.2%) was highest in 
patients with CLI compared to all other groups (Figure 4.2). Baseline monocyte CD11b was 
greatest in patients with CLI compared to all groups except those with claudication, where it 
was equivalent (56.6±18.3 versus 50.5±13.9 respectively, P>0.05; Figure 4.2) 
 
Peri-operative Platelet and Monocyte activation 
Throughout the peri-operative period, levels of all platelet and monocyte markers remained 
greater in patients with CLI in comparison to those undergoing arthroplasty (Figures 4.3 and 
4.4; P<0.0001) Platelet and monocyte activation rose immediately post-operatively in patients 
undergoing joint arthroplasty (P<0.05) before falling on the first post-operative day (Figures 
4.3 and 4.4). In contrast, platelet activation fell immediately after surgery in patients 
undergoing infra-inguinal revascularisation or amputation (P<0.05; Figure 4.3) whereas 
monocyte activation either remained unchanged (monocyte CD40, P>0.05) or rose on day one 
(monocyte CD11b, P<0.05; Figure 4.4).  
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There was no statistically significant difference in markers according to type of surgery 
performed for CLI (bypass or amputation), and no difference in post-operative trend (sub-
analysis not shown). 
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Figure 4.1 Resting in vivo platelet activation in different subject populations  
 
 
Scatter dot plots of A. % Platelet-monocyte aggregation B. % Platelet P-selectin expression C. 
Platelet-derived microparticles (/mL). ■ Healthy volunteers, ∆ Claudicants ▼ Patients with 
Critical Limb Ischaemia (CLI) ♦ Patients with Non-ST Elevation Myocardial Infarction 
(NSTEMI) ● Patients undergoing arthroplasty. (n=30 per group), Horizontal lines represent 
population means. Analysis by one-way ANOVA with Bonferroni post-tests 
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Scatter dot plots of A. % Monocyte CD40 expression B. Monocyte CD11b (Mean Fluorescent 
Intensity, MFI). ■ Healthy volunteers, ∆ Claudicants ▼ Patients with Critical Limb Ischaemia 
(CLI) ♦ Patients with Non-ST Elevation Myocardial Infarction (NSTEMI) ● Patients 
undergoing arthroplasty.  (n=30 per group) . Horizontal lines represent population means.  
Analysis by one-way ANOVA with Bonferroni post-tests 
  






































































Figure 4.3 Peri-operative platelet activation in patients undergoing surgery for  
                  CLI (▼) and arthroplasty (●) 
 
 
Platelet activation in patients undergoing infra-inguinal bypass or amputation was greater than in 
patients undergoing arthroplasty throughout the peri-operative period (P<0.0001).  In vivo platelet 
activation A. % Platelet-monocyte aggregation (P<0.05) and B. % P-selectin expression (P<0.05), rose 
immediately post-operatively in patients undergoing arthroplasty but fell in those with critical limb 
ischaemia (P<0.001).  
Mean+SD; analysis between patient groups by 2-way ANOVA with repeated measures; analysis 
between tme points for the same patient group by one way ANOVA with Bonferroni post-tests. 
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Figure 4.4 Peri-operative monocyte activation in patients undergoing surgery for  
                  CLI (▼) and arthroplasty (●) 
 
 
Monocyte activation in patients undergoing infra-inguinal bypass or amputation was 
significantly greater than in patients undergoing arthroplasty throughout the whole peri-
operative period (P<0.0001).  A. % Monocyte CD40 expression tended to rise immediately 
post-operatively in orthopaedic patients before returning to baseline (P<0.05) B. There was no 
significant post-operative change in monocyte CD11b (MFI) in arthroplasty patients (P>0.05), 
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4.5 Discussion 
Consistent with previous studies [Cassar K et al, 2003; Robless PA et al, 2003; Rajagopalan S 
et al, 2007], we have demonstrated that platelet and monocyte activation is increased in 
patients with PAD. For the first time, we have shown that patients undergoing surgery for CLI 
have even greater levels of platelet and monocyte activation than patients being treated for 
acute myocardial infarction. In addition, peri-operative platelet and monocyte activation is 
markedly increased in these patients and exceeds the increase in platelet activation and 
inflammation, attributable to surgery itself. This study supports the need for an increased 
appreciation of the cardiovascular risk associated with this group of patients and an 
improvement in cardioprotective management, especially in the peri-operative period. 
 
Peripheral arterial disease affects nearly 30 million people in Western Europe and North 
America. In up to three-quarters of cases, patients have co-existent coronary artery disease and 
a 3-fold increased risk of cardiovascular events and death [Sukhija R et al, 2004]. In spite of 
attempts to raise awareness of peripheral arterial disease as an important marker of 
cardiovascular risk, patients are often poorly provided with evidence-based therapies such as 
anti-platelet and lipid lowering therapies [Cassar K et al, 2003; Burns P et al, 2003; Hirsch AT 
et al, 2001; Khan S et al, 2007].  The reasons for this are unclear, but appear to be related to a 
lack of awareness amongst health professionals of the severity of the disease.  
 
Our study demonstrated that patients with critical limb ischaemia have a greater elevation in 
systemic markers of platelet and monocyte activation than comparator groups. We 
acknowledge that the healthy volunteer subjects and patients undergoing arthroplasty did not 
receive anti-platelet agents or lipid lowering drugs which can affect platelet activation. 
However, patients with PAD have a high incidence of adverse cardiovascular events despite 
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existing medical therapy. Indeed, the elevations in platelet activation were seen despite the 
standard medical regime of aspirin and statin therapy and were even greater than those seen in 
patients with acute myocardial infarction. It may be that there is scope for further management 
of platelet activation in these patients.  
 
Patients undergoing peripheral vascular surgery have a particularly high incidence of peri-
operative cardiovascular events. It has been postulated that this is attributable to increased 
platelet and monocyte activity caused by the surgical process itself. Patients without 
cardiovascular risk factors undergoing arthroplasty (and therefore no reason for elevated 
baseline platelet activation) were recruited in order to assess the effect of surgery alone on 
platelet activation. In our study, throughout the peri-operative period, both platelet and 
monocyte activation markers were higher in patients undergoing vascular surgery compared to 
those undergoing arthroplasty. However, although patients undergoing arthroplasty sustained a 
post-operative rise in platelet markers, we were surprised to see that platelet activation fell 
immediately following surgery in those with CLI. Patients with PAD, especially CLI, have 
high baseline levels of activated platelets and monocytes. This is due to the underlying 
endothelial dysfunction and tissue ischaemia. We therefore propose that the lack of response 
following surgery in this particular group of patients could be due to the removal of thrombotic 
stimulus by amputation or revascularisation. These patients may benefit from increased platelet 
inhibition prior to surgery. 
 
Cardiovascular disease is a critical public health issue. The prevalence of the disease and 
increased awareness of the cost-benefit associated with the management of cardiovascular risk, 
have led to the concept of potential screening programmes for vascular disease [Belch JJ et al, 
2003]. In addition, recommendations are required for the most appropriate use of interventions 
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and therapies for patients with different manifestations of peripheral arterial disease. The use of 
imaging technologies or biomarkers could help risk-stratify patients and guide management. 
This study demonstrates that sensitive markers of in vivo platelet and monocyte activation – 
known to be predictors of clinical risk – are markedly elevated in patients with severe 
peripheral arterial disease at the time of surgery, despite current medical therapy. This is in line 
with reports of the increased cardiovascular risk associated with reducing ankle brachial 
pressure index [Criqui MH et al, 1992]. However, further work is required to demonstrate the 
link between platelet activation and adverse cardiovascular outcomes in this specific patient 
group.  We are therefore conducting a trial of dual anti-platelet therapy (aspirin plus 
clopidogrel) versus aspirin alone, in patients undergoing surgery for CLI. The impact of 
intensive anti-platelet therapy on platelet markers and cardiac troponin and hsCRP will be 
noted. This may inform the design of larger scale clinical trials powered at examining clinical 
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Patients with critical limb ischaemia have a peri-operative cardiovascular morbidity 
comparable to patients with acute coronary syndromes. We hypothesised that peri-operative 
dual anti-platelet therapy would improve biomarkers of atherothrombosis without causing 
unacceptable bleeding in patients undergoing surgery for critical limb ischaemia. 
 
In a double-blind randomised controlled trial, 108 patients undergoing infra-inguinal 
revascularisation or amputation for critical limb ischaemia were maintained on aspirin (75 mg 
daily) and randomised to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; 
n=50) or matched placebo (n=58). Platelet activation and myocardial injury were assessed by 
flow-cytometry and plasma troponin concentrations respectively.  
 
Clopidogrel reduced platelet-monocyte aggregation before surgery (38% to 30%; P=0.007). 
This was sustained in the post-operative period (P=0.0019). There were 18 troponin-positive 
events (8 (16.0%) clopidogrel versus 10 (17.2%) placebo; RR 0.93, 95% CI 0.39 to 2.17; 
P=0.86). Half of troponin-positive events occurred pre-operatively with clopidogrel causing a 
greater decline in troponin concentrations (P<0.001). There was no increase in major life-
threatening bleeding (7 (14%) versus 6 (10%); RR 1.4, 95% CI 0.49 to 3.76; P=0.56) or minor 
bleeding (17 (34%) versus 12 (21%); RR 1.64, 95% CI 0.87 to 3.1; P=0.12), although blood 
transfusions were increased (28% versus 12.6%, RR 2.3 95% CI 1.0 to 5.29; P=0.037).  
 
In patients with critical limb ischaemia, peri-operative dual anti-platelet therapy reduces 
biomarkers of atherothrombosis without causing unacceptable bleeding. Large-scale 
randomised controlled trials are needed to establish whether dual anti-platelet therapy improves 
clinical outcome in high-risk patients undergoing vascular surgery. 
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5.2 Introduction 
Patients with peripheral arterial disease have an increased risk of adverse cardiovascular events 
[Criqui MH et al, 1992], particularly in the peri-operative period [Mangano DT et al, 1991]. 
Myocardial injury is the commonest life-threatening complication of vascular surgery with a 
reported incidence ranging from 8-40% [Hobbs SD et al, 2005; Kim LJ et al, 2002; 
Landesburg G et al, 2003]. This is comparable to the cardiovascular risk of patients presenting 
with an acute coronary syndrome: 30-day death and re-infarction rate of 8-20% [Bertrand et al, 
2002]. 
 
In patients with peripheral arterial disease, prophylactic use of the thienopyridine clopidogrel 
has modest additional secondary preventative benefits in comparison to [CAPRIE, 1996], or in 
combination with [Bhatt DL et al, 2006], aspirin. Combination aspirin and clopidigrel therapy 
is of major benefit in reducing recurrent ischaemic events in patients with acute coronary 
syndromes [CURE Trial, 2001]. It is therefore reasonable to postulate that dual anti-platelet 
therapy may have particular benefits in patients undergoing vascular surgery. However, many 
clinicians would question the wisdom of dual anti-platelet therapy in the operative setting 
because of the risk of increased peri-operative bleeding. The CURE trial (Clopidogrel in 
Unstable angina to prevent Recurrent ischaemic Events) reported an overall relative risk 
reduction in cardiovascular death, myocardial infarction or stroke in patients undergoing 
coronary artery bypass grafting (CABG) following non-ST segment elevation myocardial 
infarction, without an increase in major life-threatening bleeding [Fox KA et al, 2004]. 
However, the surgical sub-group was not prospectively randomised and only a small 
proportion of patients received dual anti-platelet therapy within 5 days of operation. Despite 
these limitations, the trial proposed that the potential cardiovascular benefits of dual anti-
platelet therapy may outweigh the risks of bleeding in the high-risk surgical patient. 
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Atherothrombosis is the major underlying cause of adverse cardiovascular events.  Platelets 
play a key role in this process and are associated with both the inflammatory destabilisation of 
atherosclerotic plaques, and thrombus generation [Freedman JE et al, 2002; McGregor L et al, 
2006]. Platelet activation is commonly assessed using aggregometry or detection of platelet 
surface P-selectin expression following ex vivo agonist stimulation. These approaches are 
artificial and may not truly reflect the status of in vivo platelet activation because of the 
potential for in vitro activation, and the rapid shedding of P-selectin from the platelet surface 
[Michelson AD et al, 1996]. Activated platelets are rapidly cleared from the circulation by 
monocytes and the quantification of platelet-monocyte aggregates is now emerging as the ’gold 
standard’ assessment for in vivo platelet activation [Huo Y et al, 2003; Michelson et al, 2001]. 
We and others have demonstrated that platelet-monocyte aggregates are increased in those who 
smoke or have diabetes mellitus as well as in patients with peripheral arterial disease or an 
acute coronary syndrome [Harding SA et al, 2004; Cassar K et al, 2003; Samar J et al, 2002]. 
 
To date, there have been no studies to investigate the effects of dual anti-platelet therapy in 
patients undergoing surgery for critical limb ischaemia. Given the potential for both marked 
benefit and hazard, we embarked upon a proof-of-concept pilot randomised controlled trial. We 
hypothesised that combined peri-operative aspirin and clopidogrel therapy would improve 
biomarkers of atherothrombosis (platelet-monocyte aggregates and troponin release) without 






Patients with critical limb ischaemia who were scheduled for infra-inguinal bypass, femoral 
endarterectomy or lower limb amputation under general anaesthesia were recruited into the 
study. Critical limb ischaemia was defined as the presence of rest pain or skin breakdown, 
resulting from arterial disease. Exclusion criteria included women of child bearing potential, 
non-atherosclerotic vascular disease, sudden acute limb ischaemia requiring emergency 
surgery, supra-inguinal or aortic surgery, history of acute coronary syndrome within 3 months, 
history of peptic ulcer disease, previous or current intracranial haemorrhage, bleeding diathesis, 
uncontrolled hypertension, or thrombocytopenia, planned epidural or spinal anesthesia, 
hypersensitivity or allergy to thienopyridines, and current warfarin or thienopyridine use. 
 
Study Design  
Patients were recruited between June 2005 and February 2008, and gave written informed 
consent prior to study participation. The study was approved by the local Research Ethics 
Committee, given Clinical Trial Authorisation by the Medicines and Healthcare products 
Regulatory Agency (UK), and was conducted in accordance with the Declaration of Helsinki 
and CONSORT guidelines [Moher et al, 2001; Altman DG et al, 2001].  
This was a prospective single centre double-blind randomised controlled trial at a tertiary 
referral vascular surgical unit in the Royal Infirmary of Edinburgh, South-East Scotland, UK.  
 
Treatment Allocation 
Following recruitment, clopidogrel and matched placebo were assigned in identical packs by 
the pharmacy trials unit through allocation of sequentially numbered study medication packs 
that had been randomised using an independent computer-generated sequence. Patients 
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received 600 mg of clopidogrel or matched placebo 4-28 hours prior to surgery and received 75 
mg of clopidogrel or matched placebo daily for 3 days after surgery. (Studies suggest that the 
incidence of peri-operative adverse cardiovascular events is greatest within the first 5 days of 
surgery [Mangano DT et al, 1991]. We therefore commenced therapy pre-operatively and 
continued maintenance levels into a short post-operative period. We only continued clopidogrel 
for 3 days post peratively not 5 days due to rationalisation of blood sampling. Therefore 
changes in platelet markers and troponin after this time will have been missed.) Patients 
undergoing bypass procedures received a single dose of 5000 IU of intravenous unfractioned 
heparin during surgery before arterial clamping. At the discretion of the clinical team, 
intravenous protamine was given only if excessive bleeding was felt to be present at the end of 
the operation. All patients received subcutaneous unfractionated heparin 5000 IU twice daily in 
the post-operative period and were maintained on aspirin (75 mg daily) throughout the study. 
 
Biomarkers of Atherothrombosis 
 
Platelet activation and inflammatory markers 
Blood samples were taken before, and a minimum of 4 hours after, a loading dose of 600 mg of 
clopiogrel or matched placebo, immediately after the operation in the recovery room, and on 
day 1 after surgery. Flow cytometric measurements of platelet-monocyte aggregates and 
platelet surface expression of P-selectin were used as markers of in vivo platelet activation as 
described previously [Harding SA et al, 2004, 2007; Cassar et al, 2003, Sarma J et al, 2002]. 
Directly conjugated monoclonal antibodies were obtained from DakoCytomation (Cambridge, 





The Reference Clinical Biochemistry Laboratory measured plasma troponin I concentrations 
using the ARCHITECT Troponin I STAT assay (Abbott Diagnostics, Maidenhead, UK) using 
an autoanalyser. This has an analytical sensitivity of 0.009 ng/mL and a functional sensitivity 
of 0.032 ng/mL with a co-efficient of variation of <10%. The latter threshold was employed for 
the clinical case definition of myocardial infarction (see below).  
 
In-patient Clinical Outcomes 
 
Acute Coronary Syndromes 
Clinical symptoms, plasma troponin concentrations and electrocardiograms were recorded 
daily from the pre-operative day until day 3 post-surgery. A blinded independent cardiologist 
reviewed all clinical data and applied the universal definition of myocardial infarction [The 
Joint European Soc. of Cardiology, 2007].  
 
Bleeding Complications 
Bleeding events were defined as major (life-threatening or non-life threatening) and minor 
according to CURE criteria [Fox KA et al, 2004]. Post-operative blood transfusions were 
recommended according to Scottish Intercollegiate Guidelines Network (SIGN) criteria 
[Scottish Intercollegiate Guidelines Network, 2001]. Intra-operative blood loss, post-operative 
fall in haemoglobin, blood product transfusion, length of operation and length of hospital stay 
were recorded. Incidence of gastro-intestinal bleeding, persistent (>3 days) wound leak, 




Data and Statistical Analysis 
An independent data monitoring committee performed an interim safety analysis of bleeding 
outcomes following recruitment of 50 patients and recommended continuation of the trial to 
completion. Following completion of trial recruitment, data collection and laboratory analyses, 
the data base was locked, treatment allocation unblinded and pre-specified analyses performed. 
The primary end-point was platelet-monocyte aggregation. The sample size (n=50 per group) 
was based on our previous studies  [Harding SA et al, 2004; Sarma J et al, 2002] and gave an 
80% power of detecting a 4.8% difference in platelet-monocyte aggregates at a significance 
level of 5%. Secondary outcomes included plasma troponin concentration, and rate of 
myocardial infarction and bleeding complications. Continuous variables are reported as 
mean±SD. Analysis of variance with repeated measures, two-tailed Student’s t-test and Chi-
squared analysis were performed as appropriate using GraphPad Prism Version 4 (La Jolla, 















Of the 159 potentially eligible patients, 113 were randomised to trial medication (Figure 5.1). 
Of those who completed the study protocol, 58 received placebo and 50 received clopidogrel. 





Figure 5.1 Trial profile 
  
Final analysis (n=58)  Final analysis (n=50)  
38 met exclusion criteria 











2 excluded due to 
technical failure of 
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58 for end-point analysis 52 for end-point analysis 
159 potential patients identified 
113 patients enrolled and randomised 
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Variables reported as mean±SD or n (%) and analysed with un-paired t-test or Chi-squared 




Biomarkers of Atherothrombosis 
Platelet activation  
In keeping with the patient population, baseline levels of platelet-monocyte aggregation were 
markedly elevated. There was no difference in baseline platelet-monocyte aggregates (P=0.80) 
and P-selectin expression (P=0.80) between the two groups. Platelet activation was unaffected 
by placebo (P=0.78) but clopidogrel (600 mg) caused a rapid reduction in platelet-monocyte 
aggregates (38±17% to 30±17%, P=0.007) and platelet P-selectin expression (4.9±2.7% to 
2.8±1.6%, P<0.0001). In both groups, platelet activation declined within 24 hours of surgery 
(P≤0.005), but clopidogrel treatment was associated with greater reductions throughout the 
immediate post-operative period (P=0.0019; Figure 5.2). In order to assess pharmacological 
efficacy of the trial intervention, ex vivo platelet aggregation to 5 µM adenosine diphosphate 
was performed in a sub-group of trial participants (n=10 per group). This confirmed that 
clopidogrel inhibited adenosine diphosphate-induced aggregation (59+20% to 33+18%, 
P<0.0001) throughout the peri-operative period (P=0.0015; data not shown).  
  
Myocardial Injury 
Of the 108 trial subjects, eighteen (16.7%) suffered an elevated plasma troponin concentration 
(>0.032 ng/mL): 8 (16.0%) received clopidogrel and 10 (17.2%) placebo (relative risk (RR) 
0.93, 95% confidence intervals (CI) 0.40 to 2.17; P=0.86). Nine (8.3%) patients (4 clopidogrel 
and 5 placebo) had an elevation of plasma troponin concentration prior to surgery, and nine 
patients (4 clopidogrel and 5 placebo) suffered a post-operative rise in troponin. Of those nine 
patients who sustained a pre-operative troponin rise, plasma troponin concentrations fell with 
clopidogrel therapy but remained unchanged or increased in those on placebo (Figure 5.3). 
Patients with post-operative elevation in plasma troponin concentrations had greater platelet-
monocyte aggregates (40±4% versus 30±2%; P=0.033).  
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Figure 5.2 Platelet-monocyte aggregates and platelet P-selectin expression over the  





Platelet-monocyte aggregates (squares; P<0.0001 for both groups) and platelet P-selectin 
expression (circles; P≤0.005 for both groups) fell in both groups following surgery. 
Clopidogrel (closed symbols) caused a greater reduction in both platelet-monocyte aggregates 
(P=0.0019) and platelet P-selectin expression (P=0.0035) compared to placebo (open symbols). 





















































































Figure 5.3 Change in plasma troponin concentrations in patients with pre-operative troponin 















































































Of the 108 trial participants, seven patients (6.5%) sustained an acute myocardial infarction: 3 
(6.0%) in the clopidogrel group and 4 (6.9%) in the placebo group (RR 0.87 95% CI 0.20 to 
3.7, P=0.85). There were no in-patient deaths, intracranial haemorrhages or incidences of 
inotrope use. There was no difference in life-threatening major bleeding between treatment 
groups (7 (14%) clopidogrel and 6 (10%) placebo; RR 1.35, 95% CI 0.49 to 3.76; P=0.56), 
although those who received clopidogrel had an increased risk of major non-life-threatening 
bleeding (11 (22%) clopidogrel and 4 (7%) placebo, RR 3.19, 95% CI 1.1 to 9.4; P=0.024; 
Figure 5.4). Twenty (40%) patients receiving clopidogrel underwent red-cell transfusion 
compared to only 8 (14%) on placebo (P=0.0019). Restricting analyses to transfusions 
administered in accordance with the SIGN guidelines, there remained an increased transfusion 
rate in the clopidogrel group (14 (28%) clopidogrel and 7 (12%) placebo; RR 2.32, 95%CI 
1.02 to 5.29; P=0.037). There was no difference in minor bleeding between the two groups (17 
(34%) clopidogrel and 12 (21%) placebo; RR 1.64, 95% CI 0.87 to 3.10; P=0.12). Five patients 
suffered gastrointestinal bleeding (haematemesis or malaena); four of whom were receiving 
placebo. Two patients received intra-operative protamine – one in each intervention arm. 
 
There were two re-operations for bleeding in the placebo group and one in the clopidogrel 
group. Although there was an increase in wound leak in those patients who received 
clopidogrel (13 (26%) versus 3 (5%); RR 5.03, 95% CI 1.52 to 16.6; P=0.0024), there was no 
difference in incidence of wound infection at 3 months (P=0.80). Clopidogrel therapy did not 
increase the length of operation (P=0.60) or hospital stay (P=0.72). Sub-group analysis of 
patients undergoing revascularisation compared to amputation revealed no significant 
differences in clopidogrel versus placebo in terms of peri-operative adverse cardiovascular 
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events or bleeding outcomes (major life threatening, major non-life threatening or minor). 




Figure 5.4 Bleeding Outcomes 
 
 
Major life-threatening (upper panel; RR 1.35, 95% CI 0.49 to 3.76, P=0.56), major non-life-
threatening (middle panel; RR 3.19, 95% CI 1.08 to 9.4, P=0.024) and minor (RR 1.64 95% CI 
0.87 to 3.1, P=0.12) bleeding (closed bars) in patients on clopidogrel (left-hand panels, non-
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We have conducted the first double-blind randomised controlled trial of peri-operative dual 
anti-platelet therapy in patients undergoing surgery for critical limb ischaemia. We demonstrate 
improvements in biomarkers of platelet activation and myocardial injury without causing 
unacceptable bleeding complications. These data form the first objective assessment of the 
risks and benefits of peri-operative dual anti-platelet therapy in patients undergoing high-risk 
vascular procedures. 
 
Peripheral arterial disease affects nearly 30 million people in Western Europe and North 
America. In up to three-quarters of cases, patients have co-existent coronary artery disease and 
a 3-fold increased risk of cardiovascular events and death [Hackman DG et al, 2007]. In a 
recent large observational study (n=5,460), patients with peripheral arterial disease scheduled 
for open vascular surgery had a worse prognosis (2.4-fold increase in cardiovascular 
morbidity) than matched patients with severe myocardial ischaemia referred for percutaneous 
coronary intervention [Welten GM et al, 2008]. Interestingly the occurrence of peri-operative 
cardiac complications following vascular surgery was associated with long-term cardiac death. 
There is therefore a clear unmet need to reduce cardiovascular events in patients with 
peripheral arterial disease, especially in the peri-operative period. 
 
In agreement with previous studies [Mangano DT et al, 1991;  Hobbs SD et al, 2005; Kim LJ 
et al, 2002; Landesburg G et al, 2003], we report a high incidence of peri-operative myocardial 
infarction (6.5%) and troponin elevation (16.7%) in patients undergoing surgery for critical 
limb ischaemia. We also found that post-operative elevations in troponin were associated with 
increased levels of post-operative platelet activation. However, we were surprised to find that 
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markers of platelet activation fell post-operatively (both in clopidogrel and placebo groups) and 
that half of the troponin-positive events occurred before surgery. This occurred in the absence 
of renal dysfunction. This suggests that rather than surgery being an additional thrombotic 
stimulus, removal of ischaemic tissue may actually reduce platelet activation in the majority of 
these patients. These findings highlight the prevalence of ‘silent’ pre-operative myocardial 
injury, and the important systemic pro-thrombotic consequences of critical limb ischaemia, as 
well as the need for pre-operative intervention.  
 
This study aimed to explore a proof of concept. Pre-clinical studies of platelet activation in 
coronary patients have informed the design of large scale trials which have subsequently 
shaped clinical practice. These trials required several thousands of patients to demonstrate a 
small but significant clinical benefit from anti-platelet regimes. Despite suffering significant 
cardiovascular risk, there has been little study of platelet activation in high-risk vascular 
surgical patients. The potential for adverse bleeding would seem greater for patients 
undergoing open surgery under anti-platelet therapy. Consequently, any large-scale trial 
powered to examine clinical end points should be justified by ‘pilot’ data suggesting that some 
cardiovascular benefit could be achieved without excessive bleeding. 
 
Through the use of surrogate biomarkers, we have demonstrated the potential benefits of dual 
anti-platelet therapy in the peri-operative period. Clopidogrel reduced sensitive markers of 
platelet activation (Figure 5.2) that are associated with increased clinical risk as well as the 
progression of atherothrombosis [Freedman JE et al, 2002; McGregor L et al, 2006; Michelson 
AD et al, 1996; Huo Y et al, 2003; Michelson AD et al, 2001; Harding SA et al, 2004; Furman 
MI et al, 2001; Hayes PD et al, 2003]. Although clopidogrel did not have an overall effect on 
the number of peri-operative troponin-positive events (8 clopidogrel versus 10 placebo; 
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P=0.86), half of the troponin elevations occurred pre-operatively and prior to the 
administration of the study medication. Subsequent institution of clopidogrel therapy was 
associated with a marked reduction in troponin concentrations (Figure 5.3). However, we 
readily acknowledge that our study was not primarily powered to assess cardiac troponin and 
clinical outcomes and whether these improvements in surrogate biomarkers translate into 
clinical benefit remains to be established. 
 
All therapies have potential benefits and risks, and it is inevitable that anti-platelet therapies 
will be associated with increased bleeding complications. Although it may be regarded as 
potentially reversible, the importance of major bleeding must not be underestimated as it 
remains an independent predictor of adverse clinical outcome [John W et al, 2006; Moscucci 
M et al, 2003; Yang Xin et al, 2005]. Although vascular patients are at high risk of 
cardiovascular events, bleeding concerns are a major disincentive for the investigation of peri-
operative intensive anti-platelet regimes, and perhaps underlie the paucity of such data. Most 
published reports are observational [Smout J et al, 2003; Assadian A et al, 2005] although 
randomised-controlled trials of dual anti-platelet therapy have been performed in patients 
undergoing carotid endarterectomy [Payne AD et al, 2004] and peripheral angioplasty [Cassar 
K et al, 2005], and report no major increase in bleeding complications. However, there have 
been no randomised-controlled trials of dual anti-platelet therapy in surgery for critical limb 
ischaemia, where the potential for both peri-operative bleeding and cardiac complications is 
greater. We have successfully delivered such a trial and confirmed that whilst bleeding is 
increased, there was no excess of life-threatening bleeds, re-operations or wound infections. 
Our results are consistent those reported by the CURE trial [Fox KA. et al, 2004] where those 
patients who continued clopidogrel therapy within 5 days of coronary artery bypass had a 2-
fold increased relative risk of major bleeding. Arguably our pilot data suggests that the 
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bleeding risks of dual anti-platelet therapy in the peri-operative period are modest, and perhaps 
often over estimated.  
 
Increasingly patients are undergoing surgery for critical limb ischaemia with a recent history of 
a cerebrovascular event, acute coronary syndrome or percutaneous coronary intervention, and 
will be receiving intensive anti-platelet regimes. Their peri-operative management must protect 
them from both co-existing pathology as well as the associated risks of surgery. Our study has 
shown that it is feasible to perform vascular surgery for critical limb ischaemia, under dual 
anti-platelet therapy with an acceptable bleeding profile. Although the absolute clinical benefits 
of such a regime need to be validated in a large-scale clinical trial, we believe that our study 
provides evidence for the beneficial role of peri-operative anti-platelet agents in protecting 
these patients against cardiovascular complications. 
 
Patients receiving epidural or spinal anaesthesia were not recruited into the study due to the 
theoretical risk of epidural haematoma. We are aware that many vascular units aim for epidural 
or spinal anaesthesia, thus precluding many patients from peri-operative anti-platelet therapy. 
However, there is currently no level-one evidence for superior cardiovascular outcome with 
neuraxial blockade compared to general anaesthesia. The main benefit lies in reducing 
respiratory complications associated with abdominal surgery [Rodgers A et al, 2000]. 
Although many of the patients who were recruited smoked, none had significant chronic 
obstructive airway disease (based on lung function testing) and none were undergoing 
abdominal or emergency surgery. Use of both trial medication and general anaesthesia was 
therefore deemed appropriate. 
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Persistent platelet reactivity despite anti-platelet therapy (clopidogrel ‘resistance’) has been 
proposed as a risk factor for the recurrence of ischemic events following PCI. Recent 
mechanistic and clinical data suggest that higher loading and maintenance doses of clopidogrel 
may achieve a more rapid and greater degree of platelet inhibition that translates into improved 
clinical outcomes, but this is yet to be formally evaluated in an adequately powered 
randomized trial (CURRENT-OASIS 7, 2008). We administered a relatively high pre-operative 
loading dose of clopidogrel (600 mg) to ensure efficacy of the intervention during surgery, and 
in an attempt to overcome ‘non-responders’ to the drug. It was hypothesized that if additional 
peri-operative anti-platelet therapy was to be of any therapeutic advantage then this should be 
demonstrated with the largest degree of platelet inhibition. Previous studies have reported 
increased platelet activation, [Hayes PD et al, 2003; Collins P et al, 2006; Mohan IV et al, 
2007; Samama CM et al, 2001; Rajagopalan S et al, 2007], and cardiovascular events 
occurring within the first 5 days following surgery. We therefore rationalised that clopidogrel 
therapy would be of most benefit when given pre-operatively and continued in the immediate 
post-operative period. It is possible that we could still achieve atherothrombotic protection with 
reduced bleeding complications by administering lower doses of clopidogrel and this requires 
further clarification. However, given the relatively high incidence of troponin-positive events 
before surgery, we would recommend initiation of therapy prior to surgery.  
 
In conclusion, we have demonstrated that peri-operative dual anti-platelet therapy has 
beneficial effects on reducing biomarkers of atherothrombosis without increasing life-
threatening bleeds in patients with critical limb ischaemia. We propose that large-scale 
randomised controlled trials are needed to establish whether dual anti-platelet therapy can 






INFLAMMATORY BIOMARKERS AND DUAL ANTI-PLATELET THERAPY IN 






Platelets play a key role in vascular inflammation through release of pro-inflammatory 
mediators and interactions with other inflammatory cells. We investigated the changes in 
inflammatory biomarkers during surgery for critical limb ischaemia and examined the effect of 
additional pre-operative clopidogrel therapy on peri-operative inflammation. 
 
In a double-blind randomised controlled trial of pre-operative clopidogrel therapy in surgery 
for critical limb ischaemia, peri-operative serum markers of inflammation (hsCRP, IL-6, 
sCD40L) and expression of CD40/CD40L and CD11b on platelets and monocytes, were 
measured by sensitive assays and flow cytometry, respectively. 
 
In contrast to in vivo platelet activation, levels of inflammatory markers rose in the post-
operative period (monocyte CD40 P=0.018; IL-6 P<0.0001; hsCRP P<0.0001). Pre-operative 
clopidogrel therapy reduced monocyte CD40 expression (53.4±2.3% to 46.6±2.1%, P<0.0001); 
monocyte CD11b (53.6±3.4 MFI to 39.9±2.6 MFI, P<0.0001); platelet CD40L expression 
(14.4±0.9% to 8.5±0.78%, P<0.0001); soluble CD40L (1.3±0.3 ng/mL to 0.98±0.3ng/mL, 
P=0.029) and serum IL-6 (28.3±5.2pg/mL to 16.1±3.5pg.mL, P<0.0001), but had no 
significant effect on peri-operative hsCRP (P=0.208). Patients with peri-operative elevation in 
plasma troponin concentrations had greater pre-operative levels of monocyte CD40 expression, 
serum hsCRP and IL-6 (59.0±3.9% versus 50.1±1.4%, P=0.014; 53.0±20.3mg/mL versus 




In conclusion, pre-operative clopidogrel therapy had beneficial effects on cellular and serum 
markers of inflammation, although whether this was via a platelet mediated action or direct 






Inflammation plays a central role in the pathogenesis of atherosclerosis and its complications 
[Lusis AJ, 2000]. In addition, elevations in inflammatory biomarkers have been demonstrated 
to be prognostic of clinical risk. Patients with peripheral arterial disease (PAD) have an 
increased incidence of adverse cardiovascular events compared to the healthy population, 
especially at the time of operation. Surgical stress is known to generate a pro-inflammatory 
state, yet there has been little investigation of its role in peri-operative cardiovascular events, 
especially in those with underlying vascular dysfunction.  
 
CRP 
C-reactive protein (CRP) is an acute phase protein produced by hepatocytes largely in response 
to interleukin-6 stimulation. A substantial body of evidence demonstrates that elevated CRP is 
predictive of atherothrombotic events. Large-scale studies of healthy subjects have found that 
CRP is a strong independent predictor of future cardiovascular risk [Kuller LH et al, 1996; 
Koenig W et al, 1999; Tracy RP et al, 1997; Ridker PM et al, 1997,1998, 2000]. In patients 
with acute coronary syndromes, elevated baseline levels of CRP predict increased adverse 
cardiovascular outcome at intervals ranging from 14 days [Morrow DA et al, TIMI IIa 
substudy, 1998] to several years [Lindahl B et al, FRISC study group, 2000]. Studies have also 
demonstrated baseline levels of CRP to be predictive of intermediate and long term adverse 
cardiovascular events following surgery for PAD [Padayachee L et al, 2009]. 
In addition, CRP may also play a pathogenic role in atherothrombosis. CRP promotes potent 
proatherogenic effects in endothelial cells, smooth muscle cells, platelets, and monocyte 
macrophages in vitro [Zwaka TP et al, 2001; Ballou SP et al, 1992; Pasceri V et al, 2000, 
2001]. Griselli et al, 1999, demonstrated that administration of human CRP in experimental 
acute myocardial infarction reproducibly enhanced infarct size by ~40%. The JUPITER trial 
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also reported that in patients with high CRP and no other major risk factor, statin therapy 
resulted in a significant benefit in cardiovascular outcome [Ridker PM et al, 2008]. 
 
CD40/CD40L 
A key inflammatory mediator involved in atherosclerosis is membrane glycoprotein receptor 
CD40 and its ligand CD40L [Schonbeck U et al, 2001]. CD40L stimulates the release of 
various inflammatory cytokines as well as the expression of adhesion molecules and matrix-
degrading metalloproteinases [Urbich C et al, 2004]. In addition, CD40/CD40L interaction 
increases procoagulant activity by stimulating tissue factor expression [Slupsky JR et al, 1998]. 




 mice leads to reduction in size of 
atherosclerotic lesions [Mach F et al, 1997].  
 CD40L is carried within platelet granules and translocates to the cell surface on activation, 
with platelets providing 95% of soluble CD40L in the circulation. This has led to the 
suggestion that platelet CD40L may be the pivotal link between the processes of thrombosis, 
inflammation and atherosclerosis.  
Consistent with these activities, elevations in the CD40/CD40L dyad have been associated with 
increased risk of cardiovascular events in healthy women, diabetics, smokers and patients with 
acute coronary syndromes [Schonbeck U et al, 2001; Harding SA et al, 2004; Harding SA et 
al, 2004; Heeschen C et al, 2003]. Several observational studies have also demonstrated that 
patients with PAD have higher levels of circulating inflammatory biomarkers compared to the 
healthy population [Wildman RP et al, 2005], with levels increasing with severity of disease 
[Mohler ER et al, 2003; Cassar K et al, 2005; Blann AD et al, 2005; Lee WJ et al, 2006; 




Anti-inflammatory action of anti-platelet agents 
An increasing body of evidence suggests that inhibition of platelet function with anti-platelet 
agents can modulate inflammatory markers. During platelet activation, degranulation of intra-
cellular granules occurs, releasing inflammatory chemokines, cytokines and growth factors. 
This leads to cellular adhesion, release of pro-inflammtory mediators and further vascular 
inflammation and thrombus propagation [Libby PM et al, 2002; Libby PM et al, 2006]. Thus, 
platelets play key roles in both thrombus formation and inflammation, highlighting the 
complex interplay between coagulation and inflammation in the pathogenesis of 
atherothrombosis. Anti-platelet agents have been demonstrated to reduce inflammatory 
markers, both in animal models and clinical studies [Ayral Y et al, 2007; Egan KM et al, 2005; 
Herbert JM et al, 1992; Molero L et al, 2005].  
Clopidogrel in addition to aspirin, has been shown to reduce hsCRP and soluble CD40L in 
patients with stable coronary artery disease [Heitzer T et al, 2006; Azar RR et al, 2006] and in 
acute coronary syndromes and percutaneous coronary intervention [Vavuranakis M et al, 2006; 
Xiao Z et al, 2004; Vivekananthan DP et al, 2004; Quinn MJ et al, 2004; Saw J et al, 2008; 
Chew DP et al, 2001, Gottsauner-Wolf M et al, 2000]. However, a causal relationship between 









There has been no investigation of anti-platelet agents and inflammation during the peri-
operative period in patients with severe critical limb ischaemia. As part of a double-blind 
prospective randomised trial of pre-operative clopidogrel in addition to aspirin, we studied the 
changes in peri-operative inflammatory biomarkers and the effect of dual anti-platelet therapy 
upon them. We hypothesized that: 
 
1. Inflammatory biomarkers would be increased in those patients who developed peri-
operative myocardial injury. 








Study Design and Subjects 
 
As previously outlined in Chapter 5, a prospective single centre double-blind randomised 
controlled trial was conducted at a tertiary referral vascular surgical unit in the Royal Infirmary 
of Edinburgh, South-East Scotland, UK. Patients with critical limb ischaemia who were 
scheduled for infra-inguinal bypass, femoral endarterectomy or lower limb amputation under 
general anaesthesia were recruited into the study. 
In brief, following recruitment, patients received 600 mg of clopidogrel or matched placebo 4-
28 hours prior to surgery and received 75 mg of clopidogrel or matched placebo daily for 3 
days after surgery. 
 
Assessment of inflammatory bio-markers 
Blood samples were taken before, and a minimum of 4 hours after, a loading dose of 600 mg of 
clopiogrel or matched placebo, immediately after the operation in the recovery room, and on 
days 1 and 2 after surgery. 
 
CD40/CD40L 
Flow cytometric measurements of monocyte CD40 and CD11b expression were used as 
markers of in vivo monocyte activation as described previously [Harding SA et al, 2004]. 
Immunolabelling was performed in whole blood within 5 min of collection. To evaluate
 
CD40 
and CD11b on monocytes, blood was diluted 1:2 with PBS
 
and incubated with the following 
monoclonal antibodies: anti-CD14:FITC
 
(Serotec), anti-CD40:PE (Serotec), anti-CD11b:PE 
(Serotec) and
 
appropriate isotype-matched controls for 20 min, before fixation and erythrocyte 
lysis with 500 µL of FACSLyse solution. Monocytes were identified by gating for CD14 
positive cells. 
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In addition platelet CD40L and soluble CD40L were also assessed. Platelet membrane CD40L 
expression was measured using flow cytometry as previously described [Harding SA et al, 
2004]. To evaluate CD40L on platelets, whole blood was diluted 1:10 with PBS and incubated 
with FITC-conjugated CD42a (Serotec) and PE-conjugated CD154 (eBioscience) and
 
appropriate isotype-matched controls for 20 minutes, before cells were further diluted with 1% 
paraformaldehyde. CD40L positive platelets were identified by gating for CD42a and CD154 
positive cells.  Soluble CD40L was assessed using an ELISA from Bender Med Systems.  
 
CRP 
Serum CRP concentrations were determined with a validated highly sensitive assay 
(Department of Clinical Biochemistry; Fife NHS Trust, UK) using the method of particle-
enhanced immunonephelometry (Behring BN II nephelometer, Dade Behring Inc.). This 
sensitive assay has a detection limit of 0.18mg/L. Intra-assay and inter-assay coefficients of 
variability for hs-CRP were 3.7% and 4.2% respectively. All assays were performed in 
duplicate and the mean value taken. Whole blood samples for the measurement of hsCRP were 
collected into citrated tubes, centrifuged and plasma collected at each time point. The serum 
was frozen and stored until the end of the trial when samples were processed en masse.  
 
IL-6 
Plasma interleukin- 6 (IL-6) concentrations were measured with commercially available 
ELISA (Quantikine, R&D systems). Intra-assay and inter-assay coefficients of variability were 
4.2% and 6.4% respectively. Whole blood samples for the measurement of IL-6 were collected 
at each time point and plasma prepared, frozen and stored until the end of the trial when 





The Reference Clinical Biochemistry Laboratory measured plasma troponin I (cTn I) 
concentrations using the ARCHITECT Troponin I STAT assay (Abbott Diagnostics, 
Maidenhead, UK) using an autoanalyser. This has an analytical sensitivity of 0.009 ng/mL and 
a functional sensitivity of 0.032 ng/mL with a co-efficient of variation of <10%. The latter 
threshold was employed for the clinical case definition of myocardial infarction 




The overall study was primarily powered to examine differences in peri-operative platelet-
activation. The sample size (n=50 per group), was based on power calculations derived from 
our previous studies [Sarma J et al, 2002; Harding SA et al, 2004], and were designed to give 
an 80% power of detecting a 3.6% difference in CD40 expression on monocytes, 3.7% in 
CD40L expression on platelets, and 0.11 ng/mL in plasma sCD40L concentrations, at a 
significance level of 5%. Continuous variables are reported as mean±SEM. Analysis of 
variance with repeated measures, two-tailed Student’s t-test and Spearman or Pearson 
correlation analysis were performed as appropriate using GraphPad Prism Version 4 (La Jolla, 







Of the 159 potentially eligible patients, 113 were randomised to trial medication (Figure 5.1, 
Chapter 5). Of those who completed the study protocol, 58 received placebo and 50 received 
clopidogrel. There was no difference in baseline demographics between the two groups (Table 
5.1, Chapter 5).   
 
1. Post-operative inflammation and platelet activation 
We have previously reported, in the same patient population, that markers of platelet activation 
fell following surgery in both placebo and clopidogrel groups (Figure 5.2, Chapter 5). In 
contrast, inflammatory markers rose in the post-operative period (monocyte CD40 P=0.018; 
IL-6 P<0.0001; hsCRP P<0.0001) Figure 6.1. 
 
2. Dual anti-platelet agents and peri-operative inflammatory markers  
Inflammatory markers were unaffected by placebo (P>0.05) but clopidogrel (600 mg) caused a 
rapid reduction in monocyte CD40 expression (53.4±2.3% to 46.6±2.1%, P<0.0001); 
monocyte CD11b (53.6±3.4 MFI to 39.9±2.6 MFI, P<0.0001); platelet CD40L expression 
(14.4±0.9% to 8.5±0.78%, P<0.0001); soluble CD40L (1.3±0.3 ng/mL to 0.98±0.3ng/mL, 
P=0.029) and serum IL-6 (28.3±5.2pg/mL to 16.1±3.5pg.mL, P<0.0001). Clopidogrel 
treatment was associated with greater reductions in monocyte CD40 and CD11b and IL-6 
throughout the immediate post-operative period (P=0.038; P=0.034; P=0.047 respectively. 
Figure 6.1 A, B and D). Additional clopidogrel therapy had no statistically significant effect on 









Figure 6.1 Dual anti-platelet therapy and peri-operative inflammation in patients undergoing 




Monocyte CD11b (●), B. Monocyte CD40 expression (■), C. Serum hsCRP (▼) and D. Serum 
IL-6 (♦) rose in both groups on day 1 post-surgery (P=0.008; P=0.038; P<0.0001 and P= 
respectively). Clopidogrel (closed symbols) caused a greater reduction in monocyte CD11b 
expression (P=0.034); monocyte CD40 expression (P=0.038) and serum IL-6 levels (P=0.047) 
compared to placebo (open symbols), but had no overall effect on hsCRP levels (P=0.208). 
Symbols represent mean+SEM; analysis by 2-way ANOVA.  
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3. Inflammatory markers and myocardial injury 
 
Of the 108 trial subjects, eighteen (16.7%) suffered an elevated plasma troponin concentration 
(>0.032 ng/mL): 8 (16.0%) received clopidogrel and 10 (17.2%) placebo (relative risk (RR) 
0.93, 95% confidence intervals (CI) 0.40 to 2.17; P=0.86). 
Patients with peri-operative elevation in plasma troponin concentrations had greater pre-
operative levels of monocyte CD40 expression, serum hsCRP and IL-6 (59.0±3.9% versus 
50.1±1.4%, P=0.014; 53.0±20.3mg/mL versus 17.4±2.9mg/mL, P=0.002 and 55.6±22.6pg/mL 
versus 16.1±3.5pg/mL, P=0.0038. Figure 6.2). Pre-operative monocyte CD11b, platelet CD40L 
or soluble CD40 levels were not increased in those patients suffering an increase in plasma 
Troponin concentration (cTn I) (P=0.92; P=0.62; P=0.4 respectively). Peri-operative monocyte 
CD40 and CD11b expression correlated with serum hsCRP (r=0.11, P=0.038 and r=0.11, 
P=0.046 respectively) but only hsCRP and IL-6 directly correlated with cTn I levels (r=0.29, 

























Figure 6.2 Inflammatory biomarkers in patients with or without a peri-operative 




Pre-operative levels of A. Monocyte CD11b, B. Monocyte CD40 expression, C. Serum hsCRP, 
D. Serum IL-6, in Troponin + ve (hached bars) and Troponin –ve (open bars) patients. 
Monocyte CD40 expression (59.0±3.9% versus 50.1±1.4%, P=0.014), hsCRP levels 
(53.0±20.3mg/mL versus 17.4±2.9mg/mL, P=0.002) and IL-6 levels (55.6±22.6pg/mL versus 
16.1±3.5pg/mL, P=0.0038.) were significantly greater in patients suffering a peri-operative 
Troponin elevation. There was no difference in monocyte CD11b (P=0.92). Bars represent 




We have previously demonstrated in accordance with other studies, that patients with severe 
peripheral arterial disease have increased baseline levels of inflammation in comparison to 
healthy controls, or those with claudication. In addition, their inflammatory profile is similar to 
those being treated for acute coronary syndromes (Chapter 4). In this study, surgery for critical 
limb ischaemia was associated with a rise in inflammation post-operatively. This is in contrast 
to a post-operative fall in platelet activation (Chapter 5). Additional pre-operative clopidogrel 
therapy had beneficial effects on cellular markers of inflammation and IL-6, although serum 
hsCRP, was not directly affected. Inflammatory markers correlated with peri-operative 
Troponin release, although whether this was the cause or effect of myocardial ischaemia is 
unclear. 
Vascular inflammation is an underlying mechanism central to atherosclerotic disease. Data 
from animal and human model systems suggest that modulation of platelet function may also 
modulate expression of known inflammatory mediators, including CD40L and CRP. Therefore, 
anti-platelet therapy may reduce adverse cardiovascular outcomes, not only by reducing 
platelet activation and aggregation, but also by limiting inflammatory amplification pathways.   
 
Post-operative changes in markers 
We were surprised to find that in our patient population markers of platelet activation fell 
following surgery (Chapter 5) whilst inflammatory markers increased (Figure 6.1). It is 
generally accepted that the physiological response to trauma includes an increase in circulating 
inflammatory mediators and a pro-thrombotic state (Chapter 1). Inflammatory markers show a 
sharp rise in the setting of an acute coronary syndrome or PCI that lasts for 48-72 hours, and 
then returns to baseline [Liuzzo G et al, 1994; 1998]. It has been suggested that intra-arterial 
thrombus formation during ACS may cause the subsequent increase in inflammatory markers 
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by means of CD40L and sCD40L activity [Levi M et al, 2004; Ankrust P et al, 2004; Henn V 
et al, 1998].  Perhaps the disconnect between the post-operative fall in platelet activation and 
the later rise in inflammation seen in our studies, represents this pathogenic cycle of 
thrombosis and inflammation.  
 
Effect of clopidogrel 
Together with earlier data (Chapter 5), we have shown that additional clopidogrel therapy 
reduces both peri-operative platelet activation markers (platelet-monocyte aggregation (PMA), 
platelet P-selectin, and platelet CD40L), and markers of inflammation (soluble CD40L, 
monocyte CD40 and 11b and IL-6). This is in line with the anti-inflammatory effect of 
additional clopidogrel therapy in patients with acute coronary syndromes [Xiao Z et al, 2004] 
or undergoing PCI [Quinn MJ et al, 2004].  However, it is unclear whether the reduction in 
inflammatory markers, is due to a direct action of clopidogrel; as a result of platelet inhibition 
or due to prevention of thrombosis and ischaemia (and subsequent inflammation). 
PMA correlates positively with CD40 and CD11b expression on monocytes (Chapter 3). 
Formation of platelet-monocyte aggregates is known to activate NF-B – a transcriptional 
activator involved in regulating CD40 gene expression. In addition, binding of platelets to 
leucocytes, leads to surface expression of B2 integrin Mac-1. Inhibition of platelet activation 
through the action of anti-platelet agents, with subsequent reduction of PMA formation may 
therefore reduce CD40 and CD11b expression on monocytes. Similar correlations between 
platelet and inflammatory markers, have been demonstrated in smokers and patients with acute 
coronary syndromes [Harding S et al, 2004; Zhang SZ et al, 2007]. Human platelets carry 
preformed CD40L molecules, which appear on the platelet surface after stimulation. Many 
studies support the hypothesis that platelet activation/aggregation, via CD40L and sCD40L 
activity, may induce a pro-inflammatory cytokine response [Henn V et al, 1998; Levi M et al, 
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2004; Merino A et al, 2012]. Since CD40/CD40L binding stimulates release of cytokines such 
as IL-6, inhibition of platelet activation and subsequent reduction in CD40 could be expected 
to reduce levels of this inflammatory protein.   
 
We did not demonstrate any reduction in hsCRP levels with additional clopidogrel therapy. In 
contrast, larger scale studies in patients undergoing PCI have reported reductions in post-
procedural hsCRP with combined pre-procedural clopidogrel and aspirin therapy 
[Vivekananthan DP et al, 2004; Chew DP et al, 2001, Gottsauner-Wolf M et al, 2000]. It may 
be that we were underpowered to demonstrate changes in CRP. 
In other studies of patients with acute coronary syndromes, the reduction in serum hsCRP was 
not seen until after at least 7 days of additional clopidogrel treatment [Chen YG et al, 2006] 
with a shorter duration of treatment having no effect [Montalescot G et al, 2006]. Combination 
therapy in patients with stable coronary heart disease has also had a variable result on serum 
CRP [Azar RR et al, 2006; Heitzer T et al, 2006]. Our duration of clopidogrel treatment may 
have therefore been too short to produce any change in CRP (although we had given loading 
doses). Furthermore, our-post-operative sampling period may not have been long enough to 
reveal any impact from the drug.  
 
Inflammatory markers and peri-operative Troponin 
Inflammatory markers correlated with troponin levels. However, it is unclear whether this is 
cause or effect, as ischaemia itself can induce an inflammatory state. Dual anti-platelet therapy 
reduced monocyte CD40 and IL-6, which were associated with peri-operative Troponin 
release. However, there was no significant reduction in peri-operative Troponin with additional 
clopidogrel therapy. Despite 18 (16.7%) of the study population suffering a Troponin rise, our 
study was still underpowered to examine Troponin as a primary outcome measure.  
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In summary, although there is increasing understanding of the role of inflammatory mediators 
in atherothrombotic events, the complex pathogenesis of peri-operative atherothrombotic 
complications remains poorly understood. We have demonstrated that in patients with critical 
limb ischaemia, who already have a baseline elevation in inflammatory markers, the surgical 
process causes a further increase in inflammation. Inflammation was increased in those who 
developed peri-operative troponin rises. However, whether this was the cause of subsequent 
myocardial injury or an effect of it, is unclear. Although dual anti-platelet agents reduced peri-
operative inflammation this was not translated into improved clinical outcome. It remains 
unclear whether clopidogrel causes a reduction in inflammatory markers through a direct action 
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7.1 SUMMARY OF THESIS FINDINGS 
 
Patients with peripheral arterial disease (PAD) have a significant risk of cardiovascular 
morbidity and mortality, yet are poorly provided with targeted medical therapies.  
Increased platelet activation and inflammation play key roles in the complex pathogenesis of 
atherothrombosis. Investigation of these mediators has helped guide the tailored anti-platelet 
regimes of patients with coronary disease, especially at times of invasive treatment. Although 
PAD patients are at greatest risk during the operative period, there is a paucity of data to guide 
cardio-protective management of the surgical PAD patient. In addition, perioperative platelet 
activation and inflammation has been incompletely characterised. Existing studies are 
confounded by heterogeneity of patient populations, methodological techniques and concern 
regarding the potential bleeding complications of peri-operative anti-platelet agents.  
We aimed to focus attention on this high risk patient population and address previous study 
limitations with targeted investigation of a homogeneous patient group, clear methodology and 
a robust RCT study design for the investigation of peri-operative anti-platelet therapy.  
Increased platelet activation and vascular inflammation are associated with atherothrombotic 
progression of atherosclerotic plaques [Rosenburg RD et al, 1999]. In addition, platelet 
activation and inflammatory markers are associated with elevations in cardiac Troponin [Zhang 
SZ et al; 2007] and adverse cardiovascular outcomes following PCI [Gurbel PA et al, 2005]. 
We hypothesised that in vivo platelet activation and inflammation would be increased 
following surgery for critical limb ischaemia, particularly in those developing peri-operative 
cardiac Troponin release. In this pilot study we aimed to demonstrate a beneficial effect of dual 




7.1.1 Reproducible assessment of in vivo platelet activation in patients with peripheral 
         arterial disease. 
 
Despite significant evidence for the key role of platelets in atherothrombosis, there is 
considerable variation in clinically useful tests of platelet function. This is partly due to the 
methodological issues associated with many of the techniques, and makes comparison and 
interpretation of different studies extremely difficult. We attempted to address this issue by 
deliberately employing the sensitive technique of whole blood flow cytometry to assess resting 
in vivo markers of platelet activation. Although this methodology is not without its limitations, 
we clearly discuss our reasoning behind its use and demonstrated repeatability of technique in 
our study population [Burdess et al, 2011]. Assessment of platelet-monocyte aggregation and 
platelet membrane P-selectin was our primary outcome measure in our interventional study and 
therefore validation of measurement technique was essential. We demonstrated acceptable 
within day and between day co-efficients of reproducibility and standard deviations for our 
variables (Within day PMA measurement: SD of difference 7.86%; co-efficient of 
reproducibility 15.4%. Between day: SD of difference 6.35%; co-efficient of reproducibility 
12.4%). In addition, PMA showed the best correlation with a range of platelet activation 
markers, suggesting that it may provide the best measure of in vivo platelet activation for 
clinical study. Intervention with additional clopidogrel therapy caused a 21% reduction in 
PMA and a 43% reduction in platelet P-selectin [Burdess et al, 2010]. Given the variation in 
measurement attributable to technique, the reduction seen with interventional therapy can be 





7.1.2 Patients with critical limb ischaemia (CLI) have a high-risk profile of platelet 
         activation and inflammation 
 
In a cross sectional study we demonstrated that resting in vivo platelet activation and cellular 
inflammation increase with severity of peripheral arterial disease. In addition, for the first time, 
we demonstrated that patients scheduled for surgery for critical limb ischaemia have levels of 
platelet activation comparable to those treated for an acute coronary syndrome [Burdess et al, 
2011].  
We also compared peri-operative changes in both resting platelet activation and platelet 
response to ADP in patients undergoing infra-inguinal surgery for CLI and patients undergoing 
joint replacement.  
We wished to examine the contribution of surgical stress (without underlying PAD) to in vivo 
platelet activation. Following discussion with a panel of consultant vascular surgeons and 
anaesthetists it was felt that knee or hip arthroplasty represented surgery of a similar magnitude 
to peripheral bypass or amputation, and was likely to be performed in patients of a comparable 
age. Patients undergoing elective arthroplasty over the age of 50 were approached. In order to 
limit the effect of atherosclerosis on platelet activation, patients with a history of diabetes, 
hypertension, ischaemic heart disease or stroke, smoking or anti-platelet, anti-hypertensive or 
statin use, were excluded. Markers of both resting platelet activation (PMA and platelet P-
selectin) and platelet response to ADP stimulation were significantly greater in CLI patients 
compared to those undergoing arthroplasty, throughout the peri-operative period. Although 
platelet response to ADP increased post-operatively in both patient groups, resting platelet 
activation fell in CLI patients but rose following arthroplasty (Figure 7.1). Potentially, this 
suggests that patients with CLI have elevated levels of baseline platelet activation that 
supercedes the increase in activation associated with surgery itself.  
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Figure 7.1 Peri-operative in vivo platelet activation and ex vivo reactivity in patients 




A. in vivo platelet monocyte activation  and B. ex vivo platelet aggregation to ADP in patients 
undergoing surgery for  CLI (▼) and arthroplasty (●) 
































































































7.1.3 Peri-operative platelet activation and inflammation in surgery for critical limb 
         ischaemia and impact of dual anti-platelet therapy. 
 
For the first time, we demonstrated the changes in in vivo platelet activation and inflammation 
that occur in the immediate peri-operative period for this specific group of patients. To date, 
existing data comes from heterogenous surgical groups. These have encompassed patients with 
varying severities of peripheral arterial occlusive disease and aneurysmal disease or those 
undergoing carotid surgery or endovascular intervention. 
Surprisingly, we demonstrated that platelet-monocyte aggregation and P-selectin expression 
fell following surgery, whilst markers of monocyte activation and inflammatory markers 
appeared to rise post-operatively.  In a small sub-group of patients (n=20; 10 patients receiving 
placebo, 10 patients receiving clopidogrel), ex vivo platelet reactivity to ADP stimulation 
throughout the operative period was examined (Figure 7.2). This was primarily to assess 
efficacy of study medication. In accordance with other studies, platelet reactivity increased 
post-operatively. In those patients receiving clopidogrel, the % aggregation in response to ADP 
was significantly reduced throughout the peri-operative period (P=0.0015). 
Additional pre-operative clopidogrel therapy significantly reduced peri-operative in vivo 
platelet activation, ex vivo reactivity to ADP, and inflammatory markers [Burdess et al, 2010].  
Although additional clopidogrel treatment was not directly associated with a reduction in peri-
operative c-Troponin I release, elevated markers of platelet activation and inflammation were 
related to c-Troponin I, suggesting that clopidogrel could have beneficial results on peri-
operative cardiac injury through reduction of platelet and inflammatory mediators of 
atherothrombosis. However, we acknowledge that for patients undergoing surgery for critical 
limb ischaemia an improvement in clinical end-points with intensive anti-platelet therapy still 
requires validation in a large-scale clinical study. 
 154 
Figure 7.2 Peri-operative ex vivo aggregation to ADP in patients undergoing surgery for 






Pre-operative loading with 600mg of clopidogrel (closed symbols) caused a greater reduction 
in ADP induced platelet aggregation compared to placebo (open symbols). Symbols represent 















































7.1.4 Dual anti-platelet therapy and bleeding in surgery for CLI 
 
In conducting the first prospective, double–blind, randomised controlled trial of pre-operative 
dual anti-platelet therapy in surgery for critical limb ischaemia, our study provides the first 
robust, objective evidence for the potential bleeding outcomes associated with intensive anti-
platelet therapy in this specific surgical population [Burdess et al, 2010]. In 108 patients 
undergoing infra-inguinal surgery for CLI, a 600mg loading dose of pre-operative clopidogrel 
in addition to 75mg of maintenance aspirin in 50 patients was associated with an increase in 
major non-life-threatening bleeding (transfusion of >2 but <4 units of red cells) and incidence 
of wound leak/haematoma. There were no statistically significant increases in minor or life-
threatening major bleeding. Our results are consistent those reported by the CURE trial where 
those patients who continued clopidogrel therapy within 5 days of coronary artery bypass had a 
2-fold increased relative risk of major bleeding [Fox KA et al, 2001]. 
Approximately two thirds of patients with peripheral arterial disease have co-existing coronary 
atherosclerosis, and 40% will have had a coronary intervention prior to vascular surgery. More 
than 90% of percutaneous coronary interventions involve the placement of intracoronary stents. 
This procedure requires long-term treatment with anti-platelet agents, which are mandatory for 
the re-endothelialization and success of the stent. Around 5% of patients who have undergone 
PCI will undergo non-cardiac surgery within the first year of stenting [Vicenzi MN et al, 
2006]. Objective evidence is therefore required for the management of high-risk vascular 
patients undergoing surgery.  Studies have demonstrated an increased incidence of adverse 
cardiac events in the peri-operative period, in patients undergoing non-cardiac surgery early 
after PCI and stenting [Kaluza GL et al, 2000; Wilson SH et al, 2003]. In addition, interruption 
of anti-platelet therapy is associated with an increase in major adverse cardiac events [Kaluza 
GL et al, 2000; McFadden EP et al, 2004]. Increasingly, the surgical team is confronted with 
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the decision of whether to continue anti-platelet therapy into the peri-operative period. 
Currently there is no protocol for the peri-operative use of anti-platelet therapies, and no 
prospective studies of different anti-platelet regimes during non-cardiac surgery. However, a 
recent review of the current data proposed that apart from low coronary risk situations, patients 
on anti-platelet drugs should continue their treatment throughout surgery, except when 
bleeding might occur in a closed space or massive blood loss may be expected [Chassot PG et 
al, 2007].  
Although our work does not provide comprehensive evidence for the benefits associated with 
peri-operative dual anti-platelet therapy, it does provide the first objective evidence of the 
degree of bleeding that could be expected with use of these agents in the immediate peri-
operative period. It therefore provides a valuable guide to the vascular team in the surgical 
preparation of these high-risk patients. 
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7.2 FUTURE DIRECTIONS 
 
7.2.1 Assessment of platelet activation and platelet reactivity 
 
We proposed that the high incidence of peri-operative adverse cardiovascular events associated 
with surgery for CLI was mediated by increased in vivo platelet activation and inflammation at 
the time of operation.  
We demonstrated that in vivo platelet-monocyte aggregation and platelet P-selectin expression 
fell following surgery for CLI. This profile was the same for both amputation and bypass 
procedures. In contrast, when we assessed ex vivo platelet reactivity to ADP in a small sub-
group of patients, we demonstrated a rise in platelet aggregation post-operatively (Figure 7.1). 
Previous studies, which have reported post-procedural rises in platelet activation markers, have 
predominantly examined platelet responsiveness to exogenous agonists as opposed to resting 
activation states. However, where both measures of platelet activation have been studied (both 
in vivo and ex vivo), subtle differences in the peri-operative trend have been observed [Samama 
CM et al, 2001; Rajagopalan S et al, 2007]. Therefore these conflicting results could be due to 
differences in methodology.  
In vivo platelet-monocyte aggregation and platelet P-selectin expression rose post-operatively 
in patients undergoing arthroplasty (Figure 7.1 A). Therefore it can be assumed that the stress 
of surgery alone can cause a rise in these markers. In those patients with pre-operative 
endothelial dysfunction (as in CLI), the baseline elevation in resting platelet activation may 
supersede the post-operative increase attributable to surgery.  
Alternatively, this finding could be due to removal of thrombotic stimulus with amputation or 
revascularisation of ischaemic tissue, suggesting that surgery actually protects patients from 
thrombotic risk. The fact that 50% of Troponin positive events occurred pre-operatively could 
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suggest that patients with critical limb ischaemia are actually at highest risk of 
atherothrombotic events in the run up to surgery and are experiencing silent cardiac ischaemia.  
Sequestration of circulating activated platelets within amputated tissue or a new bypass 
conduit, may also mean that post-operative rises in platelet activation were not detected by 
flow cytometry. Flow-cytometric assessment of in vivo resting platelet-monocyte aggregation 
provides information on circulating activation states. If activated platelets are rapidly cleared or 
are adherent to blood vessel walls, flow cytometry may not detect evidence of platelet 
activation [Abrams CS et al, 1990; Kestin AS et al, 1993].  
We would therefore propose to re-examine the changes in both peri-operative in vivo platelet 
activation and ex vivo reactivity in patients with critical limb ischaemia.  In a non-
interventional study in the same patient population we would assess both in vivo platelet 
monocyte aggregation and ex vivo reactivity to a panel of platelet agonists. We would expand 
our blood sampling, obtaining a further samples in the run up to surgery, in addition to 
extending the post-operative sampling period. This would provide a more detailed profile of in 
vivo platelet activation and ex vivo function during the peri-operative period. This would 
potentially provide a more specific time period of maximum risk for this patient group.  
 
7.2.2 Variability in response to clopidogrel 
 
It has been noted that clopidogrel’s anti-platelet effect is not uniform in all patients. This 
concept of variability in response to clopidogrel or clopidogrel-resistance, currently has no 
clear definition. This is largely due to differences in the technique used to measure extent of 
clopidogrel induced anti-platelet effects (different assays, different agonist doses, different cut-
off values). There is also evidence to suggest that subjects with a higher baseline (pre-
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treatment) level of platelet reactivity, contribute to an apparent reduced clopidogrel induced 
anti-platelet effect [Gurbel PA et al; 2003]. 
This inter-patient variability in clopidogrel response is multifactorial. Extrinsic mechanisms 
reflect a reduced bioavailability of clopidogrel, such as drug-drug interactions affecting the 
transformation of clopidogrel into its active metabolite. Intrinsic mechanisms encompass 
genetic polymorphisms of the P2Y12 receptor and P3A Cytochromes [Nguyen TA et al; 2005]. 
This individual variability in response to clopidogrel has been demonstrated to have significant 
clinical implications. Persistent platelet activity despite clopidogrel treatment has been linked 
with increased incidence of stent thrombosis and post-stent ischaemic events [CREST Study. 
Gurbel PA et al, 2005].  
In an attempt to manage this phenomenon, several studies have focused on the loading dose of 
clopidogrel utilized in patients undergoing PCI. Clopidogrel-induced platelet inhibition is both 
dose and time dependent. Investigations have now shown that a 600mg loading dose achieves 
maximum platelet function inhibition after 2 hours [Montalescot G et al, 2006]. 
We deliberately chose a loading dose of 600 mg in our trial and all post-treatment bloods were 
taken at least four hours after ingestion of study drug. We postulated that if patients undergoing 
surgery for CLI were to achieve a cardio-protective benefit from intensive anti-platelet therapy, 
then ensuring a significant platelet inhibition in the majority of our trial subjects would provide 
the best opportunity for demonstrating this. However we acknowledge that although this high 
loading dose will have reduced the number of ‘non-responders’ it will not have eliminated 
inter-individual variability in response. Indeed, results from the GRAVITAS trial [2011] 
suggested that a treatment strategy of high dose clopidogrel for high residual platelet reactivity 
post PCI, does not improve outcome. 
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We did not specifically examine the variability in response to clopidogrel in the 50 patients 
receiving the trial medication. Nor did we explore any relationship between low response to 
clopidogrel and incidence of cTroponin I release in this small number of patients.  
In subsequent studies, the bleeding risks associated with greater platelet inhibition must also be 
balanced against atherothrombotic protection, and other dosing regimes should ideally be 
assessed. It is clear from the evolving literature that clopidogrel-induced platelet inhibition is 
patient specific and the ideal anti-platelet regime will have to be tailored to a patient’s baseline 
reactivity, in addition to the clinical scenario [Gravitas Group, 2011].  
 
7.2.3 Peri-operative c-Troponin I release  
 
Pre-clinical studies and mechanistic data have informed the design of large-scale clinical trials 
powered to demonstrate differences in clinical outcomes in patients suffering coronary 
atherothrombotic disease. Given the greater potential for bleeding in surgical patients receiving 
intensive anti-platelet therapies, it was with this aim that we conducted our proof-of concept 
study of peri-operative platelet activation and inflammation. Our study was primarily powered 
to examine differences in platelet activation markers between patients on clopidogrel and those 
on placebo. However, by utilising a sensitive assay for cardiac Troponin I we hoped to capture 
all incidences of cardiac injury. 
Previous studies have shown that elevations in pre-procedural platelet activation or reactivity 
markers are associated with cardiac Troponin release following PCI [Zhang SZ et al, 2007; 
Ray MJ et al, 2005; Frossard M et al, 2004; Faraday N et al, 2004]. We specifically recruited 
only patients with severe PAD (CLI) and utilised a sensitive assay for cardiac-Troponin I, 
demonstrating 18 positive events in our study population (16.7%). However, equivalent sized 
studies of patients with acute coronary syndromes and PCI have displayed a greater incidence 
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of Troponin release, with a larger proportion of patients having higher levels of cardiac-
Troponin. In addition, we only measured Troponin at 4 time points and could have therefore 
missed episodes of cardiac necrosis, especially since there is a delayed increase in circulating 
levels of cardiac troponins at the time of cardiac injury [Macrae AR et al, 2006]. 
Evidence indicates that even small rises in cTnI are associated with poor outcome [Galvani M 
et al, 1997; Morrow DA et al, 2001]. Newer, highly sensitive cTnI assays (hs-cTnI) are 
therefore being developed in order to measure very low levels of cardiac Troponin in an 
attempt to improve rapid diagnosis and treatment of patients [Reichlin T et al, 2009]. Although 
we used a sensitive troponin assay we were still underpowered to demonstrate a direct effect of 
clopidogrel on cardiac troponin release. It therefore remains to be conclusively demonstrated 
that reductions in platelet activation with dual anti-platelet therapy in patients undergoing 
surgery for CLI, translate into a reduction in cardiac injury. 
 
 
7.2.4 Limitations of current clinical trials of anti-platelet agents in PAD  
 
PAD is recognised as a serious cardiovascular disorder, yet despite its epidemiological and 
prognostic importance, relatively few clinical trials with cardioprotective agents have been 
conducted specifically in this group of patients. In particular, anti-platelet therapy is used in 
PAD based essentially on meta-anlayses [Antithrombotic Trialists’ Collaboration; 2002], 
extrapolation of results from trials in other conditions [Gresele P et al; 1998], or subgroup 
analyses of large clinical trials enrolling patients with various manifestions of atherosclerotic 
disease. In coronary atherosclerotic disease there are an abundance of trials of various anti-
platelet agents, in a variety of clinical scenarios (stable disease, acute coronary syndromes, 
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peri-PCI). In comparison, the most recent AHA guidelines for anti-platelet use in PAD can still 
only cite level A evidence for the prophylactic use of aspirin only (Figure 7.1). 
 
Two large clinical trials that have contained a significant number of PAD patients include 
CAPRIE and CHARISMA. The CAPRIE trial compared clopidogrel versus aspirin in patients 
at high risk of atherosclerotic events (three pre-defined subgroups of patients with recent 
stroke, myocardial infarction, or PAD.) CHARISMA compared long-term aspirin with aspirin 
plus clopidogrel in patients with symptomatic and asymptomatic disease. In both studies, the 
PAD patients were heterogeneous in terms of disease severity and cardiovascular risk profile. 
Both trials have been criticised for the conclusions they made following post-hoc sub-group 
analysis of PAD patients [Gebel JM, 2007; Gresel P et al, 2009] and neither trial has changed 
the current therapeutic indications for PAD. 
 
At the time of our study the CASPAR trial [Belch JJ et al, 2010] was embarking on a 
randomized, placebo-controlled trial of clopidogrel and aspirin in bypass surgery for peripheral 
arterial disease. In this multi-centre study, patients undergoing unilateral, below-knee bypass 
grafting for atherosclerotic peripheral arterial disease were randomised to clopidogrel or 
placebo 2-4 days after surgery and the primary efficacy endpoint was a composite of index-
graft occlusion or revascularization, above-ankle amputation of the affected limb, or death. The 
primary safety endpoint was severe bleeding (GUSTO classification).  
Overall, additional post-operative clopidogrel did not improve limb or systemic outcomes. 
Subgroup analysis suggested that combination therapy conferred benefit in patients receiving 
prosthetic grafts without significantly increasing major bleeding risk. Although cardiovascular 
out-comes were not a primary end-point, the trial did not show any benefit from combination 
therapy. However, additional clopidogrel was not commenced until after surgery and no 
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loading dose was given, therefore any peri-operative advantage of intensive anti-platelet 






ACC/AHA Guidelines for the Management of 
Patients With Peripheral Arterial Disease (Lower 
Extremity, Renal, Mesenteric, and Abdominal Aortic) 
 
F. ANTIPLATELET AND ANTITHROMBOTIC DRUGS. 
RECOMMENDATIONS 
Class I 
1. Antiplatelet therapy is indicated to reduce the risk of MI, stroke, or vascular death in individuals with 
atherosclerotic lower extremity PAD.  
(Level of Evidence: A) 
2. Aspirin, in daily doses of 75 to 325 mg, is recommended as safe and effective antiplatelet therapy to 
reduce the risk of MI, stroke, or vascular death in individuals with atherosclerotic lower extremity 
PAD.  
(Level of Evidence: A) 
3. Clopidogrel (75 mg per day) is recommended as an effective alternative antiplatelet therapy to aspirin to 
reduce the risk of MI, stroke, or vascular death in individuals with atherosclerotic lower extremity PAD.  
(Level of Evidence: B) 
Class III 
1. Oral anticoagulation therapy with warfarin is not indicated to reduce the risk of adverse cardiovascular 
ischemic events in individuals with atherosclerotic lower extremity PAD.  
(Level of Evidence: C) 
 
 
ACC/AHA Guidelines for Cardiovascular Risk Reduction in Patients with peripheral 










In the CURE trial, subgroup analysis of the 2072 ACS patients undergoing CABG, revealed an 
overall relative reduction in adverse events. However, this reduction was only significant for 
pre-surgical events in patients progressing to early CABG at the index hospitalisation. Post-
operative clopidogrel use was not associated with a significant reduction in cardiovascular 
events, irrespective of the duration of time to CABG. However, the CURE trial examines anti-
platelet therapy in surgical patients who are progressing to surgery because of cardiac 
ischaemia. It remains to be confirmed if PAD patients are most at risk from cardiovascular 
events before or after surgery. 
In summary, no trial to date has risk stratified PAD patients and examined treatment options 
accordingly. None specifically address the cardiovascular risk associated with the peri-
operative period. Although our studies do not provide conclusive evidence for a beneficial role 
of peri-operative dual anti-platelet therapy, they highlight the need for improved medical 
treatment of these patients with robust trials of cardio-protective therapies specifically 
organised to address the spectrum of PAD.  
 
7.2.5 Novel anti-platelet agents 
 
Arguably, the role of well known anti-platelet agents, aspirin and clopidogrel, has still not been 
fully determined in the management of specific cases of PAD. However, other anti-platelet 
agents also remain to be examined in the setting of PAD. Although anti-platelet therapy is 
highly effective at reducing atherothrombotic risk, patients continue to experience thrombotic 
events despite the use of agents such as aspirin and clopidogrel. Many of these events occur, in 
part, because of the inadequate response to these drugs [Barragan P et al, 2003; Gurbel PA et 
al, 2005; Hochholzer W et al, 2006; Bonello L et al, 2008]. This has prompted the pursuit of 
novel agents with aspirations of optimising anti-platelet therapy. 
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 GP IIb/IIIa Inhibitors 
The platelet surface membrane glycoprotein (GP) IIb/IIIa receptor, binds circulating fibrinogen 
or von Willebrand factor and crosslinks platelets in the final common pathway to platelet 
aggregation. Intravenous agents directed against this receptor include the chimeric monoclonal 
antibody fragment abciximab, the peptide inhibitor eptifibatide and nonpeptide mimetics 
tirofiban and lamifiban. Several large trials involving patients with UA/NSTEMI have shown 
that the GP IIb/IIIa inhibitors are of substantial benefit for patients at high risk, those 
undergoing PCI, or both [PRISM-PLUS investigators, 1998; Boersma E et al, 2002]. The 2007 
ACC/AHA guidelines recommend that, for patients with UA/NSTEMI who will be treated 
initially according to an invasive strategy, either an intravenous GP IIb/IIIa inhibitor or 
clopidogrel should be added to aspirin and anticoagulant therapy (upstream) before diagnostic 
angiography is performed (class I recommendation). They also state that adding both agents is 
reasonable (class IIa recommendation) [Anderson JL et al, 2007]. Questions remain about their 
benefit in the setting of primary PCI, as well as in patients with acute coronary syndromes who 
do not undergo PCI.  
One disadvantage of both aspirin and clopidogrel is the irreversible nature of platelet 
inhibition. One advantage of GP IIb/IIIa inhibitors is their shorter duration of action and 
potential reversibility. Despite this, these drugs have not been specifically examined in the 
peri-operative setting. Pooled analysis of the 82 patients in the EPILOG [1997] and EPISTENT 
[1998] trials undergoing CABG during hospitalization for ACS suggested a trend towards a 
reduction in ischemic endpoints in patients treated with abciximab (14% vs 24%, P>0.2). 
Almost two thirds of these patients were operated on within 6 hours of discontinuing 
abciximab. A similar benefit has been demonstrated with the shorter acting, reversible 
eptifibatide. In the PURSUIT trial [1998], 78 patients underwent emergency CABG within 2 
hours of eptifibatide cessation. Peri-operative myocardial infarction was significantly reduced 
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in patients who received eptifibatide (46% vs 22%, p < 0.05). However, whether these findings 
apply to surgical PAD patients remains to demonstrated. 
There remains a relative paucity of data examining the use of the GPIIb/IIIa antagonists during 
peripheral arterial interventions despite years of use by coronary interventionalists. The studies 
available are conducted in small patient groups, and mostly examine the role of GP IIb/IIIa 
antagonists during the treatment of acute peripheral arterial thrombosis to enhance 
thrombolysis, and to a lesser extent, in chronic lesions and critical limb ischemia. In a 
prospective randomized controlled trial, pre-procedural Abciximab therapy in addition to 
standard dose heparin and aspirin, was demonstrated to improve patency following 
endovascular revascularisation of long segment femoropopliteal occlusions [Dörffler-Melly J 
et al, 2005]. Risk of major bleeding (TIMI criteria) was not significantly increased, while 
access-site bleeding was significantly higher amoungst patients receiving abciximab. However, 
cardiovascular outcomes were not examined and the patient group contained both claudicants 
and those with CLI. The potential for both adverse cardiovascular outcomes and bleeding 
complications in endovascular procedures would also be expected to be less than that of open 
surgery. 
 
Novel P2Y12 receptor antagonists 
New P2Y12 antagonists such as prasugrel and ticagrelor, and the reversible non-thienopyridine 
drugs AZD6140 and Cangrelor, have been developed to provide a more rapid and consistent 
platelet inhibition, and overcome the non-reversibility of clopidogrel.  
 The TRITON-TIMI 38 trial [2006], demonstrated that prasugel therapy in patients with ACS 
undergoing PCI, was associated with significantly reduced rates of ischaemic events, including 
stent thrombosis, but with an increased risk of bleeding, in comparison to clopidogrel. In the 
PLATO trial [2009], patients with acute coronary syndromes with or without ST-segment 
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elevation, who were treated with ticagrelor as compared with clopidogrel, had a significantly 
reduced rate of death from vascular causes, myocardial infarction, or stroke but without an 
increase in the rate of overall major bleeding.  
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RANDOMIZED CONTROLLED TRIALS
Randomized Controlled Trial of Dual Antiplatelet Therapy in
Patients Undergoing Surgery for Critical Limb Ischemia
Anne Burdess, MB, ChB,* Alastair F. Nimmo, MD,† O. James Garden, MD,* John A. Murie, MD,‡
A. Raymond W. Dawson, MD,‡ Keith A. A. Fox, BSc (Hons), MB ChB, FRCP, FESC, FMed Sci,§
and David E. Newby, PhD§
Background and Objective: Patients with critical limb ischemia have a
perioperative cardiovascular morbidity comparable to patients with acute coro-
nary syndromes. We hypothesized that perioperative dual antiplatelet therapy
would improve biomarkers of atherothrombosis without causing unacceptable
bleeding in patients undergoing surgery for critical limb ischemia.
Methods: In a double-blind randomized controlled trial, 108 patients under-
going infrainguinal revascularization or amputation for critical limb ischemia
were maintained on aspirin (75 mg daily) and randomized to clopidogrel
(600 mg prior to surgery, and 75 mg daily for 3 days; n  50) or matched
placebo (n  58). Platelet activation and myocardial injury were assessed by
flow cytometry and plasma troponin concentrations, respectively.
Results: Clopidogrel reduced platelet-monocyte aggregation before surgery
(38%–30%; P  0.007). This was sustained in the postoperative period (P 
0.0019). There were 18 troponin-positive events (8 16.0% clopidogrel vs.
10 17.2% placebo; relative risk RR: 0.93, 95% confidence interval CI:
0.39–2.17; P  0.86). Half of troponin-positive events occurred preopera-
tively with clopidogrel causing a greater decline in troponin concentrations
(P  0.001). There was no increase in major life-threatening bleeding (7
14% vs. 6 10%; RR: 1.4, 95% CI: 0.49–3.76; P  0.56) or minor
bleeding (17 34% vs. 12 21%; RR 1.64, 95% CI: 0.87–3.1; P  0.12),
although blood transfusions were increased (28% vs. 12.6%, RR: 2.3, 95%
CI: 1.0–5.29; P  0.037).
Conclusions: In patients with critical limb ischemia, perioperative dual
antiplatelet therapy reduces biomarkers of atherothrombosis without causing
unacceptable bleeding. Large-scale randomized controlled trials are needed
to establish whether dual antiplatelet therapy improves clinical outcome in
high-risk patients undergoing vascular surgery.
(Ann Surg 2010;252: 37–42)
Patients with peripheral arterial disease have an increased risk ofadverse cardiovascular events,1 particularly in the perioperative
period.2 Myocardial injury is the commonest life-threatening com-
plication of vascular surgery with a reported incidence ranging from
8% to 40%.3–5 This is comparable to the cardiovascular risk of
patients presenting with an acute coronary syndrome: 30-day death
and reinfarction rate of 8% to 20%.6
In patients with peripheral arterial disease, prophylactic use of
the thienopyridine clopidogrel has modest additional secondary
preventative benefits in comparison to,7 or in combination with,8
aspirin. Combination aspirin and clopidigrel therapy is of major
benefit in reducing recurrent ischemic events in patients with acute
coronary syndromes.9 It is therefore reasonable to postulate that dual
antiplatelet therapy may have particular benefits in patients under-
going vascular surgery. However, many clinicians would question
the wisdom of dual antiplatelet therapy in the operative setting
because of the risk of increased peri-operative bleeding. The CURE
(Clopidogrel in Unstable angina to prevent Recurrent ischemic
Events) trial reported an overall relative risk reduction in cardiovas-
cular death, myocardial infarction, or stroke in patients undergoing
coronary artery bypass grafting following non-ST segment elevation
myocardial infarction, without an increase in major life-threatening
bleeding.10 However, the surgical subgroup was not prospectively
randomized and only a small proportion of patients received dual
antiplatelet therapy within 5 days of operation. Despite these limi-
tations, the trial proposed that the potential cardiovascular benefits
of dual antiplatelet therapy may outweigh the risks of bleeding in the
high-risk surgical patient.
Atherothrombosis is the major underlying cause of adverse
cardiovascular events. Platelets play a key role in this process and
are associated with both the inflammatory destabilization of athero-
sclerotic plaques, and thrombus generation.11,12 Platelet activation is
commonly assessed using aggregometry or detection of platelet
surface P-selectin expression following ex vivo agonist stimulation.
These approaches are artificial and may not truly reflect the status of
in vivo platelet activation because of the potential for in vitro
activation, and the rapid shedding of P-selectin from the platelet
surface.13 Activated platelets are rapidly cleared from the circulation
by monocytes and the quantification of platelet-monocyte aggre-
gates is now emerging as the “gold standard ” assessment for in vivo
platelet activation.14,15 We and others have demonstrated that plate-
let-monocyte aggregates are increased in those who smoke or have
diabetes mellitus as well as in patients with peripheral arterial
disease or an acute coronary syndrome.16–19
To date, there have been no studies to investigate the effects
of dual antiplatelet therapy in patients undergoing surgery for
critical limb ischemia. Given the potential for both marked benefit
and hazard, we embarked upon a proof-of-concept pilot randomized
controlled trial. We hypothesized that combined perioperative aspi-
rin and clopidogrel therapy would improve biomarkers of athero-
thrombosis (platelet-monocyte aggregates and troponin release)
without causing unacceptable bleeding, in patients undergoing sur-
gery for critical limb ischemia.
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METHODS
Subjects
Patients with critical limb ischemia who were scheduled for
infra-inguinal bypass, femoral endarterectomy or lower limb ampu-
tation under general anesthesia were recruited into the study. Critical
limb ischemia was defined as the presence of rest pain or skin
breakdown, resulting from arterial disease. Exclusion criteria in-
cluded women of child bearing potential, nonatherosclerotic vascu-
lar disease, sudden acute limb ischemia requiring emergency sur-
gery, supra-inguinal or aortic surgery, history of acute coronary
syndrome within 3 months, history of peptic ulcer disease, previous
or current intracranial hemorrhage, bleeding diathesis, uncontrolled
hypertension, or thrombocytopenia, planned epidural or spinal an-
esthesia, hypersensitivity or allergy to thienopyridines, and current
warfarin or thienopyridine use.
Study Design
Patients were recruited between June 2005 and February
2008, and gave written informed consent prior to study participation.
The study was approved by the local Research Ethics Committee,
given Clinical Trial Authorization by the Medicines and Healthcare
products Regulatory Agency (United Kingdom), and was conducted
in accordance with the Declaration of Helsinki and CONSORT
guidelines.20,21
This was a prospective single center double-blind randomized
controlled trial at a tertiary referral vascular surgical unit in the Royal
Infirmary of Edinburgh, South-East Scotland, United Kingdom.
Treatment Allocation
Following recruitment, clopidogrel and matched placebo
were assigned in identical packs by the pharmacy trials unit through
allocation of sequentially numbered study medication packs that had
been randomized using an independent computer-generated se-
quence. Patients received 600 mg of clopidogrel or matched placebo
4 to 28 hours prior to surgery and received 75 mg of clopidogrel or
matched placebo daily for 3 days after surgery (Studies suggest that
the incidence of peri-operative adverse cardiovascular events is
greatest within the first 5 days of surgery.2 We therefore commenced
therapy preoperatively and continued maintenance levels into a short
postoperative period.). Patients undergoing bypass procedures re-
ceived a single dose of 5000 IU of intravenous unfractioned heparin
during surgery before arterial clamping. At the discretion of the
clinical team, intravenous protamine was given only if excessive
bleeding was felt to be present at the end of the operation. All
patients received subcutaneous unfractionated heparin 5000 IU
twice daily in the postoperative period and were maintained on
aspirin (75 mg daily) throughout the study.
Biomarkers of Atherothrombosis
Platelet Activation and Inflammatory Markers
Blood samples were taken before, and a minimum of 4
hours after, a loading dose of 600 mg of clopiogrel or matched
placebo, immediately after the operation in the recovery room,
and on day 1 after surgery. Flow cytometric measurements of
platelet-monocyte aggregates and platelet surface expression of
P-selectin were used as markers of in vivo platelet activation as
described previously.16,17,19,22 Directly conjugated monoclonal
antibodies were obtained from DakoCytomation (Cambridge,
United Kingdom) and Serotec (Oxford, United Kingdom).
Myocardial Injury
The Reference Clinical Biochemistry Laboratory measured
plasma troponin I concentrations using the ARCHITECT Troponin
I STAT assay (Abbott Diagnostics, Maidenhead, United Kingdom)
using an autoanalyzer. This has an analytical sensitivity of 0.009
ng/mL and a functional sensitivity of 0.032 ng/mL with a coefficient
of variation of 10%. The latter threshold was employed for the
clinical case definition of myocardial infarction (see below).
In-Patient Clinical Outcomes
Acute Coronary Syndromes
Clinical symptoms, plasma troponin concentrations and elec-
trocardiograms were recorded daily from the preoperative day until
day 3 postsurgery. A blinded independent cardiologist reviewed all
clinical data and applied the universal definition of myocardial
infarction.23
Bleeding Complications
Bleeding events were defined as major (life-threatening or
nonlife threatening) and minor according to CURE criteria.10 Post-
operative blood transfusions were recommended according to Scot-
tish Intercollegiate Guidelines Network (SIGN) criteria.24 Intraop-
erative blood loss, postoperative fall in hemoglobin, blood product
transfusion, length of operation and length of hospital stay were
recorded. Incidence of gastro-intestinal bleeding, persistent (3
days) wound leak, hematoma, or infection were documented.
Data and Statistical Analysis
An independent data monitoring committee performed an
interim safety analysis of bleeding outcomes following recruitment
of 50 patients and recommended continuation of the trial to com-
pletion. Following completion of trial recruitment, data collection,
and laboratory analyses, the data base was locked, treatment allo-
cation unblinded and prespecified analyses performed. The primary
end-point was platelet-monocyte aggregation. The sample size (n 
50 per group) was based on our previous studies16,17,19 and gave an
80% power of detecting a 4.8% difference in platelet-monocyte
aggregates at a significance level of 5%. Secondary outcomes
included plasma troponin concentration, and rate of myocardial
infarction and bleeding complications. Continuous variables are
reported as mean  SD. Analysis of variance with repeated mea-
sures, 2-tailed Student t test and 2 analysis were performed as
appropriate using GraphPad Prism Version 4 (La Jolla, US). Statis-
tical significance was taken as a 2-sided P value 0.05.
Statement of Responsibility
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manuscript as
written.
RESULTS
Of the 159 potentially eligible patients, 113 were randomized
to trial medication (Fig. 1). Of those who completed the study
protocol, 58 received placebo and 50 received clopidogrel. There
was no difference in baseline demographics between the 2 groups




In keeping with the patient population, baseline levels of
platelet-monocyte aggregation were markedly elevated. There was
no difference in baseline platelet-monocyte aggregates (P  0.80)
and P-selectin expression (P  0.80) between the 2 groups. Platelet
activation was unaffected by placebo (P  0.78) but clopidogrel
(600 mg) caused a rapid reduction in platelet-monocyte aggregates
(38%  17%–30%  17%, P  0.007) and platelet P-selectin
expression (4.9%  2.7%–2.8%  1.6%, P  0.0001). In both
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groups, platelet activation declined within 24 hours of surgery (P 
0.005), but clopidogrel treatment was associated with greater reduc-
tions throughout the immediate postoperative period (P  0.0019;
Fig. 2). To assess pharmacological efficacy of the trial intervention,
ex vivo platelet aggregation to 5 M adenosine diphosphate was
performed in a subgroup of trial participants (n  10 per group).
This confirmed that clopidogrel inhibited adenosine diphosphate-
induced aggregation (59%  20%–33%  18%, P  0.0001)
throughout the peri-operative period (P  0.0015; data not shown).
Myocardial Injury
Of the 108 trial subjects, 18 (16.7%) suffered an elevated
plasma troponin concentration (0.032 ng/mL): 8 (16.0%) received
clopidogrel and 10 (17.2%) placebo (relative risk RR 0.93, 95%
confidence intervals CI 0.40–2.17; P  0.86). Nine (8.3%) pa-
tients (4 clopidogrel and 5 placebo) had an elevation of plasma
troponin concentration before surgery, and 9 patients (4 clopidogrel
and 5 placebo) suffered a postoperative rise in troponin. Of those 9
FIGURE 2. Platelet-monocyte aggregates (squares; P
0.0001 for both groups) and platelet P-selectin expression
(circles; P  0.005 for both groups) over the perioperative
period in patients receiving placebo or clopidogrel. Clopi-
dogrel (closed symbols) caused a greater reduction in both
platelet-monocyte aggregates (P  0.0019) and platelet P-
selectin expression (P  0.0035) compared with placebo
(open symbols). Symbols represent mean  SD; analysis by
2-way ANOVA.
FIGURE 1. Trial profile.






n  58 P
Age (yr) 68  2 68  2 0.83
Male sex 39 (78) 45 (78) 0.96
Critical limb ischemia
Ankle-brachial pressure index 0.2 34 (68) 31 (53) 0.12
Skin changes (ulcer/gangrene) 27 (54) 34 (59) 0.63
Rest pain 42 (84) 49 (84) 1.00
Operation
Bypass 32 41 0.71
Amputation 14 14 0.71
Combined bypass and angioplasty 4 3 0.71
Lees revised cardiac risk index 325 40 43 0.47
Cardiac risk factors
Diabetes mellitus 19 (38) 19 (33) 0.57
Hypertension 41 (82) 48 (83) 0.91
Hypercholesterolemia 31 (62) 37 (64) 0.85
Family history of ischemic heart
disease
5 (11) 8 (14) 0.55
Current smoker 20 (40) 31 (53) 0.36
Serum creatinine (mol/L) 98  4 106  6 0.27
Ischemic heart disease 20 (40) 31 (56) 0.16
Cerebrovascular disease 11 (22) 15 (26) 0.64
Drugs
Aspirin 50 (100) 58 (100) 1.00
Statin 35 (70) 45 (78) 0.37
Beta-blockade 13 (26) 12 (21) 0.43
Angiotensin-converting enzyme
inhibition
19 (38) 24 (41) 0.72
Variables reported as mean  SD or n (%) and analyzed with unpaired t test or 2
analysis as appropriate.
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patients who sustained a preoperative troponin rise, plasma troponin
concentrations fell with clopidogrel therapy but remained un-
changed or increased in those on placebo (Fig. 3). Patients with
postoperative elevation in plasma troponin concentrations had greater
platelet-monocyte aggregates (40%  4% vs. 30%  2%; P  0.033).
Clinical Outcomes
Of the 108 trial participants, 7 patients (6.5%) sustained an
acute myocardial infarction: 3 (6.0%) in the clopidogrel group and
4 (6.9%) in the placebo group (RR: 0.87, 95% CI: 0.20–3.7, P 
0.85). There were no in-patient deaths, intracranial hemorrhages or
incidences of inotrope use. There was no difference in life-threat-
ening major bleeding between treatment groups (7 14% clopi-
dogrel and 6 10% placebo; RR: 1.35, 95% CI: 0.49–3.76; P 
0.56), although those who received clopidogrel had an increased risk
of major nonlife-threatening bleeding (11 22% clopidogrel and 4
7% placebo, RR: 3.19, 95% CI: 1.1–9.4; P  0.024; Fig. 4).
Twenty (40%) patients receiving clopidogrel underwent red-cell
transfusion compared with only 8 (14%) on placebo (P  0.0019).
Restricting analyses to transfusions administered in accordance with
the SIGN guidelines, there remained an increased transfusion rate in
the clopidogrel group (14 28% clopidogrel and 7 12% placebo;
RR: 2.32, 95% CI: 1.02–5.29; P  0.037). There was no difference
in minor bleeding between the 2 groups (17 34% clopidogrel and
12 21% placebo; RR: 1.64, 95% CI: 0.87–3.10; P  0.12). Five
patients suffered gastrointestinal bleeding (hematemesis or ma-
laena); 4 of whom were receiving placebo. Two patients received
intraoperative protamine—1 in each intervention arm.
There were 2 reoperations for bleeding in the placebo group
and 1 in the clopidogrel group. Although there was an increase in
wound leak in those patients who received clopidogrel (13 26% vs.
3 5%; RR: 5.03, 95% CI: 1.52–16.6; P  0.0024), there was no
difference in incidence of wound infection at 3 months (P  0.80).
Clopidogrel therapy did not increase the length of operation (P 
0.60) or hospital stay (P  0.72). Subgroup analysis of patients
undergoing revascularization compared with amputation revealed no
significant differences in clopidogrel versus placebo in terms of
perioperative adverse cardiovascular events or bleeding outcomes
(major life threatening, major nonlife threatening or minor). There
were no incidences of early graft failure in either group.
DISCUSSION
We have conducted the first double-blind randomized con-
trolled trial of perioperative dual antiplatelet therapy in patients
undergoing surgery for critical limb ischemia. We demonstrate
improvements in biomarkers of platelet activation and myocardial
injury without causing unacceptable bleeding complications. These
data form the first objective assessment of the risks and benefits of
perioperative dual antiplatelet therapy in patients undergoing high-
risk vascular procedures.
Peripheral arterial disease affects nearly 30 million people in
Western Europe and North America. In up to 3-quarters of cases,
patients have coexistent coronary artery disease and a 3-fold in-
creased risk of cardiovascular events and death.26 In a recent large
FIGURE 3. Change in plasma troponin concentrations in pa-
tients with preoperative troponin elevations on placebo
(open squares) or clopidogrel (closed squares). Symbols rep-
resent mean  SD, P  0.001; 2-way ANOVA, clopidogrel
(n  4) versus placebo (n  5).
FIGURE 4. Bleeding Outcomes. Major life-threatening (upper
panel; RR: 1.35, 95% CI: 0.49–3.76, P  0.56), major non-
life-threatening (middle panel; RR: 3.19, 95% CI: 1.08–9.4,
P  0.024), and minor (RR: 1.64, 95% CI: 0.87–3.1, P 
0.12) bleeding (closed bars) in patients on clopidogrel (left-
hand panels, nonstippled) or placebo (right-hand panels,
stippled); 2 analysis.
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observational study (n  5460), patients with peripheral arterial
disease scheduled for open vascular surgery had a worse prognosis
(2.4-fold increase in cardiovascular morbidity) than matched pa-
tients with severe myocardial ischemia referred for percutaneous
coronary intervention.27 Interestingly, the occurrence of periopera-
tive cardiac complications following vascular surgery was associ-
ated with long-term cardiac death. There is therefore a clear unmet
need to reduce cardiovascular events in patients with peripheral
arterial disease, especially in the perioperative period.
In agreement with previous studies,2–5 we report a high
incidence of perioperative myocardial infarction (6.5%) and tropo-
nin elevation (16.7%) in patients undergoing surgery for critical
limb ischemia. We also found that postoperative elevations in
troponin were associated with increased levels of postoperative
platelet activation. However, we were surprised to find that markers
of platelet activation fell postoperatively (both in clopidogrel and
placebo groups) and that half of the troponin-positive events oc-
curred before surgery. This occurred in the absence of renal dys-
function. This suggests that rather than surgery being an additional
thrombotic stimulus, removal of ischemic tissue may actually reduce
platelet activation in the majority of these patients. These findings
highlight the prevalence of “silent” preoperative myocardial injury,
and the important systemic prothrombotic consequences of critical
limb ischemia, as well as the need for preoperative intervention.
This study aimed to explore a proof of concept. Preclinical
studies of platelet activation in coronary patients have informed the
design of large scale trials which have subsequently shaped clinical
practice. These trials required several thousands of patients to
demonstrate a small but significant clinical benefit from antiplatelet
regimes. Despite suffering significant cardiovascular risk, there has
been little study of platelet activation in high risk vascular surgical
patients. The potential for adverse bleeding would seem greater for
patients undergoing open surgery under antiplatelet therapy. Conse-
quently, any large scale trial powered to examine clinical end points
should be justified by “pilot” data suggesting that some cardiovas-
cular benefit could be achieved without excessive bleeding.
Through the use of surrogate biomarkers, we have demon-
strated the potential benefits of dual antiplatelet therapy in the
peri-operative period. Clopidogrel reduced sensitive markers of
platelet activation (Fig. 2) that are associated with increased clinical
risk as well as the progression of atherothrombosis.11–17,28,29 Al-
though clopidogrel did not have an overall effect on the number of
peri-operative troponin-positive events (8 clopidogrel vs. 10 pla-
cebo; P  0.86), half of the troponin elevations occurred preoper-
atively and prior to the administration of the study medication.
Subsequent institution of clopidogrel therapy was associated with a
marked reduction in troponin concentrations (Fig. 3). However, we
readily acknowledge that our study was not primarily powered to
assess cardiac troponin and clinical outcomes and whether these
improvements in surrogate biomarkers translate into clinical benefit
remains to be established.
All therapies have potential benefits and risks, and it is
inevitable that antiplatelet therapies will be associated with in-
creased bleeding complications. Although it may be regarded as
potentially reversible, the importance of major bleeding must not be
underestimated as it remains an independent predictor of adverse
clinical outcome.30–32 Although vascular patients are at high risk of
cardiovascular events, bleeding concerns are a major disincentive
for the investigation of perioperative intensive antiplatelet regimes,
and perhaps underlie the paucity of such data. Most published
reports are observational,33,34 although randomized-controlled trials
of dual antiplatelet therapy have been performed in patients under-
going carotid endarterectomy35 and peripheral angioplasty,36 and
report no major increase in bleeding complications. However, there
have been no randomized-controlled trials of dual antiplatelet ther-
apy in surgery for critical limb ischemia, where the potential for both
perioperative bleeding and cardiac complications is greater. We
have successfully delivered such a trial and confirmed that while
bleeding is increased, there was no excess of life-threatening bleeds,
reoperations, or wound infections. Our results are consistent those
reported by the CURE trial,10 where those patients who continued
clopidogrel therapy within 5 days of coronary artery bypass had a 2-fold
increased relative risk of major bleeding. Arguably our pilot data
suggests that the bleeding risks of dual antiplatelet therapy in the
peri-operative period are modest, and perhaps often over estimated.
Increasingly patients are undergoing surgery for critical limb
ischemia with a recent history of a cerebrovascular event, acute
coronary syndrome, or percutaneous coronary intervention, and will
be receiving intensive antiplatelet regimes. Their perioperative man-
agement must protect them from both coexisting pathology as well
as the associated risks of surgery. Our study has shown that it is
feasible to perform vascular surgery for critical limb ischemia, under
dual antiplatelet therapy with an acceptable bleeding profile. Although
the absolute clinical benefits of such a regimen need to be validated in
a large-scale clinical trial, we believe that our study provides evidence
for the beneficial role of perioperative antiplatelet agents in protecting
these patients against cardiovascular complications.
Patients receiving epidural or spinal anesthesia were not
recruited into the study due to the theoretical risk of epidural
hematoma. We are aware that many vascular units aim for epidural
or spinal anesthesia, thus precluding many patients from perioper-
ative antiplatelet therapy. However, there is currently no level-one
evidence for superior cardiovascular outcome with neuraxial block-
ade compared with general anesthesia. The main benefit lies in
reducing respiratory complications associated with abdominal sur-
gery.37 Although many of the patients who were recruited smoked,
none had significant chronic obstructive airway disease (based on
lung function testing) and none were undergoing abdominal or
emergency surgery. Use of both trial medication and general anes-
thesia was therefore deemed appropriate.
Persistent platelet reactivity despite antiplatelet therapy has
been proposed as a risk factor for the recurrence of ischemic events
following PCI. Recent mechanistic and clinical data suggest that
higher loading and maintenance doses of clopidogrel may achieve a
more rapid and greater degree of platelet inhibition that translates
into improved clinical outcomes, but this is yet to be formally
evaluated in an adequately powered randomized trial.38 We admin-
istered a relatively high preoperative loading dose of clopidogrel
(600 mg) to ensure efficacy of the intervention during surgery. It was
hypothesized that if additional perioperative antiplatelet therapy was
to be of any therapeutic advantage then this should be demonstrated
with the largest degree of platelet inhibition. Previous studies have
reported increased platelet activation29,39–42 and cardiovascular
events occurring within the first 5 days following surgery. We
therefore rationalized that clopidogrel therapy would be of most
benefit when given preoperatively and continued in the immediate
postoperative period. It is possible that we could still achieve
atherothrombotic protection with reduced bleeding complications by
administering lower doses of clopidogrel and this requires further
clarification. However, given the relatively high incidence of tropo-
nin-positive events before surgery, we would recommend initiation
of therapy prior to surgery.
In conclusion, we have demonstrated that perioperative dual
antiplatelet therapy has beneficial effects on reducing biomarkers of
atherothrombosis without increasing life-threatening bleeds in pa-
tients with critical limb ischemia. We propose that large-scale
randomized controlled trials are needed to establish whether dual
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antiplatelet therapy can improve clinical outcomes in high-risk
patients undergoing vascular surgery.
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Perioperative platelet and monocyte activation in
patients with critical limb ischemia
Anne Burdess, MBChB,a Alastair F. Nimmo, MBChB,a Neil Campbell, BMedSci,a
Scott A. Harding, MBChB, MD,b O. J. Garden, MBChB, MD,a A. Raymond Dawson, MBChB, MD,c and
David E. Newby, MBChB, PhD,a Edinburgh, United Kingdom; and Wellington, New Zealand
Background: Patients with critical limb ischemia (CLI) have a high rate of adverse cardiovascular events, particularly when
undergoing surgery. We sought to determine the effect of surgery and vascular disease on platelet and monocyte
activation in vivo in patients with CLI.
Methods: An observational, cross-sectional study was performed at a tertiary referral hospital in the southeast of Scotland.
Platelet and monocyte activation were measured in whole blood in patients with CLI scheduled for infrainguinal bypass
and compared with matched healthy controls, patients with chronic intermittent claudication, patients with acute
myocardial infarction, and those undergoing arthroplasty (n  30 per group). Platelet and monocyte activation were
quantified using flow cytometric assessment of platelet-monocyte aggregation, platelet P-selectin expression, platelet-
derived microparticles, and monocyte CD40 and CD11b expression.
Results: Compared with those with intermittent claudication, subjects with CLI had increased platelet-monocyte
aggregates (41.7%  12.2% vs 32.6%  8.5%, respectively), platelet microparticles (178.7  106.9 vs 116.9  53.4), and
monocyte CD40 expression (70.0%  12.2% vs 52.4%  15.2%; P < .001 for all). Indeed, these levels were equivalent
(P-selectin, 4.4%  2.0% vs 4.9%  2.2%; P > .05) or higher (platelet-monocyte aggregation, 41.7%  12.2% vs 33.6% 
7.0%; P < .05; platelet microparticles, 178.7  106.9 vs 114.4  55.0/L; P < .05) than in patients with acute
myocardial infarction. All platelet and monocyte activation markers remained elevated throughout the perioperative
period in patients with CLI (P < .01) but not those undergoing arthroplasty.
Conclusions: Patients undergoing surgery for CLI have the highest level of in vivo platelet and monocyte activation, and
these persist throughout the perioperative period. Additional antiplatelet therapy may be of benefit in protecting vascular
patients with more severe disease during this period of increased risk. (J Vasc Surg 2010;52:697-703.)
Clinical Relevance: Peripheral arterial disease is increasingly common and is associated with a significant risk of
cardiovascular complications, especially at the time of surgery. Despite this, patients are poorly provided with evidence-
based therapies such as antiplatelet and lipid-lowering medications. Platelets play a key role in the pathogenesis of
atherothrombosis, with elevated levels of in vivo platelet activation prognostic of adverse clinical events. This study
demonstrates, for the first time to our knowledge, significantly greater levels of platelet activation in patients with severe
peripheral arterial disease compared with patients with acute myocardial infarction or patients undergoing other
moderate- to high-risk surgical procedures. This further emphasizes the need for improved risk stratification and
cardioprotection of this vulnerable group.Patients with peripheral arterial disease (PAD) are at in-
creased risk of adverse cardiovascular events.1 This risk in-
creases with the severity of disease, with progressive reductions
in the ankle brachial pressure index (ABPI) being an indepen-
dent predictor of cardiovascular outcome.2,3 Cardiovascular
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doi:10.1016/j.jvs.2010.04.024risk factor management is therefore the first-line treatment of
patients with PAD. These patients are particularly at risk
during the perioperative period. Myocardial infarction (MI) is
the commonest life-threatening complication of major vascu-
lar surgery, with a reported perioperative incidence of 8% to
40%, depending on the diagnostic criteria.4-6 This is compa-
rable to the 30-day death and reinfarction rate of 8% to 20%
seen in patients with acute coronary syndromes.7 Despite this,
patients with PAD often fail to receive evidence-based medical
therapies. There is clearly an unmet need for improved risk
stratification of these patients with appropriately tailored in-
tensive medical regimens.
Atherogenesis and its complications are complex
processes involving inflammatory and thrombotic mecha-
nisms.8-10 Monocyte adhesion to a damaged endothelium is a
central step in the initiation and progression of atherosclerosis
and appears to play a key role in plaque destabilization. In
contrast, platelets can adhere to atherosclerotic lesions in the
presence or absence of an overlying endothelium8 and contrib-
ute to thrombus formation that is responsible for acute cardio-
vascular events. Hence, platelet and monocyte activation both
predispose to plaque growth, instability, and rupture.
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platelet-monocyte aggregates that promote expression of
vascular cell adhesion molecules and increase leucocyte
adhesion to the inflamed endothelium.11 In addition, the
CD40/CD40 ligand dyad, which is expressed on the sur-
face of activated monocytes and platelets, is a major inflam-
matory trigger that promotes release of inflammatory cyto-
kines, adhesion molecules, and procoagulant activity.12
Disruption of CD40/CD40L or platelet-monocyte aggre-
gation leads to the retardation of atherosclerotic lesions in
animal studies.13,14
Raised levels of platelet-monocyte aggregates and
monocyte CD40 have been detected in smokers, patients
with diabetes mellitus, acute coronary syndromes, and in
those at risk of rethrombosis after percutaneous coronary
interventions.15-18 They are surrogate markers of clinical
risk and are predictive of adverse cardiac events. Several
studies have assessed platelet activation in peripheral ath-
erosclerosis and demonstrated a progressive increase in
activation with increasing severity of disease.19-21 How-
ever, there have been relatively few reports of platelet
activation and cellular inflammation at the time of opera-
tion,22-24 and none, to our knowledge, have compared
PAD patients with other high-risk populations.
We wished to investigate platelet and monocyte activa-
tion in patients with PAD specifically at the time of surgery
and compare this to levels of activation in other high-risk
populations. The high incidence of perioperative adverse
cardiovascular events in patients with severe PAD could be
mediated by increased systemic inflammation and platelet
Table I. Inclusion and exclusion criteria
Healthy volunteers Claudicants
Inclusion criteria Age 50 y Age 50 y
Intermittent claudicat















ABPI, Ankle-brachial pressure index; CVD, cerebrovascular disease; ECG, eactivation. These patients may potentially benefit from riskstratification and appropriately tailored medical regimens,
as occurs in patients with coronary atherosclerotic disease.
This exploratory study may support the conduct of inter-
ventional projects aimed at reducing surrogate markers of
clinical risk, before clinical trials of intensive antiplatelet and
anti-inflammatory strategies.
METHODS
This observational, cross-sectional study was per-
formed with the approval of the local ethics committee and
in accordance with the Declaration of Helsinki. All partic-
ipants provided written informed consent.
Participants. Participants were recruited from five
groups (n  30 per group): (1) patients with nonthrom-
boembolic CLI, (2) patients with chronic intermittent
claudication, (3) patients with a non-ST segment elevation
MI, (4) otherwise healthy patients undergoing hip or knee
arthroplasty, and (5) healthy volunteers. The inclusion and
exclusion criteria are summarized in Table I.
Patients with CLI, defined by the presence of rest pain
or skin ulceration, or both, and an ABPI 0.2, who were
scheduled to undergo infrainguinal bypass or amputation
were recruited from the surgical vascular unit. Patients who
had symptoms of intermittent claudication with an ABPI of
1 and 0.2, were recruited from the outpatient claudica-
tion clinic.
The 60 PAD patients received maintenance aspirin (75
mg daily) and statin therapy for at least 6 weeks before
inclusion. We wished to examine platelet activation under
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cardiogram; IHD, ischemic heart disease; MI, myocardial infarction.ion
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pyclopidogrel or warfarin were excluded. At present, the only
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PAD is coexisting history of recent (6 months) coronary
artery stenting or stroke.
Patients presenting to the coronary care unit and diag-
nosed with a non-ST elevation MI, defined as chest pain
with electrocardiographic (ECG) changes and elevated
plasma troponin I concentration (0.2 g/L), were re-
cruited.
We wished to examine the contribution of surgical
stress (without underlying PAD) to in vivo platelet activa-
tion. After discussion with a panel of consultant vascular
surgeons and anesthetists, we concluded knee or hip ar-
throplasty represented surgery of a similar magnitude to
peripheral bypass or amputation and was likely to be per-
formed in patients of a comparable age. Patients aged 50
years undergoing elective arthroplasty were approached.
To limit the effect of atherosclerosis on platelet activation,
we excluded patients with a history of diabetes, hyperten-
sion, ischemic heart disease or stroke, smoking, or anti-
platelet, antihypertensive, or statin use. Patients undergo-
ing arthroplasty did not receive perioperative heparin
according to the unit policy.
Sequential healthy individuals aged 50 were re-
cruited.
Blood sampling. Single baseline samples were taken
from all 150 participants. In patients with non-ST segment
elevation MI, samples were taken 24 hours of hospital-
ization and after the initiation of dual antiplatelet medica-
tion with aspirin and clopidogrel. To compare periopera-
tive platelet and monocyte activation, three blood samples
were taken from patients undergoing vascular or orthope-
dic surgery preoperatively, immediately postoperatively,
and on the day after the operation.
Blood was drawn by venipuncture of a large antecubital
vein using a 19-gauge needle. Care was taken to ensure a
smooth blood draw without venous stasis. Samples were
processed immediately. Blood for assessment of platelet-
monocyte aggregates, platelet expression of P-selectin, and
monocyte CD40 and CD11b, was collected into tubes
containing the direct thrombin inhibitor, D-phenylalanyl-
L-propyl-L-arginine chloromethyl ketone (PPACK, Cam-
bridge Biosciences, Cambridge, UK). Blood for the assess-
ment of platelet microparticles was collected into sodium
citrate. Platelet-poor plasma was prepared by centrifuga-
tion at 2000g at 4°C for 10 minutes and confirmed by a
platelet count of 107/L.
Assessment of in vivo platelet activation. Flow
cytometric measurements of platelet-monocyte aggregates
and platelet surface expression of P-selectin were performed
as described previously.15,16 Immunolabeling was per-
formed in whole blood 5 minutes of collection. Directly
conjugated monoclonal antibodies were obtained from
DakoCytomation (Cambridge, UK) and Serotec (Ox-
ford, UK). To assess platelet-monocyte aggregates, 60
L of blood were incubated for 15 minutes with a
fluorescein isothiocyanate (FITC)-conjugated anti-
CD42a monoclonal antibody (platelet marker) and aphycoerythrin (PE)-conjugated anti-CD14 monoclonal
antibody (monocyte marker) before fixation and eryth-
rocyte lysis with 500 L of FACSLyse solution (Becton
Dickinson, Oxfordshire, United Kingdom).17
Cells were measured by flow cytometry (EPICS XL2;
Beckman-Coulter). Samples were analysed with EXPO
32 software (Cytometry Systems). Platelet-monocyte ag-
gregates were detected by gating for cells that were
positive for both CD14 PE and CD42a FITC. Platelet
surface expression of P-selectin was assessed by gating for
cells that were positive for both FITC-conjugated anti-
CD42a monoclonal antibody, (platelet marker) and PE-
conjugated anti-CD62P monoclonal antibody (throm-
bin receptor-activating peptide [TRAP 1], immunoglobulin
G1). Isotype controls were used to reduce error from nonspe-
cific binding.
Platelet microparticles were identified by both size and
expression of platelet markers CD41 (glycoprotein [GP]
IIb) and CD31 (GPIIIa; platelet endothelial cell adhesion
molecule-1). Aliquots (25 L) of platelet-poor plasma
were incubated for 30 minutes with a PE-conjugated anti-
CD31 monoclonal antibody and a FITC-conjugated anti-
CD41 monoclonal antibody (Serotec, Oxford, UK), before
dilution with phosphate-buffered saline to form a volume
of 1 mL.
Platelet microparticles were gated according to their
size (events 1.0 m) by assessment of their forward light
scatter. TruCOUNT beads of 1.0 m (Becton Dickenson)
of a known concentration were used to calculate the vol-
ume of sample analyzed over 120 seconds at medium flow
rate. This allowed the absolute number of platelet micro-
particles to be measured. Isotype controls were used to
reduce error from nonspecific binding. Platelet micropar-
ticles were detected by gating for events that were sized 1
m (based on forward scatter) and positive for both CD31
and CD41.
Assessment of in vivo monocyte activation. Monocyte
activation was assessed by flow cytometric measurement of
percentage of monocyte CD40 expression and mean fluo-
rescent intensity (MFI) of monocyte CD11b expression, as
described previously.15,16 Immunolabeling was performed
in whole blood within 5 minutes of collection. To evaluate
CD40 and CD11b on monocytes, blood was diluted 1:2
with phosphate-buffered saline and incubated with the
following monoclonal antibodies: anti-CD14:FITC (Sero-
tec), anti-CD40:PE (Serotec), anti-CD11b:PE (Serotec),
and appropriate isotype-matched controls for 20 minutes
before fixation and erythrocyte lysis with 500 L of
FACSLyse solution. Monocytes were identified by gating
for CD14-positive cells.
Statistical analysis. Data are shown as scatter plots or
mean  standard deviation. Data were analyzed by analysis
of variance, 2 and Bonferroni post hoc tests, where appro-
priate, using Prism 4 software (GraphPad, La Jolla, Calif).
Statistical significance was taken as a two-sided value of P 
.05.
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Participants were predominantly middle-aged men,
with groups having similar distribution of ages and no
significant difference in mean age (Table II). In keeping
with their clinical presentation, patients with peripheral
arterial and coronary heart disease had a range of cardiovas-
cular risk factors and medications that were not present in
the healthy volunteers or patients undergoing orthopedic
surgery (Table II). Of the 30 patients with CLI, 18 under-
went femoral-popliteal bypass and 12 underwent below
knee amputations. None underwent endovascular proce-
dures. Dry gangrene was present in 17, but none had wet
gangrene.
Baseline platelet activation. Platelet activation mark-
ers were lowest in healthy volunteers and patients sched-
uled for arthroplasty (Fig 1). Baseline platelet-monocyte
aggregation (41.7%  12.2%) and platelet microparticles
(178.7  106.9) were highest in patients with CLI com-
pared with all other groups (Fig 1). Although patients with
CLI had higher values of platelet P-selectin than healthy
volunteers or those undergoing arthroplasty (P  .001),
there was no demonstrable difference between these pa-
tients and those with claudication or non-ST elevation MI
(4.4%  2.0% vs 4.2%  2.0% and 4.9%  2.2% respectively;
P  .05; Fig 1).
Baseline monocyte activation. Monocyte activation
markers were lowest in healthy volunteers and patients
scheduled for arthroplasty (Fig 2). Baseline monocyte ex-
pression of CD40 (70%  12.2%) was highest in patients
with CLI compared with all other groups (Fig 2). Baseline
monocyte CD11b was greatest in patients with CLI com-
pared with all groups except those with claudication, where
it was equivalent (56.6  18.3 vs 50.5  13.9, respectively;
P  .05; Fig 2).
Perioperative platelet and monocyte activation.
Table II. Participant demographics
Variablea
Healthy volunteers Intermittent claudicati
(n  30) (n  30)
Mean  SD Mean  SD
Age, y a 59  3 60  4
No. (%) No. (%)
Male sex b 16 (53) 22 (73)
CV risk factors
Hypertension 0 18 (60)
Diabetes 0 7 (23)
CAD 0 10 (33)
Current smoker 0 17 (57)
Medications
Aspirin 0 30 (100)
Clopidogrel 0 0
Statin therapy 0 30 (100)
ACE inhibitor 0 3 (10)
-blocker 0 2 (6.7)
ACE, Angiotensin converting enzyme; CAD, coronary artery disease; CV,
aP  .38, one-way analysis of variance.
bP  .24, 2 analysis.Throughout the perioperative period, levels of all plateletand monocyte markers remained greater in patients with
CLI than in those undergoing arthroplasty (Fig 3 and 4;
P  .0001). Platelet and monocyte activation rose imme-
diately postoperatively in patients undergoing joint arthro-
plasty (P  .05) before falling on the first postoperative day
(Fig 3 and 4). In contrast, platelet activation fell immedi-
ately after surgery in patients undergoing infrainguinal
revascularization or amputation (P  .05; Figure 3),
whereas monocyte activation remained unchanged (mono-
cyte CD40, P  .05) or rose on day 1 (monocyte CD11b;
P  .05; Fig 4).
There was no statistically significant difference in mark-
ers according to type of surgery performed for CLI (bypass
or amputation) and no difference in postoperative trend
(subanalysis not shown).
DISCUSSION
Consistent with previous studies,19-21 we have demon-
strated that platelet and monocyte activation is increased in
patients with PAD. We have shown for the first time, to our
knowledge, that patients undergoing surgery for CLI have
even greater levels of platelet and monocyte activation than
patients being treated for acute MI. In addition, perioper-
ative platelet and monocyte activation is markedly increased
in these patients and exceeds the increase in platelet activa-
tion and inflammation attributable to surgery itself. This
study supports the need for an increased appreciation of the
cardiovascular risks associated with these patients and an
improvement in cardioprotective management, especially
in the perioperative period.
PAD affects nearly 30 million people in Western Eu-
rope and North America, and up to three-quarters of these
patients have coexistent coronary artery disease and a three-
fold increased risk of cardiovascular events and death.25
Despite attempts to raise awareness of PAD as an important
Critical limb ischemia Acute coronary syndromes Arthroplasty
(n  30) (n  30) (n  30)
Mean  SD Mean  SD Mean  SD
68  2 58  2 57  4
No. (%) No. (%) No. (%)
23 (77) 20 (67) 17 (57)
24 (80) 20 (67) 0
10 (33) 8 (27) 0
16 (53) 13 (43) 0
16 (53) 16 (53) 0
30 (100) 30 (100) 0
0 30 (100) 0
30 (100) 24 (80) 0
12 (40) 21 (70) 0
6 (20) 16 (53) 0
vascular.on
cardiomarker of cardiovascular risk, patients are often poorly
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and lipid-lowering medications.26-29 The reasons for this
are unclear, but appear to be related to a lack of awareness
amongst health professionals of the severity of the disease.
Our study demonstrated that patients with CLI have a
greater elevation in systemic markers of platelet and mono-
cyte activation than comparator groups. We acknowledge
that the healthy volunteers and patients undergoing arthro-
plasty did not receive antiplatelet agents or lipid-lowering
drugs, which can affect platelet activation. However, pa-
Fig 1. Scatter dot plots are shown for resting in vivo platelet
activation in healthy volunteers (HV, ), claudicants (), patients
with critical limb ischemia (CLI, ’), patients with non-ST eleva-
tion myocardial infarction (NSTEMI, ), and patients undergoing
arthroplasty (●). A, Percentage of platelet-monocyte aggregation.
B, Percentage of platelet P-selectin expression. C, Platelet-derived
microparticles (/mL). The horizontal lines represent population
means (n  30 per group). Analysis by one-way analysis of variance
with Bonferroni post-tests.tients with PAD have a high incidence of adverse cardio-vascular events despite existing medical therapy. Indeed,
the elevations in platelet activation were seen despite the
standard medical regimen of aspirin and statin therapy and
were even greater than those seen in patients with acute MI.
It may be that there is scope for further management of
platelet activation in these patients.
Patients undergoing peripheral vascular surgery have a
particularly high incidence of perioperative cardiovascular
events. This has been attributed to increased platelet and
monocyte activity caused by the surgical process itself.
Patients without cardiovascular risk factors undergoing ar-
throplasty (and therefore no reason for elevated baseline
platelet activation) were recruited to assess the effect of
surgery alone on platelet activation. Our study showed that
throughout the perioperative period, platelet and mono-
cyte activation markers were higher in patients undergoing
vascular surgery than in those undergoing arthroplasty.
However, although platelet markers rose postoperatively in
Fig 2. Resting in vivo monocyte activation in healthy volunteers
(HV, ), claudicants (), patients with critical limb ischemia (CLI,
’), patients with non-ST elevation myocardial infarction (NSTEMI,
), and patients undergoing arthroplasty (●). A, Percentage of
monocyte CD40 expression. B, Monocyte CD11b (mean fluores-
cent intensity, MFI). Horizontal lines represent population means
(n  30 per group). Analysis by one-way analysis of variance with
Bonferroni post-tests.patients undergoing arthroplasty, we were surprised to see
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those with CLI. Patients with PAD, especially CLI, have
high baseline levels of activated platelets and monocytes.
This is due to the underlying endothelial dysfunction and
tissue ischemia. We therefore propose that the lack of
response after surgery in these particular patients could be
due to the removal of thrombotic stimulus by amputation
or revascularization. These patients may benefit from in-
creased platelet inhibition before surgery.
Cardiovascular disease is a critical public health issue.
The prevalence of the disease and increased awareness of
the cost-benefit associated with the management of cardio-
vascular risk have led to the concept of potential screening
programs for vascular disease.30 In addition, recommenda-
Fig 3. Perioperative in vivo platelet activation is shown in patients
undergoing surgery for critical limb ischemia (’) and arthroplasty
(●). Platelet activation in patients undergoing infrainguinal
bypass or amputation was greater than in patients undergoing
arthroplasty throughout the perioperative period (P  .0001).
In vivo platelet activation measured by (A) percentage of platelet-
monocyte aggregation (P  .05) and (B) percentage of P-selectin
expression (P  .05), rose immediately postoperatively in patients
undergoing arthroplasty but fell in those with critical limb ischemia
(P  .001). Mean  standard deviation; analysis between patient
groups by two-way analysis of variance with repeated measures;
analysis between time points for the same patient group by one-
way analysis of variance with Bonferroni post-tests.tions are required for the most appropriate use of interven-tions and therapies for patients with different manifesta-
tions of PAD. The use of imaging technologies or
biomarkers could help risk-stratify patients and guide man-
agement. This study demonstrates that sensitive markers of
in vivo platelet and monocyte activation—known to be
predictors of clinical risk—are markedly elevated in patients
with severe PAD at the time of surgery, despite current
medical therapy. This is in line with reports of the increased
cardiovascular risk associated with reducing ABPI.2
Further work is required, however, to demonstrate
the link between platelet activation and adverse cardio-
vascular outcomes in this specific patient group. We are
therefore conducting a trial of dual antiplatelet therapy
(aspirin plus clopidogrel) vs aspirin alone, in patients
undergoing surgery for CLI. The effect of intensive anti-
platelet therapy on platelet markers, cardiac troponin, and
high-selective C-reactive protein will be noted. This may
inform the design of larger-scale clinical trials powered at
Fig 4. Perioperative monocyte activation in patients undergoing
surgery for critical limb ischemia (’) and arthroplasty (●). Mono-
cyte activation in patients undergoing infrainguinal bypass or
amputation was significantly greater than in patients undergoing
arthroplasty throughout the whole perioperative period (P 
.0001). A, Percentage monocyte CD40 expression tended to rise
immediately postoperatively in orthopedic patients before return-
ing to baseline (P  .05) B, There was no significant postoperative
change in monocyte CD11b (mean fluorescent intensity) in ar-
throplasty patients (P  .05), but levels appeared to rise on day 1
after surgery in those with critical limb ischemia (P  .05).examining clinical end points in this population.
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Background: Many markers of platelet activation have been described but their reproducibility and compara-
bility in patient populations are poorly defined.
Objectives: We sought to compare markers of platelet and monocyte activation with platelet-monocyte ag-
gregates, a proposed gold standard of in vivo platelet activation, and assess their reproducibility in patients
with peripheral arterial disease: a population with substantial platelet activation, inflammation and risk of
thrombotic events.
Patients/Methods: Thirty patients with peripheral vascular disease attended on two occasions to permit
within-day and between-day comparisons. In vivo platelet and monocyte activation were determined by
flow-cytometric quantification of platelet-monocyte aggregation, platelet surface expression of P-selectin
and CD40L, platelet-derived microparticles, and monocyte surface expression of CD40 and CD11b. Plasma
concentrations of platelet-derived microparticles, soluble P-selectin and CD40L were measured by enzyme-
linked immunosorbant assays.
Results: Platelet-monocyte aggregation (36.7±7.86%), and platelet surface expression of P-selectin (5.8±
1.65%) and CD40L (3.3±1.45%) demonstrated comparable within-day (mean difference±co-efficient of repro-
ducibility; 0.9±15.4%, 0.21±1.65% and 0.2±2.8% respectively) and between-day reproducibility (2.0±12.4%,
0.10±2.25% and 0.9±6.4% respectively). Platelet-monocyte aggregates correlated well with other platelet
(r=0.30-0.50, Pb0.02) and monocyte (r=0.27-0.47, Pb0.03) activation markers. Flow cytometric and assay
quantified platelet-derived microparticles showed poorer reproducibility (co-efficient of reproducibility N40).
Conclusions: In patients with peripheral arterial disease, measurements of platelet-monocyte aggregates have
good reproducibility and consistently reflect other markers of platelet and monocyte activation.
© 2011 Elsevier Ltd. All rights reserved.Introduction
Atherothrombosis is the leading cause of mortality in the western
world. Platelets play a major role in the inflammatory and thrombotic
progression of atherosclerosis [1,2]. Indeed, increased platelet activity
is present in patients at increased risk of atherothrombotic events and
predicts adverse cardiovascular events [3–8]. The measurement of
platelet activity is therefore crucial to our understanding of the patho-
physiology of atherothrombosis, the prediction of adverse cardiovascu-
lar events, and the development of novel therapeutic interventions.Heart Foundation (FS/05/038);
and Royal College of Surgeons
Sciences, Chancellor's Building,
EH16 4SB, UK. Tel.: +44 131
2 6422.
.
rights reserved.Despite the development of several techniques, there is still no
generally accepted ideal measure of platelet activation. A variety of
methods exist, including platelet aggregometry, point of care devices,
flow cytometric assessment of platelet surface antigens, and plasma
markers of platelet activation: all have advantages and disadvantages
[9]. Historically considered the gold standard, platelet aggregometry
requires the preparation of platelet rich plasma and a high sample
volume. Centrifugation and washing procedures may produce cell
loss and artefactually activate platelets. Many of the point-of-care
systems assess ex vivo platelet aggregation to various exogenous ago-
nists. Although more labour intensive, flow cytometry is emerging as
the new sensitive gold standard with measurement of surface expres-
sion of platelet antigens providing an assessment of in vivo platelet
activation. It requires only a small sample volume, is performed on
whole blood, and allows analysis of platelets in their physiological
milieu. One of the most commonly studied markers of platelet activa-
tion is the α-granule membrane protein, P-selectin, that is present
only on the surface of activated degranulated platelets. However,
51A. Burdess et al. / Thrombosis Research 129 (2012) 50–55in vivo degranulated platelets rapidly lose their surface P-selectin, but
continue to circulate and function [10]. In contrast, P-selectin-positive
platelets very rapidly bind to leucocytes (mainly monocytes) via their
constitutively expressed counter receptor, P-selectin glycoprotein
ligand-1 (PSGL-1) [6]. Hence circulating platelet-monocyte aggre-
gates provide a more sensitive measure of in vivo platelet activation
[11]. In addition platelet-monocyte aggregation may alter leucocyte
function, causing monocyte arrest on the endothelium and potential-
ly enhance the growth of atherosclerotic plaques [12].
Manymethods and protocols for themeasurement of platelet activa-
tion have beendescribed [13–17]. Importantly, aspects of the techniques
themselves can lead to artefactual platelet activation, thus altering the
end result. However, there are few reports of test reproducibility. Even
when studying the same platelet marker, the methodology and end
unit of measurement may differ, making it extremely difficult to inter-
pret and compare results. An appreciation of these issues is crucial for
the meaningful interpretation of interventional studies, and the devel-
opment of anti-platelet therapies.
In the present study we sought to assess the reproducibility of an
established protocol (3,4,6) in measuring platelet-monocyte aggrega-
tion in a patient population expected to have elevated resting platelet
activation. In addition, we wished to compare the reproducibility and
correlation of other markers of platelet activation to a proposed gold
standard of platelet-monocyte aggregation.
Methods
The study was performed with the approval of the local ethics
committee, in accordance with the Declaration of Helsinki and the
written informed consent of all participants.
Subjects
Peripheral venous bloodwas obtained from 30 patients with periph-
eral arterial disease. Inclusion criteriawere (i) symptoms of claudication,
without rest pain or ulceration, (ii) reduced ankle brachial pressure
ratio, and (iii) evidence of arterial stenosis on Doppler scanning.
Study design
In order to assess reproducibility, four samples were taken from
each subject – two were taken on the same day one hour apart
(within-day reproducibility), and two were taken the following day
at the same time points (between-day reproducibility).
Platelet activation was assessed by measuring percent platelet-
monocyte aggregation andplatelet expression of P-selectin and platelet-
derived microparticles (no./μL) using flow cytometry. Platelet-derived
microparticles, and plasma soluble P-selectin and CD40L concentrations
were also measured by enzyme-linked immunosorbant assays (ELISAs).
Monocyte activation was measured via flow cytometric measurement
of percent monocyte CD40 expression and mean fluorescent intensity
of monocyte CD11b expression.
Blood collection
Bloodwas drawn by venepuncture of a large anticubital vein using a
19-gauge needle. Care was taken to ensure a smooth blood draw with-
out venous stasis. Samples were processed immediately. Blood samples
for assessment of platelet-monocyte aggregates, platelet expression of
P-selectin and monocyte CD40 and 11b expression, were collected
into tubes containing the direct thrombin inhibitor, D-phenylalanyl-L-
propyl-L-arginine chloromethyl ketone (PPACK, Cambridge Biosci-
ences). Flow cytometric measurement of platelet microparticles was
performed on platelet poor plasma (PPP). Blood was collected into
10 mL sodium citrate tubes and PPP prepared by centrifugation at
2000 g at 4 0 C for 10 min and confirmed by a platelet count of b109/L/(dilutionwith autologous plasma as required). Blood for the assay as-
sessment of platelet microparticles and soluble P-selectin and CD40L
was collected into tubes containing sodium citrate.
Immunolabelling and flow cytometry
Flow cytometric measurements of platelet-monocyte aggregation,
platelet surface expression of P-selectin, andmonocyte CD40 and11b ex-
pression were performed as described previously [3,4,6]. Immunolabel-
ling was performed in whole blood within 5 min of collection. Directly
conjugatedmonoclonal antibodies were obtained fromDakoCytomation
(Cambridge, UK) and Serotec (Oxford, UK). In order to assess platelet-
monocyte aggregates, 60 μL of blood were incubated for 15 min with a
FITC-conjugated anti-CD42a monoclonal antibody (GRP-P, platelet
marker) and a PE-conjugated anti-CD14 monoclonal antibody (Tuk-4,
monocyte marker) before fixation and erythrocyte lysis with 500 μL of
FACSLyse solution (6). Samples were processed using a BeckmanCoulter
flow cytometer and at least 2,500 cell events were analysed by EXPO32
software. Platelet-monocyte aggregates were detected by gating for
cells thatwere positive for both CD14 PE and CD42a FITC. Platelet surface
expression of P-selectin was assessed by gating for cells that were posi-
tive for both FITC-conjugated anti-CD42a monoclonal antibody (platelet
marker) and PE conjugated anti-CD62P monoclonal antibody (TRAP 1,
IgG1). Isotype controlswere used to reduce error fromnon-specific bind-
ing. To evaluate CD40 and CD11b on monocytes, blood was diluted 1:2
with PBS and incubated with the following monoclonal antibodies:
anti-CD14:FITC (Serotec), anti-CD40:PE (Serotec), anti-CD11b:PE (Sero-
tec) and appropriate isotype-matched controls for 20 min.
Platelet microparticles were identified by both size and expression
of platelet markers CD41 (GPIIb) and CD31 (GPIIa; PECAM). Aliquots
(25 μL) of PPP were incubated for 30 min with a PE-conjugated anti-
CD31 monoclonal antibody and a FITC-conjugated anti-CD41 mono-
clonal antibody (Serotec, Oxford, UK), before dilution with phosphate
buffered saline to form a volume of 1 mL. Platelet microparticles were
gated according to their size (eventsb1.0 μm) by assessment of their
forward light scatter. TruCOUNT beads of 1.0 μm (Becton Dickenson)
of a known concentration were used to calculate the volume of sam-
ple analysed over 120 s at medium flow rate. This allowed the abso-
lute number of platelet microparticles to be measured. Isotype
controls were used to reduce error from non-specific binding. Platelet
microparticles were detected by gating for events that were b1 μm in
size (based on forward scatter) and positive for both CD31 and CD41.
ELISAs
Platelet-derived microparticles
Platelet-derivedmicroparticles were assessed using a time-resolved
immunofluorometric assay previously reported byMichelsen et al. [18].
This method quantifies the amount of platelet-microparticle-located
CD41 (GPIIb) antigen in detergent-treated platelet-free plasma (μg/L).
In brief, PPP is filtered to remove any platelet micro-particle larger
than 0.1 μm (Ultra-free-MC Filter Units, Millipore, Billerica, MA, USA).
The GPIIb/GPIIIa complex (CD41/CD61) is then released from the mi-
croparticle membrane and solubilized by mixing 1 volume PPP and 1
volume Delfia Assay buffer containing 1% of the non-ionic detergent
Igepal CA-630. Two different monoclonal antibodies to GPIIb (CD41)
are used, one labelled with Europium (Diatec, Oslo, Norway), and the
other conjugated with biotin (clone DD4.1, Southern Biotechnology,
Birmingham, AL, USA). Samples (50 μL) of the solubilized GPIIb/IIIa
were then added to a Delfia streptavidin-coated plate (Perkin-Elmer
Life Sciences, Boston, MA, USA) and 150 μL of antibody mixture added.
Following incubation for 2 hours at room temperature, the wells are
washed and Delfia Enhancement solution (200 μL/well) added prior to
measurement of time-resolved fluorescence in a Victor21420 (Perkin-
Elmer Life Sciences, Boston, MA,USA).
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Soluble human P-selectin and CD40L were assessed using ELISAs
from RnD systems and Bender Med Systems respectively.Statistical analysis
The Bland Altman method was used to analyse the differences
between paired measurements and to test the reproducibility of
each measurement [19]. The co-efficient of reproducibility was calcu-
lated as 1.96 x the standard deviation of the differences between pairs
of measurements in the same subjects. Statistical significance was
assessed using a paired student's t-test. Correlation between variables
was analysed using Pearson and Spearman's correlation coefficients
as appropriate. The statistical package employed was GraphPad
Prism, Version 4 (La Jolla, USA). Statistical significance was taken as
a two-sided P value b0.05.Results
All 30 patients were male, aged 58±4 years and had a mean
ankle-brachial pressure index of 0.38±0.18. All patients were receiv-
ing maintenance aspirin (75–300 mg daily) and statin therapy, and
were current smokers.Reproducibility
Repeatedmeasurements were similar for all markers used (Table 1)
PN0.05. Flow cytometric measurements of per cent platelet-monocyte
aggregation, and platelet surface expression of P-selectin and CD40L,
showed good reproducibility (Table 1), with monocyte markers dem-
onstrating a wider standard deviation (although statistically not signif-
icant). There was minimal difference when comparing within-day and
between-day reproducibility although monocyte activation markers
appeared to show better within-day reproducibility. Flow cytometric-
derived measures of platelet-derived microparticles appeared to dem-
onstrate better within-day and between-day reproducibility than
immunoassay-derived measures, although both measurement tech-
niques demonstrated poor co-efficients of reproducibility in compari-
son to the other markers.Table 1
Within day and between day reproducibility of platelet activation markers.
Variable Mean Mean Difference
A. Within Day Reproducibility
PMA (%) 36.7 0.9
Platelet P-selectin (%) 5.8 0.21
Platelet CD40L (%) 3.3 0.2
PMP: Flow (no./μL) 157.2 8.1
PMP: Assay (GPIIb/μg/L) 25.9 5.7
Monocyte CD40 (%) 69.5 0.2
Monocyte 11b (MFI) 47.4 3.7
Soluble P-selectin (ng/mL) 42.3 1.2
Soluble CD40L (ng/mL) 0.6 0.1
B. Between Day Reproducibility
PMA (%) 37.3 2.0
Platelet P-selectin (%) 5.9 0.1
Platelet CD40L (%) 4.2 0.9
PMP: Flow (no./μL) 161.9 7.2
PMP: Assay (GPIIb/μg/L) 58.4 0.9
Monocyte CD40 (%) 69.6 2.5
Monocyte 11b (MFI) 49.9 0.8
Soluble P-selectin (ng/mL) 41.7 5.0
Soluble CD40L (ng/mL) 0.6 0.02Correlation between platelet markers
Platelet-monocyte aggregates correlated with all activation markers
suggesting that it represented a reliable measure of global activation
(Table 2, Fig. 1). Platelet surface expression of P-selectin showed the
best correlation with platelet-monocyte aggregation (r=0.50) although
platelet CD40L and platelet-derived microparticles also showed statisti-
cally significant correlations.Monocyte activationmarkers also correlated
with platelet-monocyte aggregation (monocyte CD11b P=0.0002;
monocyte CD40; P=0.0026) but not with other markers of platelet acti-
vation (PN0.05), suggesting that monocyte activation may also deter-
mine platelet-monocyte aggregate formation.
Immunoassay-derived measures of platelet activation, including
plasma concentrations of soluble P-selectin and soluble CD40L, demon-
strated poor or no correlations with flow cytometric-derived measures
of platelet activation, except platelet-monocyte aggregates (Table 3).
Indeed, when assessing the same variable, platelet-derived microparti-
cles or P-selectin, there was only a moderate correlation between the
two measures, or none at all (Table 3).
Discussion
We have assessed the reproducibility and consistency of platelet
activation markers in a patient population with high baseline levels
of platelet activation. We have shown that most measures of platelet
activation in patients with peripheral arterial disease have good re-
producibility both within and between days. Platelet-monocyte ag-
gregates appear to consistently reflect other markers of platelet and
monocyte activation. We suggest that platelet-monocyte aggregates
are reproducible and provide the best measure of in vivo platelet acti-
vation for clinical study.
Several reports have demonstrated an association between in-
creased platelet activation and adverse cardiovascular events [3–8].
Proof-of-concept studies hypothesise that reductions in platelet acti-
vation by anti-platelet regimes should correlate with improved clini-
cal outcomes. It is therefore useful to quantify the degree by which
antiplatelet medications reduce platelet activation markers. However,
clinically meaningful interpretation of these studies must account for
the normal variation in marker levels that occur within patient popu-
lations and that associated with measurement techniques. A variety
of methods are currently employed for the assessment of platelet




















Correlation of flow cytomteric-derived measures of platelet and monocyte activation.
Variable Platelet P-selectin (%) Platelet CD40L (%) PMP (no./μL) Monocyte CD40 (%) Monocyte 11b (MFI)
PMA (%) 0.50 0.41 0.27 0.27 0.47
Pb0.0001 P=0.0007 P=0.028 P=0.026 P=0.0002
Platelet P-selectin (%) 0.52 0.08 0.04 0.24
Pb0.0001 P=0.11 P=0.095 P=0.07
Platelet CD40L (%) 0.03 0.00 0.42
P=0.88 P=0.96 P=0.0013
PMP (no./μL) 0.00 0.08
P=1.0 P=0.98
Monocyte CD40 (%) 0.16
P=0.22
Pearson and Spearman correlation coefficient as appropriate.
Significant correlations shown in bold.
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markers can contribute to artefactual activation. Differences in tech-
nique make it difficult to compare results across studies, even
when examining the same subject population. In addition, units
of measurement often vary (e.g.% platelet expression, versus mean
fluorescent intensity). Therefore, for a given patient population, the
range of platelet activation levels often varies widely between studies.
Indeed, our reported mean sCD40L level of 0.6 ng/mL differs from
some of the reported studies by a factor of both 10-1 [20] and 101


















































Fig. 1. Comparison of percent platelet-monocyte aggregation versus (A) per cent platelet P-
(ng/mL; r=0.37, P=0.002) (C) immunoassay-derived measures of platelet microparticles
croparticles (no./μL; r=0.27, P=0.028).activation and inflammatory markers are to be utilised in guiding in-
terventional studies, readers must have a clear appreciation of the
limits of the methological techniques, and how they compare against
an accepted ‘gold standard’.
In the present study, we utilised a two-colour whole blood tech-
nique incorporating erythrocyte lysis and fixation to quantify platelet-
monocyte aggregates [3,4,6]. We have previously reported a number
of methodological considerations in the preparation and processing of
samples for flow-cytometric quantification of platelet-monocyte aggre-
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selectin expression (r=0.50, Pb0.0001), (B) plasma soluble P-selectin concentrations
(μg/L; r =0.44, P=0.0002), and (D) flow cytometric-derived measures of platelet mi-
Table 3
Comparison of Immunosorbant Assay-Derived and Flow Cytometric-Derived Markers of Platelet Activation.
Immunoassay
Flow Cytometry PMP: Assay (GPIIb μg/L) Soluble P-selectin Soluble CD40L
PMA (%) r=0.44 r=0.37 r=0.30
P=0.0002 P=0.002 P=0.018
Platelet P-selectin (%) r=0.30 r=0.05 r=0.04
P=0.015 P=0.69 P=0.73
Platelet CD40L (%) r=0.14 r=0.20 r=0.14
P=0.27 P=0.11 P=0.27
PMP: Flow (no./μL) r=0.39 r=0.03 r=0.08
P=0.015 P=0.41 P=0.19
Pearson or Spearman correlation coefficient as appropriate.
Significant correlations shown in bold.
54 A. Burdess et al. / Thrombosis Research 129 (2012) 50–55volunteers (co-efficient of variation, 7.8%) [23]. We collected whole
blood through direct venepuncture as opposed to via a cannula to
avoid turbulent flow and increased activation. We chose to anticoagu-
late bloodwith a direct thrombin inhibitor as opposed to heparin or cit-
rate as these compounds have been shown to increase and decrease
aggregates respectively. We also chose not to stimulate samples with
agonists ex vivo as wewanted to assess resting circulating in vivo levels.
We appreciate that our procedures differed when it came to the
detection of platelet microparticles (when platelet poor plasma had
to be prepared from whole blood) and when assays were used in-
stead of flow cytometry. It is inevitable that processing may differ
with the detection of different markers, however, as long as the meth-
odology is fully reported (with clarity over the stages known to affect
outcomes e.g. anti-coagulant agent) then the relationship between
measurements can still be examined.
Recently there has been increasing evidence to suggest that the role
of platelets in atherosclerosismay bemediated by the production ofmi-
croparticles [24,25]. Platelet-derived microparticles (diameter b1 μm
and bearing platelet-derived surface antigens) are involved in several
stages of atherosclerosis from coagulation (tissue factor release; inhibi-
tion of fibrinolysis) [26,27] to direct effects on the blood vessel wall
(platelet adhesion) and angiogenesis [28,29]. In addition, increased
platelet-derived microparticles have been demonstrated in individuals
with a smoking habit, diabetes mellitus, cerebrovascular disease and
acute coronary syndromes [7,8]. A variety of methods have been pro-
posed for the assessment of platelet-derived microparticles. However,
platelet microparticles are heterogeneous with respect to both size
and composition, and can carry a range of antigenic markers from
their parent platelet. We decided to compare flow cytometric and im-
munoassay based methods of quantification: both techniques identify-
ing the same platelet antigen (CD41, GPIIb). The preparation of platelet
poor plasma and use of counting beads is well validated and the assay
has been reported as demonstrating good sensitivity for in vitro gener-
ated platelet microparticles [18]. Although reproducibility was good for
othermarkers, ourmeasures of plateletmicroparticles were less consis-
tent. This is likely to reflect several factors. First, significant additional
processing was required by these assays and this will inevitably in-
crease variability. Second, the accuracy of flow cytometry is reduced
when assessing particles b1 μm in size. Finally, our flow protocol iden-
tified microparticles that were positive for two platelet markers, CD41
(GPIIb) and CD31 (GPIIa, PECAM)whereas the immunoassay only iden-
tified microparticles positive for CD41 (GPIIb).
Although platelet P-selectin and CD40L demonstrated good repro-
ducibility (co-efficientsb7), platelet monocyte aggregates showed the
best global correlation with other markers. Platelet-monocyte aggre-
gates primarily form through the binding of P-selectin on the platelet
surface to the leucocyte counter-receptor, P-selectin glycoprotein
ligand-1 (PSGL-1), on monocytes. It is therefore not surprising that
platelet expression of P-selectin shows good correlation with levelsof platelet-monocyte aggregates. Platelet microparticles modulate
monocyte interactions with other cell types by increasing expression
of adhesion molecules [30,31]. The correlatation between microparti-
cles and platelet-monocyte aggregates could reflect this, although
the relationship is less strong. It is interesting to note the lack of
correlation between soluble P-selectin and platelet expression of the
molecule ((r=0.05; P=0.69). This has been previously reported [34].
Dissociation between platelet expressed and soluble P-selectin suggests
that the soluble form cannot serve as a surrogate marker of platelet
activation.
Inflammation plays a central role in the pathogenesis of atheroscle-
rosis. Platelet-monocyte aggregation is not only a sensitive measure of
platelet activation but also has important pro-inflammatory conse-
quences. Platelet-monocyte adhesion activates (NF)-κB; a transcription-
al activator thought to be important in the regulation of CD40 gene
expression [32]. The correlation between platelet-monocyte aggregates
and CD40 expression on monocytes may reflect this process. Induction
of nuclear factor (NF)-κB also stimulates expression of Mac-1 or
CD11b/CD18 [33]. This could be reflected in the excellent correlation be-
tween monocyte CD11b expression and platelet-monocyte aggregation
(Table 3). Subsequent activation of CD11b is associated with neutrophil
recruitment to sites of inflammation.
In conclusion,wehave demonstrated that, in patientswithperipheral
arterial disease, our measurement of platelet and monocyte activation
markers demonstrated good reproducibility. Platelet-monocyte aggre-
gates consistently reflected othermarkers of platelet andmonocyte acti-
vation and we propose them as a sensitive ‘gold standard’ of in vivo
platelet activation. In contrast, measures of platelet-derived microparti-
cles appeared less reproducible. We plan to employ these techniques in
a study of different anti-platelet regimes in this patient population. The
co-efficients of reproducibility will allow us to interpret the true contri-
bution of such drugs to reductions in platelet activation. With increasing
interest in the manipulation of platelet and inflammatory mediators for
therapeutic gain, an understanding of the reproducibility and compara-
bility of techniques for in vivo assessment of platelet activation is
imperative.
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